Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2019 | May 01, 2021 | |
Document Information Line Items | ||
Entity Registrant Name | NUTRA PHARMA CORP. | |
Document Type | 10-Q | |
Current Fiscal Year End Date | --12-31 | |
Entity Common Stock, Shares Outstanding | 7,214,349,714 | |
Amendment Flag | false | |
Entity Central Index Key | 0001119643 | |
Entity Current Reporting Status | No | |
Entity Filer Category | Non-accelerated Filer | |
Document Period End Date | Jun. 30, 2019 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q2 | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Document Quarterly Report | true | |
Document Transition Report | false | |
Entity File Number | 000-32141 | |
Entity Incorporation, State or Country Code | CA | |
Entity Tax Identification Number | 91-2021600 | |
Entity Address, Address Line One | 1537 NW 65th Avenue | |
Entity Address, City or Town | Plantation | |
Entity Address, State or Province | FL | |
Entity Address, Postal Zip Code | 33313 | |
City Area Code | 954 | |
Local Phone Number | 509–0911 | |
Entity Interactive Data Current | No |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Current assets: | ||
Cash | $ 113,713 | |
Accounts receivable | 28,134 | 17,065 |
Inventory | 36,528 | 35,302 |
Prepaid expenses and other current assets | 44,348 | 63,000 |
Total current assets | 222,723 | 115,367 |
Property and equipment, net | 8,290 | 10,500 |
Operating lease right-of-use assets | 251,887 | |
Security deposit | 15,550 | 15,550 |
Total assets | 498,450 | 141,417 |
Current liabilities: | ||
Accounts payable | 553,277 | 475,409 |
Accrued expenses | 887,948 | 831,849 |
Accrued payroll due to officers | 1,153,893 | 1,050,993 |
Accrued interest to related parties | 150,372 | 141,808 |
Due to officer | 161,418 | 186,497 |
Derivative warrant liability | 1,934 | 1,468 |
Other debt, net of discount, current portion | 4,867,086 | 3,338,576 |
Operating lease obligations, current portion | 68,806 | |
Total current liabilities | 7,844,734 | 6,026,600 |
Promissory note, less current portion | 4,616 | 51,410 |
Convertible note, less current portion | 119,879 | |
Operating lease obligations, less current portion | 181,379 | |
Total liabilities | 8,150,608 | 6,078,010 |
Commitments and Contingencies | ||
Stockholders' deficit: | ||
Preferred stock, $0.001 par value, 20,000,000 shares authorized: 3,000,000 Series A Preferred shares issued and outstanding at June 30, 2019 and December 31, 2018 | 3,000 | 3,000 |
Common stock, $0.001 par value, 8,000,000,000 shares authorized: 5,038,246,111 and 4,046,746,110 shares issued and outstanding at June 30, 2019 and December 31, 2018 | 5,038,246 | 4,046,746 |
Additional paid-in capital | 50,648,088 | 51,286,503 |
Accumulated deficit | (63,341,492) | (61,272,842) |
Total stockholders' deficit | (7,652,158) | (5,936,593) |
Total liabilities and stockholders' deficit | $ 498,450 | $ 141,417 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - $ / shares | Jun. 30, 2019 | Dec. 31, 2018 |
Preferred stock par value (in Dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock shares authorized | 20,000,000 | 20,000,000 |
Common stock par value (in Dollars per share) | $ 0.001 | $ 0.001 |
Common stock shares authorized | 8,000,000,000 | 8,000,000,000 |
Common stock shares issued | 5,038,246,111 | 4,046,746,110 |
Common stock shares outstanding | 5,038,246,111 | 4,046,746,110 |
Series A Preferred Stock [Member] | ||
Series A Preferred shares issued | 3,000,000 | 3,000,000 |
Series A Preferred shares outstanding | 3,000,000 | 3,000,000 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Income Statement [Abstract] | ||||
Net sales | $ 10,215 | $ 29,381 | $ 51,537 | $ 60,357 |
Cost of sales | (3,774) | (16,570) | (19,399) | (20,929) |
Gross profit | 6,441 | 12,811 | 32,138 | 39,428 |
Operating expenses: | ||||
Selling, general and administrative - including stock based compensation of $26,500 and $10,000 for the three months ended June 30, 2019 and 2018, and $56,500 and $10,000 for the six months ended June 30, 2019 and 2018, respectively | 334,287 | 348,660 | 608,922 | 712,733 |
Total operating expenses | 334,287 | 348,660 | 608,922 | 712,733 |
Loss from operations | (327,846) | (335,849) | (576,784) | (673,305) |
Other income (expenses) | ||||
Interest expense | (59,832) | (161,312) | (134,977) | (432,872) |
Interest expense to related parties | (4,368) | (3,882) | (8,564) | (7,611) |
Change in fair value of convertible notes and derivatives | (1,275,111) | (849,376) | (1,404,528) | (1,982,864) |
Gain (Loss) on settlement of debt and accounts payable, net | (1,050) | 19,677 | 56,203 | 768,323 |
Total Other income (expenses) | (1,340,361) | (994,893) | (1,491,866) | (1,655,024) |
Loss before income taxes | (1,668,207) | (1,330,742) | (2,068,650) | (2,328,329) |
Provision for income taxes | ||||
Net loss | $ (1,668,207) | $ (1,330,742) | $ (2,068,650) | $ (2,328,329) |
Net loss per share - basic and diluted (in Dollars per share) | $ 0 | $ 0 | $ 0 | $ 0 |
Weighted average number of shares outstanding during the year - basic and diluted (in Shares) | 4,612,987,869 | 2,723,756,675 | 4,336,212,961 | 2,458,305,604 |
Consolidated Statements of Op_2
Consolidated Statements of Operations (Parentheticals) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Income Statement [Abstract] | ||||
Stock based compensation | $ 26,500 | $ 10,000 | $ 56,500 | $ 10,000 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Changes in Stockholders' Deficit - USD ($) | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Total |
Balance at Dec. 31, 2017 | $ 3,000 | $ 2,032,234 | $ 49,942,719 | $ (57,388,147) | $ (5,410,194) |
Balance (in Shares) at Dec. 31, 2017 | 3,000,000 | 2,032,233,701 | |||
Balance at Mar. 31, 2018 | $ 3,000 | $ 2,332,105 | 50,887,528 | (58,385,734) | (5,163,101) |
Balance (in Shares) at Mar. 31, 2018 | 3,000,000 | 2,332,105,170 | |||
Balance at Dec. 31, 2017 | $ 3,000 | $ 2,032,234 | 49,942,719 | (57,388,147) | (5,410,194) |
Balance (in Shares) at Dec. 31, 2017 | 3,000,000 | 2,032,233,701 | |||
Issuance of common stock in exchange for services to consultants | $ 100,000,000,000 | 20,000,000,000 | 120,000,000,000 | ||
Issuance of common stock in exchange for services to consultants (in Shares) | 100,000,000 | ||||
Common stock issued for debt modification and penalty | $ 71,621 | 28,949 | 100,570 | ||
Common stock issued for debt modification and penalty (in Shares) | 71,621,469 | ||||
Common stock issued for conversion of debt | $ 1,027,947 | 1,130,691 | 2,158,638 | ||
Common stock issued for conversion of debt (in Shares) | 1,027,946,997 | ||||
Common stock issued with Debt--Debt discount | $ 9,250 | 9,315 | 18,565 | ||
Common stock issued with Debt--Debt discount (in Shares) | 9,250,000 | ||||
Beneficial conversion features | 235,913 | 235,913 | |||
Net loss | (2,328,329) | (2,328,329) | |||
Balance at Jun. 30, 2018 | $ 3,000 | $ 3,241,052 | 51,367,587 | (59,716,476) | (5,104,837) |
Balance (in Shares) at Jun. 30, 2018 | 3,000,000 | 3,241,052,167 | |||
Balance at Dec. 31, 2017 | $ 3,000 | $ 2,032,234 | 49,942,719 | (57,388,147) | (5,410,194) |
Balance (in Shares) at Dec. 31, 2017 | 3,000,000 | 2,032,233,701 | |||
Balance at Dec. 31, 2018 | $ 3,000 | $ 4,046,746 | 51,286,503 | (61,272,842) | (5,936,593) |
Balance (in Shares) at Dec. 31, 2018 | 3,000,000 | 4,046,746,110 | |||
Balance at Mar. 31, 2018 | $ 3,000 | $ 2,332,105 | 50,887,528 | (58,385,734) | (5,163,101) |
Balance (in Shares) at Mar. 31, 2018 | 3,000,000 | 2,332,105,170 | |||
Issuance of common stock in exchange for services to consultants | $ 100,000,000,000 | 20,000,000,000 | 120,000,000,000 | ||
Issuance of common stock in exchange for services to consultants (in Shares) | 100,000,000 | ||||
Common stock issued for debt modification and penalty | $ 1,000 | 700 | 1,700 | ||
Common stock issued for debt modification and penalty (in Shares) | 1,000,000 | ||||
Common stock issued for conversion of debt | $ 802,947 | 350,681 | 1,153,628 | ||
Common stock issued for conversion of debt (in Shares) | 802,946,997 | ||||
Common stock issued with Debt--Debt discount | $ 5,000 | 3,678 | 8,678 | ||
Common stock issued with Debt--Debt discount (in Shares) | 5,000,000 | ||||
Beneficial conversion features | 105,000 | 105,000 | |||
Net loss | (1,330,742) | (1,330,742) | |||
Balance at Jun. 30, 2018 | $ 3,000 | $ 3,241,052 | 51,367,587 | (59,716,476) | (5,104,837) |
Balance (in Shares) at Jun. 30, 2018 | 3,000,000 | 3,241,052,167 | |||
Balance at Dec. 31, 2018 | $ 3,000 | $ 4,046,746 | 51,286,503 | (61,272,842) | (5,936,593) |
Balance (in Shares) at Dec. 31, 2018 | 3,000,000 | 4,046,746,110 | |||
Issuance of common stock in exchange for services to consultants | $ 135,000,000,000 | (105,000,000,000) | 30,000,000,000 | ||
Issuance of common stock in exchange for services to consultants (in Shares) | 135,000,000 | ||||
Common stock issued for debt modification and penalty | $ 3,500 | (2,450) | 1,050 | ||
Common stock issued for debt modification and penalty (in Shares) | 3,500,000 | ||||
Common stock issued for conversion of debt | $ 750,000 | (475,000) | 275,000 | ||
Common stock issued for conversion of debt (in Shares) | 750,000,000 | ||||
Common stock issued with Debt--Debt discount | $ 22,000 | (15,512) | 6,488 | ||
Common stock issued with Debt--Debt discount (in Shares) | 22,000,001 | ||||
Common stock issued for settlement of debt | $ 81,000 | (48,600) | 32,400 | ||
Common stock issued for settlement of debt (in Shares) | 81,000,000 | ||||
Warrants issued with Debt--Debt discount | 8,147 | 8,147 | |||
Net loss | (2,068,650) | (2,068,650) | |||
Balance at Jun. 30, 2019 | $ 3,000 | $ 5,038,246 | 50,648,088 | (63,341,492) | (7,652,158) |
Balance (in Shares) at Jun. 30, 2019 | 3,000,000 | 5,038,246,111 | |||
Balance at Mar. 31, 2019 | $ 3,000 | $ 4,127,746 | 51,246,050 | (61,673,285) | (6,296,489) |
Balance (in Shares) at Mar. 31, 2019 | 3,000,000 | 4,127,746,110 | |||
Issuance of common stock in exchange for services to consultants | $ 135,000,000,000 | (105,000,000,000) | 30,000,000,000 | ||
Issuance of common stock in exchange for services to consultants (in Shares) | 135,000,000 | ||||
Common stock issued for debt modification and penalty | $ 3,500 | (2,450) | 1,050 | ||
Common stock issued for debt modification and penalty (in Shares) | 3,500,000 | ||||
Common stock issued for conversion of debt | $ 750,000 | (475,000) | 275,000 | ||
Common stock issued for conversion of debt (in Shares) | 750,000,000 | ||||
Common stock issued with Debt--Debt discount | $ 22,000 | (15,512) | 6,488 | ||
Common stock issued with Debt--Debt discount (in Shares) | 22,000,001 | ||||
Net loss | (1,668,207) | (1,668,207) | |||
Balance at Jun. 30, 2019 | $ 3,000 | $ 5,038,246 | $ 50,648,088 | $ (63,341,492) | $ (7,652,158) |
Balance (in Shares) at Jun. 30, 2019 | 3,000,000 | 5,038,246,111 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows | 3 Months Ended | 6 Months Ended | |
Jun. 30, 2019USD ($) | Jun. 30, 2019USD ($) | Jun. 30, 2018USD ($) | |
Net loss | $ (1,668,207) | $ (2,068,650) | $ (2,328,329) |
Bad debt expense | 31,789 | ||
Accrued interest expense for amount due to officer | 3,536 | ||
Gain on settlement of debt and accounts payable | 1,050 | (56,203) | (768,323) |
Depreciation | 2,210 | 3,753 | |
Stock-based compensation | 26,500 | 56,500 | 10,000 |
Stock-based loan modification cost | 126,700 | ||
Change in fair value of convertible notes and derivatives | 1,404,528 | 1,982,864 | |
Amortization of loan discount | 62,078 | 207,837 | |
Amortization of operating lease right-of-use assets | 29,288 | ||
Changes in operating assets and liabilities: | |||
Increase in accounts receivables | (13,858) | (1,137) | |
Increase in inventory | (1,226) | (39,282) | |
Increase in prepaid expenses and other current assets | (7,848) | (44,257) | |
Increase in accounts payable | 77,868 | 113,083 | |
Increase in accrued expenses | 115,811 | 58,610 | |
Increase in accrued payroll due to officers | 102,900 | ||
Decrease in deferred revenue | (22,490) | ||
Increase in accrued interest to related parties | 8,564 | ||
Decrease in operating lease obligations | (30,990) | ||
Net cash used in operating activities | (283,703) | (700,971) | |
Cash flows from financing activities: | |||
Loans from officer | 4,100 | 105,100 | |
Repayment of officers loans | (61,715) | (106,150) | |
Proceeds from convertible notes, net of debt discount and loan issuance cost $5,000 and $14,650, respectively | 484,879 | 729,000 | |
Repayment of convertible notes | (10,000) | ||
Repayments of other notes payable | (19,848) | (4,000) | |
Net cash provided by financing activities | 397,416 | 723,950 | |
Net increase in cash | 113,713 | 22,979 | |
Cash - beginning of period | |||
Cash - end of period | 113,713 | 113,713 | 22,979 |
Supplemental Cash Flow Information: | |||
Cash paid for interest | 5,425 | ||
Cash paid for income taxes | |||
Non cash Financing and Investing: | |||
Note and stock issued in settlement of notes and accounts payable | 32,400 | ||
Shares issued to satisfy debt | 275,000 | 275,000 | 2,158,638 |
Discounts on notes payable | 14,635 | 18,565 | |
Debt discount for beneficial conversion features | 235,913 | ||
Operating lease liabilities due to adoption of ASC 842 | 250,185 | 250,185 | |
Related Party [Member] | |||
Non cash Financing and Investing: | |||
Shares issued to satisfy debt | 275,000 | $ 5,242,524 | |
Under ASC 842 [Member] | |||
Non cash Financing and Investing: | |||
Right-of-use asset due to adoption of ASC 842 | 281,175 | 281,175 | |
Operating lease liabilities due to adoption of ASC 842 | $ 281,175 | $ 281,175 |
BASIS OF PRESENTATION AND SUMMA
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 6 Months Ended |
Jun. 30, 2019 | |
Accounting Policies [Abstract] | |
Basis of Presentation and Significant Accounting Policies [Text Block] | 1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® Basis of Presentation and Consolidation The Unaudited Condensed Consolidated Financial Statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K. The accompanying Unaudited Condensed Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation. Reclassification of Prior Year Presentation Reclassification occurred to certain prior year amounts in order to conform to the current year classifications. The reclassifications have no effect on the reported net loss. Restatement of Prior Period Presentation Certain prior period amounts have been restated. Restatements have been made for the three and six months ended June 30, 2018 to correct the change in the fair value of convertible notes and to record a gain on settlement of debt and accounts payable. As a result of these changes, the following occurred: 1. Net loss for the three months ended June 30, 2018 decreased by $19,143 ($0.00 per share) (see table below). 2. Net loss for the six months ended June 30, 2018 decreased by $3,110,017 ($0.00 per share) (see table below). 3. At June 30, 2018, there was no change to total stockholders' deficit but additional paid-in capital and accumulated deficit decreased by $3,110,017. 4. Certain amounts in cash flows from operating activities were updated for the six months ended June 30, 2018, but there was no change to the total net cash used in operating activities in the Unaudited Condensed Consolidated Statements of Cash Flows. For the Three Months Amounts Amounts Adjustments Decrease in Net Loss Change in fair value of convertible notes and derivatives $ (849,376) $ (868,519) $ 19,143 Net effect of restatement on net loss $ 19,143 For the Six Months Amounts Amounts Adjustments Decrease in Net Loss Change in fair value of convertible notes and derivatives $ (1,982,864) $ (4,344,235) $ 2,361,371 Gain on settlement of debt and accounts payable 768,323 19,677 748,646 Net effect of restatement on net loss $ 3,110,017 Liquidity and Going Concern Our Unaudited Condensed Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $63,341,492 at June 30, 2019. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $7,622,011 and a stockholders’ deficit of $7,652,158 at June 30, 2019. There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from SBA to fund our request for a PPP loan for $64,895 (See Note 12). During April and June 2020, we obtained a loan in the amount of $154,900 from the SBA under its Economic Injury Disaster Loan assistance program. We intended to use the proceeds primarily for working capital purpose (See Note 12). The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the development of widespread testing or a vaccine. Use of Estimates The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and warrant liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. Revenue from Contracts with Customers On January 1, 2018, we adopted Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, "Revenue from Contracts with Customers" Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon delivery of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor. Accounting for Shipping and Handling Costs We account for shipping and handling as fulfillment activities and record shipping and handling costs incurred within revenue. Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivables. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. Management believes that the receivables are fully collectable. Therefore, no allowance for doubtful account is deemed to be required at June 30, 2019 and December 31, 2018. Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at June 30, 2019 and December 31, 2018, and increased the reserve on supplier advances for future venom purchases included in the prepaid expenses and other current assets by $0 and $47,757, respectively. At June 30, 2019 and December 31, 2018, the total valuation allowance for prepaid venom is $200,911. Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the three months ended June 30, 2019, there was one customer that accounted for 27% of the total revenues. For the three months ended June 30, 2018, there was one customer that accounted for 45% of the total revenues. For the six months ended June 30, 2019, there were two customers that accounted for 25% and 49% of the total revenues, respectively. For the six months ended June 30, 2018, there was one customer that accounted for 22% of the total revenues. As of June 30, 2019 and December 31, 2018, 100% and 84% of the accounts receivable balance are reserves due from two payment processors. Operating Lease Right-of-Use Asset and Liability In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases” (Topic 842), as amended (“ASC Topic 842”). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classify as either operating or finance leases. We adopted this standard effective January 1, 2019 using the modified retrospective approach for all leases entered into before the effective date. Adoption of the ASC Topic 842 had a significant effect on our balance sheet resulting in increased non-current assets and increased current and non-current liabilities. There was no impact to retained earnings upon adoption of the new standard. We did not have any finance leases (formerly referred to as capital leases prior to the adoption of ASC Topic 842), therefore there was no change in accounting treatment required. For comparability purposes, the Company will continue to comply with the previous disclosure requirements in accordance with the existing lease guidance and prior periods are not restated. The Company elected the package of practical expedients as permitted under the transition guidance, which allowed us: (1) to carry forward the historical lease classification; (2) not to reassess whether expired or existing contracts are or contain leases; and, (3) not to reassess the treatment of initial direct costs for existing leases. In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. For periods prior to the adoption of ASC Topic 842, the Company recorded rent expense based on the term of the related lease. The expense recognition for operating leases under ASC Topic 842 is substantially consistent with prior guidance. As a result, there are no significant differences in our results of operations presented. The impact of the adoption of ASC 842 on the balance sheet was: As reported Adoption of ASC 842 – increase (decrease) Balance January 1, Operating lease right-of-assets $ - $ 281,175 $ 281,175 Total assets $ 141,417 $ 281,175 $ 422,592 Operating lease liabilities, current portion $ - $ 64,573 $ 64,573 Operating lease liabilities, net of current portion $ - $ 216,602 $ 216,602 Total liabilities $ 6,078,010 $ 281,175 $ 6,359,185 Total liabilities and stockholders’ equity $ 141,417 $ 281,175 $ 422,592 Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature ("BCF"). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging Property and Equipment and Long-Lived Assets Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years. Income Taxes The Company recorded no income tax expense for the six months ended June 30, 2019 and 2018 because the estimated annual effective tax rate was zero. As of June 30, 2019, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized. Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation Net Loss Per Share Net loss per share is calculated in accordance with FASB ASC Topic 260, Earnings per Share June 30, 2019 June 30, 2018 Options and warrants 118,500,000 13,475,000 Convertible notes payable 7,050,986,979 1,625,457,403 Total 7,169,486,979 1,638,932,403 Recent Accounting Pronouncements In June 2018, the FASB issued ASU 2018-07, “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). ASU No 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance also specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and is effective for the Company as of January 1, 2019. The Company noted that all share based payments were settled as of the date of the adoption, so there was no impact on the Company's financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable. |
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS | 6 Months Ended |
Jun. 30, 2019 | |
Fair Value Disclosures [Abstract] | |
Fair Value Disclosures [Text Block] | 2. FAIR VALUE MEASUREMENTS Certain assets and liabilities that are measured at fair value on a recurring basis at June 30, 2019 are measured in accordance with FASB ASC Topic 820-10-05, Fair Value Measurements The statement requires fair value measurement be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active or inputs which are observable either directly or indirectly for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity). The following table summarizes our financial instruments measured at fair value at June 30, 2019 and December 31, 2018: Fair Value Measurements at June 30, 2019 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,934 $ - $ - $ 1,934 Convertible notes at fair value $ 2,821,182 $ - $ - $ 2,821,182 Fair Value Measurements at December 31, 2018 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,468 $ - $ - $ 1,468 Convertible notes at fair value $ 1,156,341 $ - $ - $ 1,156,341 The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the six months ended June 30, 2019 and the year ended December 31, 2018: Description June 30, December 31, Beginning balance $ 1,468 $ 5,903 Total (gain) loss included in earnings (1) 466 (4,435) Ending balance $ 1,934 $ 1,468 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. We valued our warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 1.75% to 2.81% risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 256%-305% (4) zero expected dividends (5) exercise price set forth in the agreements (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted. The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at June 30, 2019 and December 31, 2018: Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back June 30, 2019 $1,066,479 8%-20% 18%-24% 23.95-27.95 $0.00015-$0.05 50%-60% 3 to 25 Days December 31, 2018 $1,566,433 8%-12% 18%-20% 25.95-27.95 $0.0002-$0.20 40%-60% 3 to 25 Days Using the stated assumptions summarized in table above, we calculated the inception date and reporting period fair values of each note issued. The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2019 and the year ended December 31, 2018: Description June 30, 2019 December 31, 2018 Beginning balance $ 1,156,341 $ 1,925,959 Purchases and issuances 535,779 472,029 Day one loss on value of hybrid instrument (1) 671,476 2,021,041 Loss from change in fair value (1) 732,586 130,344 Gain on settlement - (958,581) Conversion to common stock (275,000) (2,434,451) Ending balance $ 2,821,182 $ 1,156,341 (1) The losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
INVENTORIES
INVENTORIES | 6 Months Ended |
Jun. 30, 2019 | |
Inventory Disclosure [Abstract] | |
Inventory Disclosure [Text Block] | 3. INVENTORIES Inventories are valued at the lower of cost or net realizable value on an average cost basis. At June 30, 2019 and December 31, 2018, inventories were as follows: June 30, December 31, 2018 Raw Materials $ 34,433 $ 33,431 Finished Goods 2,095 1,871 Total Inventories $ 36,528 $ 35,302 |
PROPERTY AND EQUIPMENT
PROPERTY AND EQUIPMENT | 6 Months Ended |
Jun. 30, 2019 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment Disclosure [Text Block] | 4. PROPERTY AND EQUIPMENT Property and equipment consists of the following at June 30, 2019 and December 31, 2018: June 30, December 31, 2018 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 53,711 53,711 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 216,033 216,033 Less: Accumulated depreciation (207,743) (205,533) Property and equipment, net $ 8,290 $ 10,500 We review our long-lived assets for recoverability if events or changes in circumstances indicate the assets may be impaired. At June 30, 2019, we believe the carrying values of our long-lived assets are recoverable. Depreciation expense for the six-months ended June 30, 2019 and 2018 was $2,210 and $3,753, respectively, and $1,105 and $1,825 for the three-months ended June 30, 2019 and 2018, respectively. |
DUE TO_FROM OFFICERS
DUE TO/FROM OFFICERS | 6 Months Ended |
Jun. 30, 2019 | |
Due to Officers [Abstract] | |
Due to Officers [Text Block] | 5. DUE TO/FROM OFFICER At June 30, 2019, the balance due to our President and CEO, Rik Deitsch, is $161,418, which is an unsecured demand loan that bears interest at 4%. During the six months ended June 30, 2019, we repaid $61,715 to and collected $4,100 from Mr. Deitsch and the Companies owned by him. Additionally, accrued interest on the demand loan was $3,536 and is included in the due to officer account. At December 31, 2018, the balance due to our President and CEO, Rik Deitsch, is $186,497, which is an unsecured demand loan that bears interest at 4%. . During the six months ended June 30, 2018, we repaid $106,150 to and collected $105,100 from Mr. Deitsch and the Companies owned by him. Additionally, accrued interest on the demand loan was $7,674 and is included in the due to officer account. The Company has fully reserved receivables from companies owned by the Company's CEO. The reserve was $534,470 and $505,470 as of June 30, 2019 and December 31, 2018. |
DEBTS
DEBTS | 6 Months Ended |
Jun. 30, 2019 | |
Debt Disclosure [Abstract] | |
Debt Disclosure [Text Block] | 6. DEBTS Debts consist of the following at June 30, 2019 and December 31, 2018: June 30, 2019 December 31, 2018 Note payable– Related Party (Net of discount of $1,200 and $2,400, $ 13,200 $ 12,000 Notes payable – Unrelated third parties (Net of discount of $1,000 1,387,877 1,469,690 Convertible notes payable – Unrelated third parties (Net of discount of 814,016 751,955 Convertible notes payable, at fair value (Net of discount of $44,694 and $0, respectively) (4) 2,776,488 1,156,341 Ending balances 4,991,581 3,389,986 Less: Long-term portion-Notes payable-Unrelated third parties $ (4,616) $ (51,410) Less: Long-term portion-Convertible Notes payable-Unrelated third parties (119,879) - Current portion $ 4,867,086 $ 3,338,576 (1) During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At June 30, 2019 and December 31, 2018, we owed this director accrued interest of $150,372 and $141,808. The interest expense for the six-months ended June 30, 2019 and 2018 was $8,564 and $7,611, respectively, and $4,368 and $3,882 for the three-months ended June 30, 2019 and 2018, respectively. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. At June 30, 2019 and December 31, 2018, the principal balance of the loan is $13,200 and $12,000, net of debt discount of $1,200 and $2,400, respectively. The Note was settled in June 2020. (2) At June 30, 2019 and December 31, 2018, the balance of $1,387,877 and $1,469,690 net of discount of $1,000 and $17,870, respectively, consisted of the following loans: ● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At June 30, 2019 and December 31, 2018, we owed principal balance of $169,634 and $192,974, and accrued interest of $45,456 and $40,033, respectively. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020 (See Note 11) ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2019 and December 31, 2018, the accrued interest is $3,242 and $2,739. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the outstanding principal balance is $50,000 and accrued interest is $43,834 and $37,801. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2019 and December 31, 2018, the outstanding principal balance is $50,000 and accrued interest is $37,033 and $31,000. ● In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest were restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest were restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018.The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest were restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and was due June 17, 2019. The note is in default and negotiation of settlement. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the six months ended June 30, 2019 and 2018 was $3,616 and $2,765, respectively. The debt discount at June 30, 2019 and December 31, 2018 was $0 and $3,616. At June 30, 2019 and December 31, 2018, the principal balance is $282,983, and the accrued interest is $36,977 and $2,830, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. In January 2019, the principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). The remaining note of $15,000 was assigned to an unrelated third party and is in negotiation of settlement. At June 30, 2019 and December 31, 2018, the principal balance is $15,000 and $75,000, and the accrued interest is $1,371 and $17,271, respectively. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the accrued interest is $33,333 and $27,300. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the accrued interest is $2,573 and $1,944. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of June 30, 2019. At December 31, 2017, the principal balance of the loan was $191,329 and in negotiation of settlement. During June 2018, the loan was settled for $170,402 with scheduled repayments of approximately $7,000 per month through July 2020. We recorded a gain on settlement of debt in other income for $20,927 in June 2018. The Company repaid $34,976 during 2018 and $13,848 during the six months ended June 30, 2019. At June 30, 2019 and December 31, 2018, the principal balance is $121,578 and $135,426. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the principal balance of the note is $50,000. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 each due in September 2019 and 2020, respectively. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and is due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the six months ended June 30, 2019 and 2018 was $5,000 and $1,500, respectively. The debt discount at June 30, 2019 and December 31, 2018 is $2,500 and $6,000. Repayments of $1,500 and $7,000 have been made during 2017 and 2018, respectively. During the six months ended June 30, 2019, repayment of $1,500 has been made. The Note is under personal guarantee by Mr. Deitsch. At June 30, 2019 and December 31, 2018, the principal balance of the note is $31,000 and $27,500, net of debt discount of $1,000 and $6,000, respectively. The note is in default and in negotiation of settlement. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment. The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the six months ended June 30, 2019 was $1,587 and $6,667. Amortization for the debt discount and original issuance discount was $3,616 and $4,617, respectively for the six months ended June 30, 2018. As of June 30, 2019 and December 31, 2018, the amount due is $70,000 and $61,746, net of discount of $0 and $8,254. During January and July 2020, this Note and the Note of $76,076 amended in August 2018(See Note 6(3)) were combined and restated and was due January 2021. The Note is in negotiation of restatement. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. 1,500,000 shares of common stocks were issued due to the default of repayments with a fair value of $2,250 in 2018. During March 2020, $50,000 of the Note of $120,000 with original issuance discount of 20,000 originated in November 2017 was settled for 125,000,000 shares. An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $119,700. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. At June 30, 2019 and December 31, 2018, the principal balance of the loan is $120,000. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600 during 2018. At June 30, 2019 and December 31, 2018, the principal balance of the note is $18,000 and the accrued interest is $2,000 and $0, respectively. (3) At June 30, 2019 and December 31, 2018, the balance of $814,016 and $751,955 net of discount of $6,710 and $29,371, respectively, consisted of the following convertible loans: ● On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. The first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014. The notes carry interest at 8% and were due on March 19, 2018. The note holders have the right to convert the notes into shares of Common Stock at a price of $0.20. During 2018, repayment of $3,000 was made. At December 31, 2018, the principal balance of the note is $27,000 and the accrued interest is $11,412. The two outstanding Notes were settled in connection with issuance of the convertible note in the amount of up to $1,000,000 in February 2019 (See Note 6(4)), as a result, we recorded a gain on settlement of debt in other income for $38,412. ● During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and is due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The remaining debt discount of $950 was fully amortized during the three months ended March 31, 2019. The note is under personal guarantee by Mr. Deitsch. At June 30, 2019 and December 31, 2018, the convertible note payable was recorded at $76,076 and $75,126, net of discount of $0 and $950, respectively. The accrued interest as of June 30, 2019 and December 31, 2018 is $12,150 and $8,177. During January and July 2020, this Note and the Note of $60,000 amended in November 2018(See Note 6(2)) were combined and restated and was due January 2021. The Note is in negotiation of restatement. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of June 30, 2019. The loan is in default and in negotiation of settlement. 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500 during 2018. At June 30, 2019 and December 31, 2018, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock. The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. These Notes are in default and in negotiation of settlement. During the first quarter of 2019, we issued convertible notes payable of $70,000 with original issuance discount of $5,000. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price of $0.0005 per share. In addition, upon the issuance of convertible notes, the Company granted the total of 110,000,000 warrants at an exercise price of $0.001 per share. The warrants were valued at $8,147 using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. The Notes were further restated in December 2019, and August and October 2020. They are in default and in negotiation of settlement. During the second quarter of 2019, we restated two convertible notes payable with additional original issue discount of $6,400 and issued 6,000,001 shares of common stock with a fair value of $1,800 (See Note 7). The two restated notes were due in August 2019 and are in default. The total discount of $8,200 was amortized over the term of the notes. Repayment of $10,000 was made in May 2019. Amortization for the six months ended June 30, 2019 and 2018 was $43,058 and $144,062. At June 30, 2019 and December 31, 2018, the principal balance of the notes, net of discount of $6,710 and $28,421 is $677,940 and $589,829. (4) At June 30, 2019 and December 31, 2018, the balance of $2,821,182 and $1,156,341, respectively, consisted of the following convertible loans: ● During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carries interest at 12% and matured on September 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 179,800,000 shares of stock satisfying the principal balance of $63,001 and accrued interest for a fair value of $298,575. At December 31, 2017, the convertible note payable, at fair value, was recorded at $147,314. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. During February and July, 2018, we issued a total of 105,157,409 shares of our restricted common stock to the original Note holder with a fair value of $147,220. At December 31, 2018, the Company owed additional shares to the original noteholder and recorded an accrual of $32,400 to account for the cost of the shares, and the shares were issued in January 2019 (See Notes 7). The new note of $49,819 carries interest at 8% and was due on February 13, 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During September 2018, the Noteholder made a conversions of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full. At June 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $34,819, at fair value, was recorded at $90,965 and $62,508. ● During February 2018, we issued a convertible denture in the amount of $200,000 to an unrelated third party. The note carries interest at 8% and was due in February 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $1,646,242. At June 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $200,000, at fair value, was recorded at $520,037 and $358,665. The note carries additional $200,000 “Back-end Note” ($100,000 each) with the same terms as the original note. ● During April 2018, $65,000 of one of the $100,000 Back-end Note was funded. The note carries interest at 8% and is due in February 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $110,700. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $169,012 and $115,165. ● During March 2018, we issued a convertible denture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and was due in March 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $48,418. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $153,556 and $107,329. The note carries an additional “Back-end Note” with the same terms as the original note that enables the lender to lend to us another $60,000. ● During June 2018, the $60,000 Back-end Note was funded. The note carries interest at 8% and is due in March 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $68,067. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $153,556 and $105,334. ● During May 2018, we issued a convertible denture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and was due in May 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $59,257. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $148,033 and $106,681. ● During August 2018, we issued a convertible denture in the amount of $31,500 to an unrelated third party. The note carries interest at 8% and was due in August 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $23,794. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $75,133 and $55,409. All of the above convertible notes with principal balance of a total of $511,319 were settled in ● During May 2017, we issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. The note carries interest at 8% and was due on May 4, 2018. We have accrued interest at default interest rate of 20% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty trading days preceding the conversion date. During November 2017, the Note holder made a conversion of our restricted common stocks satisfying the principal balance of $856 and penalty of $6,400 for a fair value of $21,399. At December 31, 2017, the convertible note payable, at fair value, was recorded at $185,765. During February 2018, the remaining balance of $63,144 with accrued interest and penalty of $12,442 was assigned and sold to three unrelated third parties. During June 2018, a Note holder made a conversion of 50,670,000 shares of our restricted common stock with a fair value of $70,938 in satisfaction of the balance of $34,060 plus accrued interest of $8,607. At June 30, 2019 and December 31, 2018, the remaining principal of $29,381, at fair value, was recorded at $90,948 and $63,315. ● On March 28, 2016, we signed an expansion agreement with Brewer and Associates Consulting, LLC (“B+A”) to the original consulting agreement dated on October 15, 2015 for consulting services for twelve months for a monthly fee of $7,000. To relieve our cash obligation of $36,000 per original agreement, we issued three convertible notes for a total of $120,000 which includes the fees due under the original agreement and the new monthly fees due under the expansion agreement. The $40,000 and $60,000 of the Notes were paid in full as of December 31, 2016 and December 31, 2017, respectively. The remaining balance of $20,000 Notes is in default and negotiation of settlement. We have accrued interest at default interest rate of 20% after the note’s maturity date. The conversion price is equal to |
STOCKHOLDERS' DEFICIT
STOCKHOLDERS' DEFICIT | 6 Months Ended |
Jun. 30, 2019 | |
Stockholders' Equity Note [Abstract] | |
Stockholders' Equity Note Disclosure [Text Block] | 7 . STOCKHOLDERS' DEFICIT Common Stock Issued for Accrued Expense During January 2019, in connection with the settlement of a default penalty of debt of $110,000 originated in December 2016, we issued a total of 81,000,000 shares of our restricted common stock with a fair value of $32,400 to the Note holder (See Note 6). We had an accrual of $32,400 to account for the cost of the shares at December 31, 2018. Common Stock Issued for Services During June 2018, the Company signed an agreement with a consultant for investor relation services for twelve months. In connection with the agreement, 100,000,000 shares of the Company’s restricted common stocks were issued. The shares were valued at $0.0012 per share. The Company recorded an equity compensation charge of $20,000 and $50,000 during the three and six months ended June 30, 2019. The Company recorded an equity compensation charge of $10,000 during the three and six months ended June 30, 2018. During April 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 120,000,000 shares of our restricted common stock were issued. The shares were valued at $24,000. During June 2019, we signed an agreement with a consultant to provide investor relation services for twelve months. In connection with the agreement, 15,000,000 shares of our restricted common stock were issued. The shares were valued at $6,000. The Company recorded an equity compensation charge of $6,500 during the three and six months ended June 30, 2019. The remaining unrecognized compensation cost of $23,500 will be recognized by the Company over the remaining service period. Common Stock Issued with Indebtedness In May 2019, in connection with amendment of two convertible notes payable, we issued a total of 6,000,001 shares of our common stock with a fair value of $1,800 (See Note 6). In June 2019, in connection with issuance of a convertible notes payable, we issued a total of 16,000,000 shares of our common stock with a fair value of $4,688 (See Note 6). Common Stock Issued for Conversion of Debt During May and June 2019, the Note holder made conversions of a total of 750,000,000 shares of stock for a fair value of $275,000 satisfying the principal balance of $100,000 of a $219,879 Note originated in February 2019 (See Note 6). Date Number of Fair Value of shares converted Debt Converted 5/6/2019 250,000,000 $75,000 5/31/2019 250,000,000 $100,000 6/6/2019 250,000,000 $100,000 Common Stock Issued for Debt Modification During May and June 2019, we issued a total of 3,500,000 restricted shares to three Note holders due to the default on repayment of the convertible notes. The shares were valued at fair value of $1,050. |
STOCK WARRANTS
STOCK WARRANTS | 6 Months Ended |
Jun. 30, 2019 | |
Stock Options and Warrants [Abstract] | |
Stock Options and Warrants [Text Block] | 8. STOCK WARRANTS Common Stock Warrants During March, 2013, the Company issued a total of 65,000 warrants to purchase common stock at an exercise price of $0.01 per share in connection with issuance of a convertible note payable to Coventry. The warrants expired on March 22, 2018. On September 3, 2013 and September 12, 2013, the Company issued 500,000 and 375,000 warrants, respectively, to purchase common stock at an exercise price of $0.025 and $0.01 per share in connection with issuances of convertible notes payable to Coventry. The warrants expired on September 3, 2018 and September, 12, 2018, respectively. On March 31, 2017, in connection with the issuance of an $80,000 Note, we granted three-year warrants to purchase an aggregate of 6,000,000 shares of our common stock at an exercise price of $0.005 per share. The warrants were valued at their fair value of $1,203 and $977 using the Black-Scholes method on June 30, 2019 and December 31, 2018. The warrants expire on March 30, 2020. On March 3, 2016, in connection with the issuance of a convertible note, we granted five-year warrants to purchase an aggregate of 2,500,000 shares of our common stock at an exercise price of $0.03 per share. The warrants were valued at their fair value of $731 and $491 using the Black-Scholes method at June 30, 2019 and December 31, 2018. The warrants expire on March 3, 2021. On April 4, 2016, in connection with the issuance of convertible notes, we granted three-year warrants to purchase an aggregate of 4,000,000 shares of our common stock at an exercise price of $0.05 per share. The warrants were valued at their fair value of $0 using the Black-Scholes method at June 30, 2019 and December 31, 2018. The warrants expired on April 4, 2019. During April, 2014, the Company issued a total of 100,000 warrants to purchase common stock at an exercise price of $0.025 per share in connection with issuance of a convertible note payable to Coventry. The warrants were valued at their fair value of $0 using the Black-Scholes method at June 30, 2019 and December 31, 2018. The warrants expired on April 9, 2019. During February 2019, the Company granted the total of 110,000,000 warrants to purchase common stock at an exercise price of $0.001 per share in connection with issuance of three convertible notes. The warrants were valued at $8,147 using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. The warrants expire in August 2019. A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the six months ended June 30, 2019 and the year ended December 31, 2018: Number Of shares Weighted average Balance December 31, 2017 13,540,000 $ 0.023 Exercised - - Issued - - Forfeited (940,000) 0.015 Balance December 31, 2018 12,600,000 $ 0.026 Exercised - - Issued 110,000,000 0.001 Forfeited (4,100,000) 0.021 Balance June 30, 2019 118,500,000 $ 0.01 The following table summarizes information about fixed-price warrants outstanding as of June 30, 2019 and December 31, 2018 : Exercise Price Weighted Average Number Outstanding Weighted Average Weighted Average Exercise Price June 30, 2019 $ 0.001-0.03 86,233,702 0.55 years $ 0.01 December 31, 2018 $ 0.005-0.05 12,600,000 1.11 years $ 0.026 At June 30, 2019, the aggregate intrinsic value of all warrants outstanding and expected to vest was $0. The intrinsic value of warrant share is the difference between the fair value of our restricted common stock and the exercise price of such warrant share to the extent it is “in-the-money”. Aggregate intrinsic value represents the value that would have been received by the holders of in-the-money warrants had they exercised their warrants on the last trading day of the year and sold the underlying shares at the closing stock price on such day. The intrinsic value calculation is based on the $0.0004, closing stock price of our restricted common stock on June 28, 2019. There were no in-the-money warrants at June 30, 2019. |
ACCRUED EXPENSES
ACCRUED EXPENSES | 6 Months Ended |
Jun. 30, 2019 | |
Payables and Accruals [Abstract] | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 9. ACCRUED EXPENSES Accrued expenses consisted of the following: June 30, December 31, 2018 Accrued consulting fees $ 192,050 $ 161,550 Accrued settlement expenses 315,000 347,400 Accrued payroll taxes 144,093 120,182 Accrued interest 217,972 180,509 Accrue others 18,833 22,208 Total $ 887,948 $ 831,849 |
PREPAID EXPENSES AND OTHER CURR
PREPAID EXPENSES AND OTHER CURRENT ASSETS | 6 Months Ended |
Jun. 30, 2019 | |
Prepaid Expenses [Abstract] | |
Prepaid Expenses [Text Block] | 10. PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consist of the following: June 30, December 31, Supplier advances for future purchases $ 221,759 $ 200,911 Reserve for supplier advances (200,911) (200,911) Net supplier advances 20,848 - Prepaid professional fees - 13,000 Deferred stock compensation 23,500 50,000 Total $ 44,348 $ 63,000 We performed an evaluation of our inventory and related accounts at June 30, 2019 and December 31, 2018, and increased the reserve on supplier advances for future venom purchases by $0 and $47,757, respectively. At June 30, 2019 and December 31, 2018, the total valuation allowance for prepaid venom is $200,911. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 6 Months Ended |
Jun. 30, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | 11. COMMITMENTS AND CONTINGENCIES Operating Leases In February 2016, we entered into our current three-year operating lease for monthly payments of approximately $3,200 which expired in February 2019. The lease is currently month-to-month, thus classified as short-term and not reported on the balance sheet under ASC 842. ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year. June 30, Lease cost Operating lease cost $ 29,288 Short-term lease cost 33,776 Total lease cost $ 63,064 Balance sheet information Operating ROU Assets $ 251,887 Operating lease obligations, current portion 68,806 Operating lease obligations, non-current portion 181,379 Total operating lease obligations $ 250,185 Weighted average remaining lease term (in years) – operating leases 3.17 Weighted average discount rate-operating leases 8% Supplemental cash flow information related to leases were as follows, for the six months ended June 30, 2019: Cash paid for amounts included in the measurement of operating lease liabilities $ 46,211 Future minimum payments under these lease agreements are as follows: June 30, Total 2020 $ 86,345 2021 89,651 2022 93,122 2023 15,567 Total future lease payments $ 284,685 Less imputed interest 34,500 Total $ 250,185 Consulting Agreements During July 2015, we signed an agreement with a company to provide for consulting services for five years. In connection with the agreement, 500,000 shares of our restricted common stock and a one year 8% note of $50,000 were granted. The shares were valued at $0.18 per share. As the services provided were in dispute, the shares and note payable have not been issued as of June 30, 2019. We have accrued the $142,500 in accrued expense as of June 30, 2019 and December 31, 2018. During October 2015, the Company signed an agreement with a consultant for consulting services for a year. In connection with the agreement, 2,500,000 shares of the Company’s restricted common stock were granted and the Company was to make monthly cash payments of $3,000. As of December 31, 2016, the Company recorded an equity compensation charge of $31,750, however, only 1,000,000 of the shares have been issued. As of June 30, 2019 and December 31, 2018, $19,150 has been recorded in accrued expense to account for the 1,500,000 shares of common stock that have not been issued. Litigation Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc. On June 1, 2015, ReceptoPharm entered into a settlement agreement with Patricia Meding, a former officer and shareholder of ReceptoPharm. The settlement relates to a lawsuit filed by Ms. Meding against ReceptoPharm (Patricia Meding, et. al. v. ReceptoPharm, Inc. f/k/a Receptogen, Inc., Index No.: 18247/06, New York Supreme Court, Queens County) in which she claimed to own certain shares of ReceptoPharm stock and claimed to be owed amounts on a series of promissory notes allegedly executed in 2001 and 2002. The settlement agreement executed on June 1, 2015 provides that ReceptoPharm will pay Ms. Meding a total of $360,000 over 35 months. The first payment of $20,000 was made on July 1, 2015. A second payment of $20,000 was made on August 17, 2015 with 32 subsequent monthly $10,000 payments due on the 15th of every month thereafter. To date, ReceptoPharm has made all monthly payments due under the agreement. In the event of default on any of the payments due under the settlement agreement, the settlement amount would increase by an additional $200,000. As of December 31, 2018, all payments were made and the settlement is concluded. We have recorded $200,000 in gain on settlement of debt on the consolidated statements of operations upon payments in full in April 2018. Paul Reid et al. v. Nutra Pharma Corp. et al. On August 26, 2016, certain of former ReceptoPharm employees and a former ReceptoPharm consultant filed a lawsuit in the 17th Judicial Circuit in and for Broward County, Florida (Case No. CACE16–015834) against Nutra Pharma and Receptopharm to recover $315,000 allegedly owing to them under a settlement agreement reached in an involuntary bankruptcy action that was brought by the same individuals in 2012 and for payment of unpaid wages/breach of written debt confirms. Nutra Pharma and Receptopharm believe that the lawsuit is without merit, especially in light of gross misconduct by these former employees that was discovered after execution of the aforementioned settlement agreement. On October 9, 2020, the Court entered an Order denying the plaintiffs’ motion for summary judgment with respect to Count I of the Complaint (for alleged breach of the aforementioned settlement agreement), and the parties continue to engage in discovery regarding their respective claims and defenses. The case is currently set for trial during the period from May 10, 2021 to May 28, 2021, but it is unclear at this time with the ongoing COVID-19 pandemic (and the resultant cessation of jury trials in Broward County) whether the trial will proceed at that time. Get Credit Healthy, Inc. v. Nutra Pharma Corp. and Rik Deitsch, Case No. CACE 18-017055 On August 1, 2018, Get Credit Healthy, Inc. filed a lawsuit against the Company and Rik Deitsch (collectively the “Defendants”) in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-017055) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. Counsel for Get Credit Healthy, Inc. requested an early mediation conference in an attempt to resolve our dispute. We agreed to this request, and mediation took place on February 15, 2019. At December 31, 2018, we owed principal balance of $101,818 and accrued interest of $21,023. At mediation, Get Credit Healthy, Inc. claimed that the individual that breached the binding memorandum of understanding with the Company was never an owner of Get Credit Healthy, Inc., but rather, a close friend that encouraged Get Credit Healthy, Inc. to make the subject loan to the Company ultimately, the parties were able to reach a Confidential Settlement Agreement to resolve the dispute, and an Agreed Order was entered dismissing the lawsuit. The lawsuit was settled on February 15, 2019 for $104,000 with scheduled payments. The repayments were made in full as of November 2020 (See Note 6). CSA 8411, LLC v. Nutra Pharma Corp., Case No. CACE 18-023150 On October 12, 2018, CSA 8411, LLC filed a lawsuit against the Company in the 17th Judicial Circuit Court in and for Broward County, Florida (Case No. CACE 18-023150) to recover $100,000 allegedly owed under an amended promissory note dated April 12, 2017. On November 1, 2018, the Company filed its Answer and Affirmative Defenses to the Complaint. The Company believes that this lawsuit is without merit. Moreover, the Company believes that it has a number of valid defenses to this claim. Among other things, the owner of CSA 8411, LLC violated the terms of a Binding Memorandum of Understanding by failing to invest in the Company and fraudulently inducing the Company to enter into the subject amended promissory note (contrary to the Get Credit Healthy lawsuit discussed above, we are certain that this individual is the majority owner of CSA 8411, LLC). Opposing counsel reached out to schedule mediation, and mediation was set for June 21, 2019 in Plantation, FL however the mediation was unsuccessful. At June 30, 2019, we owed principal balance of $91,156 and accrued interest of $24,433 (See Note 6) if the defenses and our new claims are deemed to be of no merit. The Company also filed affirmative claims against the Plaintiff, its owner Dan Oran and several relate entities. The case has not been set for trial as of this date. Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus On September 28, 2018, the United States Securities and Exchange Commission (the “SEC”) filed a lawsuit in the United States District Court for the Eastern District of New York (Case No. 2:18-cv-05459) against the Company, Mr. Deitsch, and Mr. McManus. The lawsuit alleges that, from July 2013 through June 2018, the Company and the other defendants’ defrauded investors by making materially false and misleading statements about the Company and violated anti-fraud and other securities laws. The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief. On May 29, 2019 (following each of the defendants filing motions to dismiss), the SEC filed a First Amended Complaint which generally alleged the same conduct as its original Complaint, but accounted for certain guidance provided by the United States Supreme Court in a case that had been recently decided. Each of the defendants then moved to dismiss the SEC’s First Amended Complaint. On March 31, 2020, the Court entered an Order granting in part and denying in part the various motions to dismiss. Following that Order, the SEC filed a Second Amended Complaint (the operative pleading) and the defendants have filed their answers which generally deny liability. At this time, discovery is closed and the SEC has indicated an intent to file a summary judgment motion regarding certain non-fraud claims asserted in its Second Amended Complaint. The defendants have opposed the SEC’s request to file such motion(s). The Court conducted a hearing on February 23, 2021 and set an initial briefing schedule for the SEC’s Motion for Partial Summary Judgment wherein the Plaintiffs’ Motion for Partial Summary Judgment was due on April 5, 2021, the Defendants’ Consolidated (i.e., collectively, Nutra Pharma Corporation, Erik “Rik” Deitsch, and Sean McManus) Response Brief to the SEC’s Motion is due May 3, 2021, and the Plaintiffs’ Reply Brief is due on May 19, 2021. On March 23, 2021, the Plaintiff filed a Motion for Extension of Time to file the Motion for Partial Summary Judgment. On March 24, 2021, the Court entered an order granting the Motion for Extension of Time and modified the briefing schedule as follows: Plaintiffs’ Motion is due on or before April 9, 2021, the Defendants’ Response is due on or before May 7, 2021, and the Plaintiffs’ Reply is due on or before May 21, 2021. The Company disputes the allegations in this lawsuit and continues to vigorously defend against the SEC’s claims. Mr. Deitsch and Mr. McManus have similarly defended the lawsuit since its filing and each contest liability. The Company does not believe that it engaged in any fraudulent activity or made any material misrepresentations concerning the Company and/or its products. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 6 Months Ended |
Jun. 30, 2019 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | 12. SUBSEQUENT EVENTS Convertible Notes Payable The convertible promissory notes to unrelated third parties for a total of $55,000 with original issuance discount of $5,000 issued in February 2019 were due in August 2019. During December 2019, $22,000 of the Note was amended to extend the maturity date to June 2020. During August 2020, $38,500 of the Notes was amended with additional original issuance discount of $7,550 due February 2021. During October 2020, $16,500 of the Notes was amended with additional original issuance discount of $1,650 due April 2021.The Noteholders have the right to convert the note into shares of Common Stock at a conversion price of $0.0005. In connection with the issuance of amended convertible notes, the Company granted the following warrants at an exercise price of $0.001 per share. The warrants were valued using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. No warrants have been exercised. Month of Issuance Number of Fair Value of Month of Expiration Warrants Warrants December, 2019 44,000,000 7,370 August, 2020 August, 2020 92,100,000 22,879 August, 2021 October, 2020 39,930,000 9,497 October, 2022 During January 2020 through February 2020, the Note holder received a total of 500,000,000 shares of our restricted common stock in satisfaction the $175,000 of the Note originated in February 2019 with a fair value of $425,000. . During February through March 2021, the Note holder received a total of 205,080,000 shares of our restricted common stock in satisfaction the $102,540 of the Note with a fair value of $2,100,612. The remaining balance of $19,373 is due September 2022. Date Number of Fair Value of shares converted Debt Converted 1/21/2020 250,000,000 150,000 2/18/2020 250,000,000 275,000 2/25/2021 137,700,000 1,500,930 3/3/2021 67,380,000 599,682 During November 2019, we issued a convertible promissory note to an unrelated third party for $137,500 with original issuance discount of $12,500. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.000275. The Note is in default and negotiation of settlement. During December 2019, we issued a convertible promissory note to an unrelated third party for $22,000 with original issuance discount of $2,000. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0002. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature (BCF) in the amount of $20,000. The BCF was recorded as a debt discount that was amortized over the life of the notes. The Note is in default and negotiation of settlement. During January and March 2020, we issued convertible promissory notes to an unrelated third party for a total of $68,750 with original issuance discount of $6,250. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $5,500. The BCF was recorded as a debt discount that was amortized over the life of the notes. The Notes were due in January and March 2021. The Notes are in default and negotiation of settlement. During February and March 2020, we issued convertible promissory notes to an unrelated third party for a total of $22,000 with original issuance discount of $2,000. The notes were due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0003. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $20,000. The BCF was recorded as a debt discount that was amortized over the life of the notes. The Notes are in default and negotiation of settlement. During March 2020, we issued a convertible promissory note to an unrelated third party for $5,500 with original issuance discount of $500. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0002. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $5,000. The BCF was recorded as a debt discount that was amortized over the life of the notes. The Note is in default and negotiation of settlement. During March 2020, we issued a convertible promissory note to an unrelated third party for $5,500 with original issuance discount of $500. The note was due six months from the execution and funding of the notes. The Noteholder had the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $3,300. The BCF was recorded as a debt discount that was amortized over the life of the notes. The Note is in default and negotiation of settlement. During August 2020, we issued a convertible promissory note to an unrelated third party for a $22,000 with original issuance discount of $2,000. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $13,200. The BCF was recorded as a debt discount that was amortized over the life of the notes. The note is due August 2021. During July 2020, we issued a convertible promissory note to an unrelated third party for $20,900 with original issuance discount of $1,900. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.00052. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $15,273. The BCF was recorded as a debt discount that was amortized over the life of the notes. The note was due January 2021. The Note is in default and negotiation of settlement. During August 2020, we issued convertible promissory notes to an unrelated third party for $5,500 with original issuance discount of $500. The Noteholder has the right to convert the note into shares of Common Stock at a fixed conversion price of $0.0005. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a BCF in the amount of $1,100. The BCF was recorded as a debt discount that was amortized over the life of the notes. The note was due February 2021. The Note is in default and negotiation of settlement. During November 2020, the Note holder assigned $20,000 of the $75,900 convertible note restated in January 2019 to a third party. The third party subsequently received a total of 100,000,000 shares of our restricted common stock in satisfaction the $20,000 of the Note with a fair value of $120,000. PPP Loan During May 2020, we entered into a long-term loan agreement with the U. S. Small Business Administration for a Payroll Protection Program (PPP) loan, for $64,895 with an annual interest rate of one percent (1%), with a term of twenty-four (24) months, whereby a portion of the loan proceeds have been used for certain labor costs, office rent costs and utilities, which may be subject to a loan forgiveness, pursuant to the terms of the SBA/PPP program. Economic Injury Disaster Loan During April and June 2020, the Company executed the standard loan documents required for securing a loan from the SBA under its Economic Injury Disaster Loan assistance program (the “EIDL Loan”) considering the impact of the COVID-19 pandemic on the Company’s business. Pursuant to the Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL Loan was $154,900, with proceeds to be used for working capital purposes. Interest accrues at the rate of 3.75% per annum. Installment payments, including principal and interest, are due twelve months from the date of the SBA Loan Agreement in the amount of $731. The balance of principal and interest is payable over a 360 month period from the date of the SBA Loan Agreement. In connection therewith, the Company received a $5,000 advance, which does not have to be repaid. The SBA requires that the Company collateralize the loan to the maximum extent up to the loan amount. If business fixed assets do not “fully secure” the loan the lender may include trading assets (using 10% of current book value for the calculation), and must take available equity in the personal real estate (residential and investment) of the principals as collateral. Restatement of Promissory Notes During September 2019, the Notes of $282,983 plus accrued interest amended in December 2018 were restated. The restated principal balance of $333,543 were due September 2020. In connection with this restated note, we issued 20,000,000 shares of our common stock. The common stock was valued at $5,090 and recorded as a debt discount that was amortized over the life of the note. The Note is in default and negotiation of settlement. During September 2019, the Note of $36,000 with original issuance discount of $6,000 amended in September 2018 was restated. The $6,000 original issuance discount from the Note amended in September 2018 has been repaid in full as of September 2019. The restated principal balance was $36,000 with the original issuance discount of $6,000 and was due September 2020. The $6,000 original issuance discount from the Note amended in September 2019 has been repaid in full as of September 2020. The Note was further restated in September 2020. The restated principal balance was $36,000 with the original issuance discount of $6,000 and is due March 2021. The Note is in default and negotiation of settlement. During January 2020, the Note of $60,000 with original issuance discount of $10,000 amended in November 2018 and the Note of $88,225 plus accrued interest at a rate of 2.5% monthly to an unrelated third party were combined and restated. The restated principal balance was $148,225 that carries interest at a rate of 2.0% monthly due July 2020. During July 2020, the restated Note of $148,225 plus accrued interest of $18,701 was further restated. The new principal balance was $166,926 that carries interest at a rate of 2.0% monthly and was due January 2021. During February 2021, we issued 29,072,500 shares of common stock to satisfy the accrued interest of $23,258 with fair value of $343,056. The settlement of accrued interest resulted in a loss on settlement of debt in other income for $319,798. The principal balance of $166,926 was further restated. The restated balance is $183,619 with an original issuance discount of $16,693 and is due August 2021. Settlement of Convertible Promissory Notes During August 2019, the Note of $12,000 with original issuance discount of $2,000 originated in December 2019 was settled for $12,000 with scheduled payments through December 1, 2019. In connection with this settlement, we issued 1,500,000 shares of common stocks with a fair value of $450. Repayment of $3,500 was made as of December 2020. The remaining balance of $8,500 is in default and in negotiation of settlement. During December 2019, two Notes for a total of $9,900 with original issuance discount of $900 originated in February 2018 were settled with 40,000,000 shares of common stocks. The shares were valued at fair value of $24,000. During December 2019, three Notes for a total of $49,684 with original issuance discount of $2,700 originated in May 2017, January and September 2018, respectively, were settled with 260,000,000 shares of common stocks. The shares were valued at fair value of $130,000. During December 2019, two Notes for a total of $46,500 originated in October and November 2018 and the accounts payable of $39,000 for consulting fees were settled with 500,000,000 shares of common stocks. The shares were valued at fair value of $300,000, and have not been issued. During February through August 2018, we issued seven convertible promissory notes to an unrelated third party due one year from the execution dates. The principal balance of these Notes on June 30, 2019 was $511,319. During September 2020, a Note holder received a total of 107,133,333 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,140. During October 2020, the Note holder received a total of 107,817,770 shares of our restricted common stock in satisfaction of the principal balance of $22,000 and accrued interest of $10,345. During October 2020, the Note holder sold the remaining debt of $467,000 and accrued interest of $166,168 for $250,000 to a non-related party. Date Number of Fair Value of shares converted Debt Converted 9/22/2020 107,133,333 $171,413 10/5/2020 107,817,770 64,691 Settlement and Restatement of Promissory Notes During March 2020, $50,000 of the Note of $120,000 with original issuance discount of 20,000 originated in November 2017 was settled for 125,000,000 shares. An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $119,700. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. Settlement of a Related-Party Note During June 2020, the Note of $14,400 with original issuance discount of $2,400 to a related party amended in December 2018 was settled with cash payment of $14,400 and 5,000,000 shares of common stocks. The shares were valued at fair value of $3,000. Advances During the periods from October 2019 through May 2020, the Company received a total of $175,000 in deposits from a third party in connection with a Joint Venture proposal. The deposits were considered as payments towards the purchase of equity in the joint venture. The joint venture is currently on hold pending the outcome of the lawsuit with the SEC. Common Stock Issued for Default Payments During August 2019, we issued a total of 2,000,000 additional restricted shares to the two Note holders due to default on repayments. These shares were valued at fair value of $700. During July 2019, we issued a total of 5,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $282,983 plus accrued interest amended in December 2018. The shares were valued at fair value of $1,500. During September 2019, we issued a total of 10,000,000 restricted shares to a Note holder due to the default on repayments of the original issuance discount of $10,000 for the convertible promissory notes of $60,000 amended in November 2018. The shares were valued at fair value of $4,000. During January 2020, we issued a total of 75,000,000 restricted shares to a Note holder due to the default on repayments of the convertible promissory note of a total of $148,225 amended in August and November 2018. The shares were valued at fair value of $45,000. During July 2020, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $22,000 originated in December 2019. The shares were valued at fair value of $700. During September 2020, we issued a total of 10,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $333,543 plus accrued interest amended in September 2019. The shares were valued at fair value of $6,000. During October 2020, we issued a total of 1,500,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $84,000 amended in March 2020. The shares were valued at fair value of $900. During January 2021, we issued a total of 25,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $166,926 amended in July 2020. The shares were valued at fair value of $107,500. During July 2019, we issued a total of 5,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $282,983 plus accrued interest amended in December 2018. The shares were valued at fair value of $1,500. During September 2019, we issued a total of 10,000,000 restricted shares to a Note holder due to the default on repayments of the original issuance discount of $10,000 for the convertible promissory notes of $60,000 amended in November 2018. The shares were valued at fair value of $4,000. During January 2020, we issued a total of 75,000,000 restricted shares to a Note holder due to the default on repayments of the convertible promissory note of a total of $148,225 amended in August and November 2018. The shares were valued at fair value of $45,000. During July 2020, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $22,000 originated in December 2019. The shares were valued at fair value of $700. During September 2020, we issued a total of 10,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $333,543 plus accrued interest amended in September 2019. The shares were valued at fair value of $6,000. During October 2020, we issued a total of 1,500,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $84,000 amended in March 2020. The shares were valued at fair value of $900. During January 2021, we issued a total of 25,000,000 restricted shares to a Note holder due to the default on repayments of the promissory note of $166,926 amended in July 2020. The shares were valued at fair value of $107,500. |
Accounting Policies, by Policy
Accounting Policies, by Policy (Policies) | 6 Months Ended |
Jun. 30, 2019 | |
Accounting Policies, by Policy (Policies) [Line Items] | |
Business Description and Accounting Policies [Text Block] | Organization Nutra Pharma Corp. (“Nutra Pharma”), is a holding company that owns intellectual property and operates in the biotechnology industry. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Through its wholly-owned subsidiary, ReceptoPharm, Inc. (“ReceptoPharm”), Nutra Pharma conducts drug discovery research and development activities. In October 2009, Nutra Pharma launched its first consumer product called Cobroxin ® ® ® |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | Basis of Presentation and Consolidation The Unaudited Condensed Consolidated Financial Statements and notes are presented in accordance with the rules and regulations of the Securities and Exchange Commission and do not contain certain information included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and are of a normal, recurring nature. Interim results are not necessarily indicative of results for a full year. Therefore, the interim Unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and notes thereto contained in the Company’s Annual Report on Form 10-K. The accompanying Unaudited Condensed Consolidated Financial Statements include the results of Nutra Pharma and its wholly-owned subsidiaries Designer Diagnostics Inc. and ReceptoPharm (collectively “the Company”, “us”, “we” or “our”). We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation. |
Reclassification, Comparability Adjustment [Policy Text Block] | Reclassification of Prior Year Presentation Reclassification occurred to certain prior year amounts in order to conform to the current year classifications. The reclassifications have no effect on the reported net loss. |
Restatement of Prior Period Presentation [Policy Text Block] | Restatement of Prior Period Presentation Certain prior period amounts have been restated. Restatements have been made for the three and six months ended June 30, 2018 to correct the change in the fair value of convertible notes and to record a gain on settlement of debt and accounts payable. As a result of these changes, the following occurred: 1. Net loss for the three months ended June 30, 2018 decreased by $19,143 ($0.00 per share) (see table below). 2. Net loss for the six months ended June 30, 2018 decreased by $3,110,017 ($0.00 per share) (see table below). 3. At June 30, 2018, there was no change to total stockholders' deficit but additional paid-in capital and accumulated deficit decreased by $3,110,017. 4. Certain amounts in cash flows from operating activities were updated for the six months ended June 30, 2018, but there was no change to the total net cash used in operating activities in the Unaudited Condensed Consolidated Statements of Cash Flows. For the Three Months Amounts Amounts Adjustments Decrease in Net Loss Change in fair value of convertible notes and derivatives $ (849,376) $ (868,519) $ 19,143 Net effect of restatement on net loss $ 19,143 For the Six Months Amounts Amounts Adjustments Decrease in Net Loss Change in fair value of convertible notes and derivatives $ (1,982,864) $ (4,344,235) $ 2,361,371 Gain on settlement of debt and accounts payable 768,323 19,677 748,646 Net effect of restatement on net loss $ 3,110,017 |
Liquidity and Going Concern [Policy Text Block] | Liquidity and Going Concern Our Unaudited Condensed Consolidated Financial Statements are presented on a going concern basis, which contemplate the realization of assets and satisfaction of liabilities in the normal course of business. We have experienced recurring, significant losses from operations, and have an accumulated deficit of $63,341,492 at June 30, 2019. In addition, we have a significant amount of indebtedness in default, a working capital deficit of $7,622,011 and a stockholders’ deficit of $7,652,158 at June 30, 2019. There is substantial doubt regarding our ability to continue as a going concern which is contingent upon our ability to secure additional financing, increase ownership equity and attain profitable operations. In addition, our ability to continue as a going concern must be considered in light of the problems, expenses and complications frequently encountered in established markets and the competitive environment in which we operate. We do not have sufficient cash to sustain our operations for a period of twelve months from the issuance date of this report and will require additional financing in order to execute our operating plan and continue as a going concern. Since our sales are not currently adequate to fund our operations, we continue to rely principally on debt and equity funding; however, proceeds from such funding have not been sufficient to execute our business plan. Our plan is to attempt to secure adequate funding until sales of our pain products are adequate to fund our operations. We cannot predict whether additional financing will be available, and/or whether any such funding will be in the form of equity, debt, or another form. In the event that these financing sources do not materialize, or if we are unsuccessful in increasing our revenues and profits, we will be unable to implement our current plans for expansion, repay our obligations as they become due and continue as a going concern. The accompanying Unaudited Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. |
Impact of COVID-19 [Policy Text Block] | Impact of COVID-19 on our Operations The ramifications of the outbreak of the novel strain of COVID-19, reported to have started in December 2019 and spread globally, are filled with uncertainty and changing quickly. Our operations have continued during the COVID-19 pandemic and we have not had significant disruption. Beginning in June 2020, the Company experienced a delay in retail rollout as a downstream implication of the slowing economy. We also closed our Coral Springs office in effort to save money. During May 2020, we received approval from SBA to fund our request for a PPP loan for $64,895 (See Note 12). During April and June 2020, we obtained a loan in the amount of $154,900 from the SBA under its Economic Injury Disaster Loan assistance program. We intended to use the proceeds primarily for working capital purpose (See Note 12). The Company is operating in a rapidly changing environment so the extent to which COVID-19 impacts its business, operations and financial results from this point forward will depend on numerous evolving factors that the Company cannot accurately predict. Those factors include the following: the duration and scope of the pandemic; governmental, business and individuals’ actions that have been and continue to be taken in response to the pandemic; and the development of widespread testing or a vaccine. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The accompanying Unaudited Condensed Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States of America which require management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense. Significant estimates include our ability to continue as going concern, the recoverability of inventories and long-lived assets, the recoverability of amounts due from officer, the valuation of stock-based compensation and certain debt and warrant liabilities, recognition of loss contingencies and deferred tax valuation allowances. Actual results could differ from those estimates. Changes in facts and circumstances may result in revised estimates, which would be recorded in the period in which they become known. |
Revenue Recognition, Dividends [Policy Text Block] | Revenue from Contracts with Customers On January 1, 2018, we adopted Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) Topic 606, "Revenue from Contracts with Customers" Our revenues are primarily derived from customer orders for the purchase of our products. We recognize revenues as performance obligations are fulfilled upon delivery of products. We record revenues net of promotions and discounts. For certain product sales to a distributor, we record revenue including a portion of the cash proceeds that is remitted back to the distributor. |
Shipping and Handling Cost, Policy [Policy Text Block] | Accounting for Shipping and Handling Costs We account for shipping and handling as fulfillment activities and record shipping and handling costs incurred within revenue. |
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] | Accounts Receivable and Allowance for Doubtful Accounts We grant credit without collateral to our customers based on our evaluation of a particular customer’s credit worthiness. Accounts receivable are due 30 days after the issuance of the invoice. In addition, allowances for doubtful accounts are maintained for potential credit losses based on the age of the accounts receivable and the results of periodic credit evaluations of our customers’ financial condition. Accounts receivable are written off after collection efforts have been deemed to be unsuccessful. Accounts written off as uncollectible are deducted from the allowance for doubtful accounts, while subsequent recoveries are netted against the provision for doubtful accounts expense. We generally do not charge interest on accounts receivable. We use third party payment processors and are required to maintain reserve balances, which are included in accounts receivables. Accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. Management believes that the receivables are fully collectable. Therefore, no allowance for doubtful account is deemed to be required at June 30, 2019 and December 31, 2018. |
Inventory, Policy [Policy Text Block] | Inventories Inventories, which are stated at the lower of average cost or net realizable value, consist of packaging materials, finished products, and raw venom that is utilized to make the API (active pharmaceutical ingredient). The raw unprocessed venom has an indefinite life for use. The Company regularly reviews inventory quantities on hand. If necessary, it records a net realizable value adjustment for excess and obsolete inventory based primarily on its estimates of product demand and production requirements. Write-downs are charged to cost of goods sold. We performed an evaluation of our inventory and related accounts at June 30, 2019 and December 31, 2018, and increased the reserve on supplier advances for future venom purchases included in the prepaid expenses and other current assets by $0 and $47,757, respectively. At June 30, 2019 and December 31, 2018, the total valuation allowance for prepaid venom is $200,911. |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Financial Instruments and Concentration of Credit Risk Our financial instruments include cash, accounts receivable, accounts payable, accrued expenses, loans payable, due to officers and derivative financial instruments. Other than certain warrant and convertible instruments (derivative financial instruments) and liabilities to related parties (for which it was impracticable to estimate fair value due to uncertainty as to when they will be satisfied and a lack of similar type transactions in the marketplace), we believe the carrying values of our financial instruments approximate their fair values because they are short term in nature or payable on demand. Our derivative financial instruments are carried at a measured fair value. Balances in various cash accounts may at times exceed federally insured limits. We have not experienced any losses in such accounts. We do not hold or issue financial instruments for trading purposes. In addition, for the three months ended June 30, 2019, there was one customer that accounted for 27% of the total revenues. For the three months ended June 30, 2018, there was one customer that accounted for 45% of the total revenues. For the six months ended June 30, 2019, there were two customers that accounted for 25% and 49% of the total revenues, respectively. For the six months ended June 30, 2018, there was one customer that accounted for 22% of the total revenues. As of June 30, 2019 and December 31, 2018, 100% and 84% of the accounts receivable balance are reserves due from two payment processors. |
Operating Lease Right-of-Use Asset and Liabilty [Policy Text Block] | Operating Lease Right-of-Use Asset and Liability In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases” (Topic 842), as amended (“ASC Topic 842”). The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classify as either operating or finance leases. We adopted this standard effective January 1, 2019 using the modified retrospective approach for all leases entered into before the effective date. Adoption of the ASC Topic 842 had a significant effect on our balance sheet resulting in increased non-current assets and increased current and non-current liabilities. There was no impact to retained earnings upon adoption of the new standard. We did not have any finance leases (formerly referred to as capital leases prior to the adoption of ASC Topic 842), therefore there was no change in accounting treatment required. For comparability purposes, the Company will continue to comply with the previous disclosure requirements in accordance with the existing lease guidance and prior periods are not restated. The Company elected the package of practical expedients as permitted under the transition guidance, which allowed us: (1) to carry forward the historical lease classification; (2) not to reassess whether expired or existing contracts are or contain leases; and, (3) not to reassess the treatment of initial direct costs for existing leases. In accordance with ASC Topic 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether we obtain the right to substantially all the economic benefit from the use of the asset, and whether we have the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. Lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected lease term. The implicit rate within our operating leases are generally not determinable and, therefore, the Company uses the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company’s incremental borrowing rate requires judgment. The Company determines the incremental borrowing rate for each lease using our estimated borrowing rate. For periods prior to the adoption of ASC Topic 842, the Company recorded rent expense based on the term of the related lease. The expense recognition for operating leases under ASC Topic 842 is substantially consistent with prior guidance. As a result, there are no significant differences in our results of operations presented. The impact of the adoption of ASC 842 on the balance sheet was: As reported Adoption of ASC 842 – increase (decrease) Balance January 1, Operating lease right-of-assets $ - $ 281,175 $ 281,175 Total assets $ 141,417 $ 281,175 $ 422,592 Operating lease liabilities, current portion $ - $ 64,573 $ 64,573 Operating lease liabilities, net of current portion $ - $ 216,602 $ 216,602 Total liabilities $ 6,078,010 $ 281,175 $ 6,359,185 Total liabilities and stockholders’ equity $ 141,417 $ 281,175 $ 422,592 |
Derivatives, Reporting of Derivative Activity [Policy Text Block] | Derivative Financial Instruments Management evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based simple derivative financial instruments, the Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. We do not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks |
Debt, Policy [Policy Text Block] | Convertible Debt For convertible debt that does not contain an embedded derivative that requires bifurcation, the conversion feature is evaluated to determine if the rate of conversion is below market value and should be categorized as a beneficial conversion feature ("BCF"). A BCF related to debt is recorded by the Company as a debt discount and with the offset recorded to equity. The related convertible debt is recorded net of the discount for the BCF. The discount is amortized as additional interest expense over the term of the debt with the resulting debt discount being accreted over the term of the note. |
Fair Value Measurement, Policy [Policy Text Block] | The Fair Value Measurement Option We have elected the fair value measurement option for convertible debt with embedded derivatives that require bifurcation, and record the entire hybrid financing instrument at fair value under the guidance of ASC Topic 815, Derivatives and Hedging |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment and Long-Lived Assets Property and equipment is recorded at cost. Expenditures for major improvements and additions are added to property and equipment, while replacements, maintenance and repairs which do not extend the useful lives are expensed. Depreciation is computed using the straight-line method over the estimated useful lives of the assets of 3 – 7 years. |
Income Tax, Policy [Policy Text Block] | Income Taxes The Company recorded no income tax expense for the six months ended June 30, 2019 and 2018 because the estimated annual effective tax rate was zero. As of June 30, 2019, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized |
Stockholders' Equity, Policy [Policy Text Block] | Stock-Based Compensation We account for stock-based compensation in accordance with FASB ASC Topic 718, Stock Compensation |
Earnings Per Share, Policy [Policy Text Block] | Net Loss Per Share Net loss per share is calculated in accordance with FASB ASC Topic 260, Earnings per Share June 30, 2019 June 30, 2018 Options and warrants 118,500,000 13,475,000 Convertible notes payable 7,050,986,979 1,625,457,403 Total 7,169,486,979 1,638,932,403 |
Accounting Standards Update 2018-07 [Member] | |
Accounting Policies, by Policy (Policies) [Line Items] | |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In June 2018, the FASB issued ASU 2018-07, “Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). ASU No 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance also specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. This guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and is effective for the Company as of January 1, 2019. The Company noted that all share based payments were settled as of the date of the adoption, so there was no impact on the Company's financial statements. All other newly issued accounting pronouncements but not yet effective have been deemed either immaterial or not applicable |
BASIS OF PRESENTATION AND SUM_2
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Accounting Policies [Abstract] | |
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] | For the Three Months Amounts Amounts Adjustments Decrease in Net Loss Change in fair value of convertible notes and derivatives $ (849,376) $ (868,519) $ 19,143 Net effect of restatement on net loss $ 19,143 For the Six Months Amounts Amounts Adjustments Decrease in Net Loss Change in fair value of convertible notes and derivatives $ (1,982,864) $ (4,344,235) $ 2,361,371 Gain on settlement of debt and accounts payable 768,323 19,677 748,646 Net effect of restatement on net loss $ 3,110,017 |
Accounting Standards Update and Change in Accounting Principle [Table Text Block] | The impact of the adoption of ASC 842 on the balance sheet was: As reported Adoption of ASC 842 – increase (decrease) Balance January 1, Operating lease right-of-assets $ - $ 281,175 $ 281,175 Total assets $ 141,417 $ 281,175 $ 422,592 Operating lease liabilities, current portion $ - $ 64,573 $ 64,573 Operating lease liabilities, net of current portion $ - $ 216,602 $ 216,602 Total liabilities $ 6,078,010 $ 281,175 $ 6,359,185 Total liabilities and stockholders’ equity $ 141,417 $ 281,175 $ 422,592 |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | As of June 30, 2019 and 2018, the following items were not included in dilutive loss as the effect is anti-dilutive: June 30, 2019 June 30, 2018 Options and warrants 118,500,000 13,475,000 Convertible notes payable 7,050,986,979 1,625,457,403 Total 7,169,486,979 1,638,932,403 |
FAIR VALUE MEASUREMENTS (Tables
FAIR VALUE MEASUREMENTS (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Fair Value Disclosures [Abstract] | |
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] | The following table summarizes our financial instruments measured at fair value at June 30, 2019 and December 31, 2018: Fair Value Measurements at June 30, 2019 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,934 $ - $ - $ 1,934 Convertible notes at fair value $ 2,821,182 $ - $ - $ 2,821,182 Fair Value Measurements at December 31, 2018 Liabilities: Total Level 1 Level 2 Level 3 Warrant liability $ 1,468 $ - $ - $ 1,468 Convertible notes at fair value $ 1,156,341 $ - $ - $ 1,156,341 |
Fair Value Measurements, Nonrecurring [Table Text Block] | The following table shows the changes in fair value measurements for the warrant liability using significant unobservable inputs (Level 3) during the six months ended June 30, 2019 and the year ended December 31, 2018: Description June 30, December 31, Beginning balance $ 1,468 $ 5,903 Total (gain) loss included in earnings (1) 466 (4,435) Ending balance $ 1,934 $ 1,468 (1) The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. We valued our warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 1.75% to 2.81% risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 256%-305% (4) zero expected dividends (5) exercise price set forth in the agreements (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted. |
Debentures [Table Text Block] | The following table summarizes assumptions and the significant terms of the convertible notes for which the entire hybrid instrument is recorded at fair value at June 30, 2019 and December 31, 2018: Conversion Price - Lower of Fixed Debenture Face Interest Default Discount Anti-Dilution % of stock price for look-back period Look-back June 30, 2019 $1,066,479 8%-20% 18%-24% 23.95-27.95 $0.00015-$0.05 50%-60% 3 to 25 Days December 31, 2018 $1,566,433 8%-12% 18%-20% 25.95-27.95 $0.0002-$0.20 40%-60% 3 to 25 Days |
Convertible Debt [Table Text Block] | The following table shows the changes in fair value measurements for the convertible notes at fair value using significant unobservable inputs (Level 3) during the six months ended June 30, 2019 and the year ended December 31, 2018: Description June 30, 2019 December 31, 2018 Beginning balance $ 1,156,341 $ 1,925,959 Purchases and issuances 535,779 472,029 Day one loss on value of hybrid instrument (1) 671,476 2,021,041 Loss from change in fair value (1) 732,586 130,344 Gain on settlement - (958,581) Conversion to common stock (275,000) (2,434,451) Ending balance $ 2,821,182 $ 1,156,341 (1) The losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
INVENTORIES (Tables)
INVENTORIES (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventory, Current [Table Text Block] | Inventories are valued at the lower of cost or net realizable value on an average cost basis. At June 30, 2019 and December 31, 2018, inventories were as follows: June 30, December 31, 2018 Raw Materials $ 34,433 $ 33,431 Finished Goods 2,095 1,871 Total Inventories $ 36,528 $ 35,302 |
PROPERTY AND EQUIPMENT (Tables)
PROPERTY AND EQUIPMENT (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Property, Plant and Equipment [Abstract] | |
Property, Plant and Equipment [Table Text Block] | Property and equipment consists of the following at June 30, 2019 and December 31, 2018: June 30, December 31, 2018 Computer equipment $ 25,120 $ 25,120 Furniture and fixtures 34,757 34,757 Lab equipment 53,711 53,711 Telephone equipment 12,421 12,421 Office equipment – other 16,856 16,856 Leasehold improvements 73,168 73,168 Total 216,033 216,033 Less: Accumulated depreciation (207,743) (205,533) Property and equipment, net $ 8,290 $ 10,500 |
DEBTS (Tables)
DEBTS (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Debt Disclosure [Abstract] | |
Schedule of Debt [Table Text Block] | Debts consist of the following at June 30, 2019 and December 31, 2018: June 30, 2019 December 31, 2018 Note payable– Related Party (Net of discount of $1,200 and $2,400, $ 13,200 $ 12,000 Notes payable – Unrelated third parties (Net of discount of $1,000 1,387,877 1,469,690 Convertible notes payable – Unrelated third parties (Net of discount of 814,016 751,955 Convertible notes payable, at fair value (Net of discount of $44,694 and $0, respectively) (4) 2,776,488 1,156,341 Ending balances 4,991,581 3,389,986 Less: Long-term portion-Notes payable-Unrelated third parties $ (4,616) $ (51,410) Less: Long-term portion-Convertible Notes payable-Unrelated third parties (119,879) - Current portion $ 4,867,086 $ 3,338,576 (1) During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At June 30, 2019 and December 31, 2018, we owed this director accrued interest of $150,372 and $141,808. The interest expense for the six-months ended June 30, 2019 and 2018 was $8,564 and $7,611, respectively, and $4,368 and $3,882 for the three-months ended June 30, 2019 and 2018, respectively. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. At June 30, 2019 and December 31, 2018, the principal balance of the loan is $13,200 and $12,000, net of debt discount of $1,200 and $2,400, respectively. The Note was settled in June 2020. (2) At June 30, 2019 and December 31, 2018, the balance of $1,387,877 and $1,469,690 net of discount of $1,000 and $17,870, respectively, consisted of the following loans: ● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At June 30, 2019 and December 31, 2018, we owed principal balance of $169,634 and $192,974, and accrued interest of $45,456 and $40,033, respectively. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020 (See Note 11) ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2019 and December 31, 2018, the accrued interest is $3,242 and $2,739. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the outstanding principal balance is $50,000 and accrued interest is $43,834 and $37,801. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2019 and December 31, 2018, the outstanding principal balance is $50,000 and accrued interest is $37,033 and $31,000. ● In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest were restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest were restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018.The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest were restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and was due June 17, 2019. The note is in default and negotiation of settlement. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the six months ended June 30, 2019 and 2018 was $3,616 and $2,765, respectively. The debt discount at June 30, 2019 and December 31, 2018 was $0 and $3,616. At June 30, 2019 and December 31, 2018, the principal balance is $282,983, and the accrued interest is $36,977 and $2,830, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. In January 2019, the principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). The remaining note of $15,000 was assigned to an unrelated third party and is in negotiation of settlement. At June 30, 2019 and December 31, 2018, the principal balance is $15,000 and $75,000, and the accrued interest is $1,371 and $17,271, respectively. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the accrued interest is $33,333 and $27,300. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the accrued interest is $2,573 and $1,944. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of June 30, 2019. At December 31, 2017, the principal balance of the loan was $191,329 and in negotiation of settlement. During June 2018, the loan was settled for $170,402 with scheduled repayments of approximately $7,000 per month through July 2020. We recorded a gain on settlement of debt in other income for $20,927 in June 2018. The Company repaid $34,976 during 2018 and $13,848 during the six months ended June 30, 2019. At June 30, 2019 and December 31, 2018, the principal balance is $121,578 and $135,426. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the principal balance of the note is $50,000. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 each due in September 2019 and 2020, respectively. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and is due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the six months ended June 30, 2019 and 2018 was $5,000 and $1,500, respectively. The debt discount at June 30, 2019 and December 31, 2018 is $2,500 and $6,000. Repayments of $1,500 and $7,000 have been made during 2017 and 2018, respectively. During the six months ended June 30, 2019, repayment of $1,500 has been made. The Note is under personal guarantee by Mr. Deitsch. At June 30, 2019 and December 31, 2018, the principal balance of the note is $31,000 and $27,500, net of debt discount of $1,000 and $6,000, respectively. The note is in default and in negotiation of settlement. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment. The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the six months ended June 30, 2019 was $1,587 and $6,667. Amortization for the debt discount and original issuance discount was $3,616 and $4,617, respectively for the six months ended June 30, 2018. As of June 30, 2019 and December 31, 2018, the amount due is $70,000 and $61,746, net of discount of $0 and $8,254. During January and July 2020, this Note and the Note of $76,076 amended in August 2018(See Note 6(3)) were combined and restated and was due January 2021. The Note is in negotiation of restatement. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. 1,500,000 shares of common stocks were issued due to the default of repayments with a fair value of $2,250 in 2018. During March 2020, $50,000 of the Note of $120,000 with original issuance discount of 20,000 originated in November 2017 was settled for 125,000,000 shares. An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $119,700. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. At June 30, 2019 and December 31, 2018, the principal balance of the loan is $120,000. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600 during 2018. At June 30, 2019 and December 31, 2018, the principal balance of the note is $18,000 and the accrued interest is $2,000 and $0, respectively. (3) At June 30, 2019 and December 31, 2018, the balance of $814,016 and $751,955 net of discount of $6,710 and $29,371, respectively, consisted of the following convertible loans: ● On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. The first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014. The notes carry interest at 8% and were due on March 19, 2018. The note holders have the right to convert the notes into shares of Common Stock at a price of $0.20. During 2018, repayment of $3,000 was made. At December 31, 2018, the principal balance of the note is $27,000 and the accrued interest is $11,412. The two outstanding Notes were settled in connection with issuance of the convertible note in the amount of up to $1,000,000 in February 2019 (See Note 6(4)), as a result, we recorded a gain on settlement of debt in other income for $38,412. ● During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and is due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The remaining debt discount of $950 was fully amortized during the three months ended March 31, 2019. The note is under personal guarantee by Mr. Deitsch. At June 30, 2019 and December 31, 2018, the convertible note payable was recorded at $76,076 and $75,126, net of discount of $0 and $950, respectively. The accrued interest as of June 30, 2019 and December 31, 2018 is $12,150 and $8,177. During January and July 2020, this Note and the Note of $60,000 amended in November 2018(See Note 6(2)) were combined and restated and was due January 2021. The Note is in negotiation of restatement. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of June 30, 2019. The loan is in default and in negotiation of settlement. 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500 during 2018. At June 30, 2019 and December 31, 2018, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock. The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. These Notes are in default and in negotiation of settlement. During the first quarter of 2019, we issued convertible notes payable of $70,000 with original issuance discount of $5,000. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price of $0.0005 per share. In addition, upon the issuance of convertible notes, the Company granted the total of 110,000,000 warrants at an exercise price of $0.001 per share. The warrants were valued at $8,147 using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. The Notes were further restated in December 2019, and August and October 2020. They are in default and in negotiation of settlement. During the second quarter of 2019, we restated two convertible notes payable with additional original issue discount of $6,400 and issued 6,000,001 shares of common stock with a fair value of $1,800 (See Note 7). The two restated notes were due in August 2019 and are in default. The total discount of $8,200 was amortized over the term of the notes. Repayment of $10,000 was made in May 2019. Amortization for the six months ended June 30, 2019 and 2018 was $43,058 and $144,062. At June 30, 2019 and December 31, 2018, the principal balance of the notes, net of discount of $6,710 and $28,421 is $677,940 and $589,829. (4) At June 30, 2019 and December 31, 2018, the balance of $2,821,182 and $1,156,341, respectively, consisted of the following convertible loans: ● During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carries interest at 12% and matured on September 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 179,800,000 shares of stock satisfying the principal balance of $63,001 and accrued interest for a fair value of $298,575. At December 31, 2017, the convertible note payable, at fair value, was recorded at $147,314. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. During February and July, 2018, we issued a total of 105,157,409 shares of our restricted common stock to the original Note holder with a fair value of $147,220. At December 31, 2018, the Company owed additional shares to the original noteholder and recorded an accrual of $32,400 to account for the cost of the shares, and the shares were issued in January 2019 (See Notes 7). The new note of $49,819 carries interest at 8% and was due on February 13, 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During September 2018, the Noteholder made a conversions of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full. At June 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $34,819, at fair value, was recorded at $90,965 and $62,508. ● During February 2018, we issued a convertible denture in the amount of $200,000 to an unrelated third party. The note carries interest at 8% and was due in February 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $1,646,242. At June 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $200,000, at fair value, was recorded at $520,037 and $358,665. The note carries additional $200,000 “Back-end Note” ($100,000 each) with the same terms as the original note. ● During April 2018, $65,000 of one of the $100,000 Back-end Note was funded. The note carries interest at 8% and is due in February 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $110,700. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $169,012 and $115,165. ● During March 2018, we issued a convertible denture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and was due in March 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $48,418. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $153,556 and $107,329. The note carries an additional “Back-end Note” with the same terms as the original note that enables the lender to lend to us another $60,000. ● During June 2018, the $60,000 Back-end Note was funded. The note carries interest at 8% and is due in March 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $68,067. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $153,556 and $105,334. ● During May 2018, we issued a convertible denture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and was due in May 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $59,257. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $148,033 and $106,681. ● During August 2018, we issued a convertible denture in the amount of $31,500 to an unrelated third party. The note carries interest at 8% and was due in August 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $23,794. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $75,133 and $55,409. All of the above convertible notes with principal balance of a total of $511,319 were settled in ● During May 2017, we issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. The note carries interest at 8% and was due on May 4, 2018. We have accrued interest at default interest rate of 20% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty trading days preceding the conversion date. During November 2017, the Note holder made a conversion of our restricted common stocks satisfying the principal balance of $856 and penalty of $6,400 for a fair value of $21,399. At December 31, 2017, the convertible note payable, at fair value, was recorded at $185,765. During February 2018, the remaining balance of $63,144 with accrued interest and penalty of $12,442 was assigned and sold to three unrelated third parties. During June 2018, a Note holder made a conversion of 50,670,000 shares of our restricted common stock with a fair value of $70,938 in satisfaction of the balance of $34,060 plus accrued interest of $8,607. At June 30, 2019 and December 31, 2018, the remaining principal of $29,381, at fair value, was recorded at $90,948 and $63,315. ● On March 28, 2016, we signed an expansion agreement with Brewer and Associates Consulting, LLC (“B+A”) to the original consulting agreement dated on October 15, 2015 for consulting services for twelve months for a monthly fee of $7,000. To relieve our cash obligation of $36,000 per original agreement, we issued three convertible notes for a total of $120,000 which includes the fees due under the original agreement and the new monthly fees due under the expansion agreement. The $40,000 and $60,000 of the Notes were paid in full as of December 31, 2016 and December 31, 2017, respectively. The remaining balance of $20,000 Notes is in default and negotiation of settlement. We have accrued interest at default interest rate of 20% after the note’s maturity date. The conversion price is equal to 55% of t |
STOCKHOLDERS' DEFICIT (Tables)
STOCKHOLDERS' DEFICIT (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Stockholders' Equity Note [Abstract] | |
Schedule of Stockholders Equity [Table Text Block] | Date Number of Fair Value of shares converted Debt Converted 5/6/2019 250,000,000 $75,000 5/31/2019 250,000,000 $100,000 6/6/2019 250,000,000 $100,000 |
STOCK WARRANTS (Tables)
STOCK WARRANTS (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Stock Options and Warrants [Abstract] | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | A summary of warrants outstanding in conjunction with private placements of common stock were as follows during the six months ended June 30, 2019 and the year ended December 31, 2018: Number Of shares Weighted average Balance December 31, 2017 13,540,000 $ 0.023 Exercised - - Issued - - Forfeited (940,000) 0.015 Balance December 31, 2018 12,600,000 $ 0.026 Exercised - - Issued 110,000,000 0.001 Forfeited (4,100,000) 0.021 Balance June 30, 2019 118,500,000 $ 0.01 |
Summary of fixed-price warrants outstanding [Table Text Block] | The following table summarizes information about fixed-price warrants outstanding as of June 30, 2019 and December 31, 2018: Exercise Price Weighted Average Number Outstanding Weighted Average Weighted Average Exercise Price June 30, 2019 $ 0.001-0.03 86,233,702 0.55 years $ 0.01 December 31, 2018 $ 0.005-0.05 12,600,000 1.11 years $ 0.026 |
ACCRUED EXPENSES (Tables)
ACCRUED EXPENSES (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Expenses [Table Text Block] | Accrued expenses consisted of the following: June 30, December 31, 2018 Accrued consulting fees $ 192,050 $ 161,550 Accrued settlement expenses 315,000 347,400 Accrued payroll taxes 144,093 120,182 Accrued interest 217,972 180,509 Accrue others 18,833 22,208 Total $ 887,948 $ 831,849 |
PREPAID EXPENSES AND OTHER CU_2
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Prepaid Expenses [Abstract] | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] | Prepaid expenses and other current assets consist of the following: June 30, December 31, Supplier advances for future purchases $ 221,759 $ 200,911 Reserve for supplier advances (200,911) (200,911) Net supplier advances 20,848 - Prepaid professional fees - 13,000 Deferred stock compensation 23,500 50,000 Total $ 44,348 $ 63,000 |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Tables) | 6 Months Ended |
Jun. 30, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Lease, Cost [Table Text Block] | ReceptoPharm leases a lab and renewed its operating lease agreement for five years beginning August 1, 2017 for monthly payments of approximately $6,900 with a 5% increase each year. June 30, Lease cost Operating lease cost $ 29,288 Short-term lease cost 33,776 Total lease cost $ 63,064 Balance sheet information Operating ROU Assets $ 251,887 Operating lease obligations, current portion 68,806 Operating lease obligations, non-current portion 181,379 Total operating lease obligations $ 250,185 Weighted average remaining lease term (in years) – operating leases 3.17 Weighted average discount rate-operating leases 8% Supplemental cash flow information related to leases were as follows, for the six months ended June 30, 2019: Cash paid for amounts included in the measurement of operating lease liabilities $ 46,211 |
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | Future minimum payments under these lease agreements are as follows: June 30, Total 2020 $ 86,345 2021 89,651 2022 93,122 2023 15,567 Total future lease payments $ 284,685 Less imputed interest 34,500 Total $ 250,185 |
SUBSEQUENT EVENTS (Tables)
SUBSEQUENT EVENTS (Tables) - Subsequent Event [Member] | 6 Months Ended |
Jun. 30, 2019 | |
SUBSEQUENT EVENTS (Tables) [Line Items] | |
Schedule of Derivative Instruments [Table Text Block] | Month of Issuance Number of Fair Value of Month of Expiration Warrants Warrants December, 2019 44,000,000 7,370 August, 2020 August, 2020 92,100,000 22,879 August, 2021 October, 2020 39,930,000 9,497 October, 2022 |
Schedule of Stockholders Equity [Table Text Block] | Date Number of Fair Value of shares converted Debt Converted 1/21/2020 250,000,000 150,000 2/18/2020 250,000,000 275,000 2/25/2021 137,700,000 1,500,930 3/3/2021 67,380,000 599,682 Date Number of Fair Value of shares converted Debt Converted 9/22/2020 107,133,333 $171,413 10/5/2020 107,817,770 64,691 |
BASIS OF PRESENTATION AND SUM_3
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||
Jun. 30, 2019USD ($) | Jun. 30, 2018USD ($)$ / shares | Mar. 31, 2018USD ($)$ / shares | Jun. 30, 2019USD ($) | Jun. 30, 2018USD ($)$ / shares | Dec. 31, 2018USD ($) | Jun. 30, 2020USD ($) | May 31, 2020USD ($) | Mar. 31, 2019USD ($) | Dec. 31, 2017USD ($) | |
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||||||||
Number of Reportable Segments | 1 | |||||||||
Net Income (Loss) Attributable to Parent | $ (1,668,207) | $ (1,330,742) | $ (2,068,650) | $ (2,328,329) | ||||||
Retained Earnings (Accumulated Deficit) | (63,341,492) | (63,341,492) | $ (61,272,842) | |||||||
Capital Deficit | 7,622,011 | 7,622,011 | ||||||||
Stockholders' Equity Attributable to Parent | $ (7,652,158) | $ (5,104,837) | $ (5,163,101) | $ (7,652,158) | (5,104,837) | (5,936,593) | $ (6,296,489) | $ (5,410,194) | ||
Deferred Revenue, Period Increase (Decrease) | 1,280 | 2,780 | ||||||||
Increase (Decrease) in Deferred Revenue | (22,490) | |||||||||
Deferred Tax Assets, Valuation Allowance | $ 200,911 | |||||||||
Effective Income Tax Rate Reconciliation, Percent | 0.00% | |||||||||
Payment processor 2 [Member] | ||||||||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||||||||
Concentration Risk, Percentage | 100.00% | |||||||||
Payment processor 1 [Member] | ||||||||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||||||||
Concentration Risk, Percentage | 84.00% | |||||||||
PPP Loan [Member] | ||||||||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||||||||
Short-term Non-bank Loans and Notes Payable | $ 64,895 | |||||||||
Economic Injury Disaster Loan [Member] | ||||||||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||||||||
Short-term Non-bank Loans and Notes Payable | $ 154,900 | |||||||||
Minimum [Member] | ||||||||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||||||||
Property, Plant and Equipment, Useful Life | 3 years | |||||||||
Maximum [Member] | ||||||||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||||||||
Property, Plant and Equipment, Useful Life | 7 years | |||||||||
Restated [Member] | ||||||||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||||||||
Net Income (Loss) Attributable to Parent | $ 19,143 | $ 3,110,017 | ||||||||
Net Asset Value Per Share (in Dollars per share) | $ / shares | $ 0 | $ 0 | $ 0 | |||||||
Additional Paid-In Capital and Accumulated Deficit Increase(Decrease) | $ (3,110,017) | $ (3,110,017) | ||||||||
Customer 1 [Member] | ||||||||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||||||||
Concentration Risk, Percentage | 27.00% | 25.00% | ||||||||
Concentration Risk, Customer | two | |||||||||
Customer 2 [Member] | ||||||||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||||||||
Concentration Risk, Percentage | 45.00% | 49.00% | ||||||||
Concentration Risk, Customer | two | |||||||||
Customer 3 [Member] | ||||||||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||||||||
Concentration Risk, Percentage | 22.00% | |||||||||
Prepaid Venom [Member] | ||||||||||
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items] | ||||||||||
Increase (Decrease) in Deferred Revenue | $ 0 | $ 47,757 | ||||||||
Deferred Tax Assets, Valuation Allowance | $ 200,911 | $ 200,911 | $ 200,911 |
BASIS OF PRESENTATION AND SUM_4
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Restatement of Prior Period Presentation - USD ($) | 3 Months Ended | 6 Months Ended |
Jun. 30, 2018 | Jun. 30, 2018 | |
Restated [Member] | ||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||
Change in fair value of convertible notes and derivatives | $ (849,376) | $ (1,982,864) |
Gain on settlement of debt and accounts payable | 768,323 | |
Previously Reported [Member] | ||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||
Change in fair value of convertible notes and derivatives | (868,519) | (4,344,235) |
Gain on settlement of debt and accounts payable | 19,677 | |
Revision of Prior Period, Adjustment [Member] | ||
Error Corrections and Prior Period Adjustments Restatement [Line Items] | ||
Change in fair value of convertible notes and derivatives | 19,143 | 2,361,371 |
Gain on settlement of debt and accounts payable | 748,646 | |
Net effect of restatement on net loss | $ 19,143 | $ 3,110,017 |
BASIS OF PRESENTATION AND SUM_5
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Impact of ASC 842 | Dec. 31, 2018USD ($) |
Adoption of ASC 842 increase (decrease) [Member] | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |
Operating lease right-of-assets | $ 281,175 |
Total assets | 281,175 |
Operating lease liabilities, current portion | 64,573 |
Operating lease liabilities, net of current portion | 216,602 |
Total liabilities | 281,175 |
Total liabilities and stockholders’ equity | 281,175 |
Scenario, Adjustment [Member] | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |
Operating lease right-of-assets | 281,175 |
Total assets | 422,592 |
Operating lease liabilities, current portion | 64,573 |
Operating lease liabilities, net of current portion | 216,602 |
Total liabilities | 6,359,185 |
Total liabilities and stockholders’ equity | 422,592 |
Before Adjustment [Member] | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |
Total assets | 141,417 |
Total liabilities | 6,078,010 |
Total liabilities and stockholders’ equity | $ 141,417 |
BASIS OF PRESENTATION AND SUM_6
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities excluded from computation of Earnings Per Share - shares | 6 Months Ended | |
Jun. 30, 2019 | Jun. 30, 2018 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive Securities | 7,169,486,979 | 1,638,932,403 |
Options and warrants [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive Securities | 118,500,000 | 13,475,000 |
Convertible Debt Securities [Member] | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive Securities | 7,050,986,979 | 1,625,457,403 |
FAIR VALUE MEASUREMENTS (Detail
FAIR VALUE MEASUREMENTS (Details) | 6 Months Ended |
Jun. 30, 2019 | |
FAIR VALUE MEASUREMENTS (Details) [Line Items] | |
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate | 0.00% |
Minimum [Member] | |
FAIR VALUE MEASUREMENTS (Details) [Line Items] | |
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate | 1.75% |
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate | 256.00% |
Maximum [Member] | |
FAIR VALUE MEASUREMENTS (Details) [Line Items] | |
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate | 2.81% |
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate | 305.00% |
FAIR VALUE MEASUREMENTS (Deta_2
FAIR VALUE MEASUREMENTS (Details) - Schedule of Financial Instruments Measured at Fair Value - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
FAIR VALUE MEASUREMENTS (Details) - Schedule of Financial Instruments Measured at Fair Value [Line Items] | ||
Warrant liability | $ 1,934 | $ 1,468 |
Convertible notes at fair value | 2,821,182 | 1,156,341 |
Fair Value, Inputs, Level 1 [Member] | ||
FAIR VALUE MEASUREMENTS (Details) - Schedule of Financial Instruments Measured at Fair Value [Line Items] | ||
Warrant liability | ||
Convertible notes at fair value | ||
Fair Value, Inputs, Level 2 [Member] | ||
FAIR VALUE MEASUREMENTS (Details) - Schedule of Financial Instruments Measured at Fair Value [Line Items] | ||
Warrant liability | ||
Convertible notes at fair value | ||
Fair Value, Inputs, Level 3 [Member] | ||
FAIR VALUE MEASUREMENTS (Details) - Schedule of Financial Instruments Measured at Fair Value [Line Items] | ||
Warrant liability | 1,934 | 1,468 |
Convertible notes at fair value | $ 2,821,182 | $ 1,156,341 |
FAIR VALUE MEASUREMENTS (Deta_3
FAIR VALUE MEASUREMENTS (Details) - Schedule of Changes in Fair Value Measurements Using Significant Unobservable Inputs - USD ($) | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2019 | Dec. 31, 2018 | ||
Schedule of Changes in Fair Value Measurements Using Significant Unobservable Inputs [Abstract] | |||
Beginning balance | $ 1,468 | $ 5,903 | |
Total (gain) loss included in earnings | [1] | 466 | (4,435) |
Ending balance | $ 1,934 | $ 1,468 | |
[1] | The gain related to the revaluation of our warrant liability is included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. We valued our warrants using a Dilution-Adjusted Black-Scholes Model. Assumptions used include (1) 1.75% to 2.81% risk-free rate, (2) warrant life is the remaining contractual life of the warrants, (3) expected volatility of 256%-305% (4) zero expected dividends (5) exercise price set forth in the agreements (6) common stock price of the underlying share on the valuation date, and (7) number of shares to be issued if the instrument is converted. |
FAIR VALUE MEASUREMENTS (Deta_4
FAIR VALUE MEASUREMENTS (Details) - Schedule of Significant Terms of Each of the Debentures - USD ($) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2019 | Dec. 31, 2018 | |
FAIR VALUE MEASUREMENTS (Details) - Schedule of Significant Terms of Each of the Debentures [Line Items] | ||
Face Amount (in Dollars) | $ 1,066,479 | $ 1,566,433 |
Minimum [Member] | ||
FAIR VALUE MEASUREMENTS (Details) - Schedule of Significant Terms of Each of the Debentures [Line Items] | ||
Interest Rate | 8.00% | 8.00% |
Default Interest Rate | 18.00% | 18.00% |
Discount Rate (in Dollars per share) | $ 23.95 | $ 25.95 |
Anti-Dilution Adjusted Price (in Dollars per share) | $ 0.00015 | $ 0.0002 |
% of stock price for look-back period | 50.00% | 40.00% |
Look-back Period | 3 days | 3 days |
Maximum [Member] | ||
FAIR VALUE MEASUREMENTS (Details) - Schedule of Significant Terms of Each of the Debentures [Line Items] | ||
Interest Rate | 20.00% | 12.00% |
Default Interest Rate | 24.00% | 20.00% |
Discount Rate (in Dollars per share) | $ 27.95 | $ 27.95 |
Anti-Dilution Adjusted Price (in Dollars per share) | $ 0.05 | $ 0.20 |
% of stock price for look-back period | 60.00% | 60.00% |
Look-back Period | 25 days | 25 days |
FAIR VALUE MEASUREMENTS (Deta_5
FAIR VALUE MEASUREMENTS (Details) - Schedule of Changes in Fair Value Measurements Using Significant Unobservable Inputs for the Convertible Notes - Convertible Notes [Member] - USD ($) | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2019 | Dec. 31, 2018 | ||
FAIR VALUE MEASUREMENTS (Details) - Schedule of Changes in Fair Value Measurements Using Significant Unobservable Inputs for the Convertible Notes [Line Items] | |||
Beginning balance | $ 1,156,341 | $ 1,925,959 | |
Purchases and issuances | 535,779 | 472,029 | |
Day one loss on value of hybrid instrument | [1] | 671,476 | 2,021,041 |
Loss from change in fair value | [1] | 732,586 | 130,344 |
Gain on settlement | (958,581) | ||
Conversion to common stock | (275,000) | (2,434,451) | |
Ending balance | $ 2,821,182 | $ 1,156,341 | |
[1] | The losses related to the valuation of the convertible notes are included in “Change in fair value of convertible notes and derivatives” in the accompanying consolidated statement of operations. |
INVENTORIES (Details) - Schedul
INVENTORIES (Details) - Schedule of Inventories - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Schedule of Inventories [Abstract] | ||
Raw Materials | $ 34,433 | $ 33,431 |
Finished Goods | 2,095 | 1,871 |
Total Inventories | $ 36,528 | $ 35,302 |
PROPERTY AND EQUIPMENT (Details
PROPERTY AND EQUIPMENT (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | |
Property, Plant and Equipment [Abstract] | ||||
Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment | $ 1,105 | $ 1,825 | $ 2,210 | $ 3,753 |
PROPERTY AND EQUIPMENT (Detai_2
PROPERTY AND EQUIPMENT (Details) - Schedule of Property and Equipment - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Property, Plant and Equipment [Line Items] | ||
Property and equipment | $ 216,033 | $ 216,033 |
Less: Accumulated depreciation | (207,743) | (205,533) |
Property and equipment, net | 8,290 | 10,500 |
Computer Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment | 25,120 | 25,120 |
Furniture and Fixtures [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment | 34,757 | 34,757 |
Lab Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment | 53,711 | 53,711 |
Telephone Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment | 12,421 | 12,421 |
Office Equipment [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment | 16,856 | 16,856 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment [Line Items] | ||
Property and equipment | $ 73,168 | $ 73,168 |
DUE TO_FROM OFFICERS (Details)
DUE TO/FROM OFFICERS (Details) - Deitsch [Member] - USD ($) | 6 Months Ended | ||
Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | |
DUE TO/FROM OFFICERS (Details) [Line Items] | |||
Due from Related Parties | $ 161,418 | $ 186,497 | |
Debt Instrument, Interest Rate, Effective Percentage | 4.00% | 4.00% | |
Proceeds from (Repayments of) Short-term Debt | $ 61,715 | ||
Proceeds from Short-term Debt | 4,100 | $ 105,100 | |
Interest Income (Expense), Net | 3,536 | 7,674 | |
Repayments of Short-term Debt | $ 106,150 | ||
Other Receivables | $ 534,470 | $ 505,470 |
DEBTS (Details) - (1)
DEBTS (Details) - (1) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | Dec. 31, 2010 | Dec. 31, 2017 | |
Director [Member] | |||||||
DEBTS (Details) - (1) [Line Items] | |||||||
Notes Payable | $ 200,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | ||||||
Short-term Debt, Interest Rate Increase | 12.00% | ||||||
Line of Credit Facility, Increase, Accrued Interest | $ 150,372 | $ 141,808 | |||||
Interest Expense, Debt | $ 4,368 | $ 3,882 | 8,564 | $ 7,611 | |||
Related Party [Member] | |||||||
DEBTS (Details) - (1) [Line Items] | |||||||
Notes Payable | 13,200 | 13,200 | 12,000 | $ 12,000 | |||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 1,200 | $ 1,200 | 2,400 | $ 2,000 | |||
Promissary Note Amendment [Member] | Related Party [Member] | |||||||
DEBTS (Details) - (1) [Line Items] | |||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 2,400 |
DEBTS (Details) - (2)
DEBTS (Details) - (2) - USD ($) | Feb. 15, 2019 | Oct. 12, 2017 | Aug. 02, 2011 | Mar. 31, 2020 | Jul. 31, 2019 | Feb. 28, 2019 | Jan. 31, 2019 | Nov. 30, 2018 | Sep. 30, 2018 | Jul. 31, 2018 | Jun. 30, 2018 | Feb. 28, 2018 | Jun. 30, 2017 | May 31, 2017 | Mar. 31, 2017 | May 31, 2016 | Jun. 30, 2012 | Mar. 31, 2012 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Sep. 30, 2020 | Sep. 30, 2019 | Jun. 17, 2019 | Oct. 31, 2018 | Aug. 31, 2018 | Jul. 12, 2018 | Apr. 30, 2018 | Mar. 31, 2018 | Nov. 30, 2017 | Oct. 31, 2017 | Oct. 20, 2017 | Sep. 30, 2017 | Jul. 31, 2017 | Feb. 28, 2017 | Jan. 31, 2017 | Oct. 31, 2016 | Sep. 26, 2016 | Aug. 31, 2016 | Jul. 31, 2016 | Jun. 30, 2016 | Apr. 30, 2016 | Aug. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Other Notes Payable | [1] | $ 1,387,877 | $ 1,469,690 | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 1,000 | $ 1,000 | 17,870 | ||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | 4,991,581 | $ 3,389,986 | |||||||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 5,038,246,111 | 4,046,746,110 | |||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | $ 62,078 | 207,837 | |||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | 5,038,246 | $ 4,046,746 | |||||||||||||||||||||||||||||||||||||||||||||
Notes Payable, Current | 4,867,086 | 3,338,576 | |||||||||||||||||||||||||||||||||||||||||||||
Amortization of Debt Issuance Costs and Discounts | 14,635 | 18,565 | |||||||||||||||||||||||||||||||||||||||||||||
Director [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | $ 101,818 | $ 201,818 | 169,634 | 192,974 | $ 200,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 12.00% | ||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.008 | ||||||||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 8,844 | $ 6,365 | 4,500 | ||||||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Converted Instrument, Rate | 12.00% | ||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Increase, Accrued Interest | 21,023 | 45,456 | 40,033 | ||||||||||||||||||||||||||||||||||||||||||||
Repayments of Lines of Credit | 104,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | $ 18,841 | ||||||||||||||||||||||||||||||||||||||||||||||
Director [Member] | Being disputed in court [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | 99,500 | ||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Increase, Accrued Interest | 21,023 | ||||||||||||||||||||||||||||||||||||||||||||||
Director [Member] | Not Disputed In Court [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | 91,156 | ||||||||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Increase, Accrued Interest | 24,433 | ||||||||||||||||||||||||||||||||||||||||||||||
Liquid Packaging Resources [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | $ 350,000 | $ 281,772 | |||||||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Investment Owned, Balance, Principal Amount | $ 175,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fee Amount | $ 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Sale of Stock, Number of Shares Issued in Transaction (in Shares) | 142,858 | ||||||||||||||||||||||||||||||||||||||||||||||
Cash Settlement | $ 450,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Debt Default, Amount | $ 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Other Significant Noncash Transaction, Value of Consideration Received | $ 281,772 | ||||||||||||||||||||||||||||||||||||||||||||||
University Centre West Ltd [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Debt, Approximate | $ 55,410 | ||||||||||||||||||||||||||||||||||||||||||||||
Non-Related Party 2 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | $ 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 3,242 | 2,739 | |||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 52,244,433 | ||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 37,011 | ||||||||||||||||||||||||||||||||||||||||||||||
Non-Related Party 3 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | $ 200,000 | $ 75,000 | 50,000 | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 2.00% | ||||||||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 25,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 43,834 | 37,801 | |||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Non-Related Party 4 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | 50,000 | 50,000 | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 2.00% | ||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 37,033 | 31,000 | |||||||||||||||||||||||||||||||||||||||||||||
Non-Related Party 5 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | 282,983 | 282,983 | $ 220,506 | $ 60,000 | $ 180,250 | $ 150,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 2.00% | 2.50% | 2.50% | 2.50% | |||||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 220,506 | ||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 36,977 | 2,830 | |||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 5,000,000 | 10,000,000 | 2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | 0 | 3,616 | $ 3,945 | $ 2,765 | |||||||||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 3,616 | 2,765 | 2,765 | ||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 5,500 | ||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable, Current | $ 282,983 | ||||||||||||||||||||||||||||||||||||||||||||||
Non-Related Party 6 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | $ 60,000 | 15,000 | 75,000 | $ 75,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 15,900 | 1,371 | 17,271 | ||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two and Three | 15,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Non-Related Party 7 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | 120,000 | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 2.00% | ||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 33,333 | 27,300 | |||||||||||||||||||||||||||||||||||||||||||||
Non-Related Party 8 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | $ 12,500 | ||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 10.00% | ||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 2,573 | 1,944 | |||||||||||||||||||||||||||||||||||||||||||||
Non-Related Party 9 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | 170,402 | 121,578 | $ 170,402 | 135,426 | $ 191,329 | $ 200,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 15.00% | ||||||||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | 34,060 | $ 21,399 | 13,848 | 34,976 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | $ 8,607 | $ 12,442 | |||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 50,670,000 | 50,670,000 | |||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 70,938 | $ 70,938 | |||||||||||||||||||||||||||||||||||||||||||||
Debt Issuance Costs, Gross | $ 5,500 | ||||||||||||||||||||||||||||||||||||||||||||||
Gains (Losses) on Restructuring of Debt | 20,927 | ||||||||||||||||||||||||||||||||||||||||||||||
Non-Related Party 10 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | 50,000 | 50,000 | 50,000 | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Non-Related Party 11 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 3,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | 31,000 | 27,500 | 33,000 | $ 36,000 | |||||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | 1,500 | 7,000 | 1,500 | ||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | 2,500 | 6,000 | $ 6,000 | ||||||||||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 5,000 | 1,500 | |||||||||||||||||||||||||||||||||||||||||||||
Non-Related Party 11 [Member] | Deitsch [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | 1,000 | 6,000 | |||||||||||||||||||||||||||||||||||||||||||||
Non-Related Party 12 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 0 | 8,254 | |||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | 75,000 | $ 60,000 | 70,000 | $ 61,746 | $ 60,000 | $ 60,000 | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 10,000 | $ 10,000 | |||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | $ 15,900 | ||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 5,000,000 | 10,000,000 | 5,000,000 | 1,000,000 | 5,000,000 | ||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 2,381 | $ 8,678 | $ 10,000 | ||||||||||||||||||||||||||||||||||||||||||||
Amortization of Debt Discount (Premium) | 1,587 | 3,616 | |||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 3,000 | $ 1,700 | |||||||||||||||||||||||||||||||||||||||||||||
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two and Three | $ 76,076 | ||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium), Net | $ 10,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Amortization of Debt Issuance Costs | $ 6,667 | ||||||||||||||||||||||||||||||||||||||||||||||
Amortization of Debt Issuance Costs and Discounts | $ 4,617 | ||||||||||||||||||||||||||||||||||||||||||||||
Non-Related Party 12 [Member] | Common Stock [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 3,200 | ||||||||||||||||||||||||||||||||||||||||||||||
Non-Related Party 13 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 20,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | $ 219,879 | $ 120,000 | |||||||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 50,000 | $ 27,000 | $ 2,250 | ||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 125,000,000 | 750,000,000 | 1,500,000 | 10,000,000 | |||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 5,600 | ||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 119,700 | ||||||||||||||||||||||||||||||||||||||||||||||
Non-Related Party 14 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | $ 18,000 | $ 18,000 | $ 18,000 | ||||||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | 5,600 | ||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | $ 2,000 | $ 0 | |||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 7,000,000 | 5,000,000 | |||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 2,900 | ||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium), Net | $ 3,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Monthly [Member] | Liquid Packaging Resources [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Monthly [Member] | Non-Related Party 9 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Repayments of Lines of Credit | $ 7,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Pre Reverse Stock Split [Member] | Liquid Packaging Resources [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Sale of Stock, Number of Shares Issued in Transaction (in Shares) | 5,714,326 | ||||||||||||||||||||||||||||||||||||||||||||||
Default Penalties [Member] | Non-Related Party 13 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 36,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Issued With Restatement [Member] | Non-Related Party 13 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 10,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Currently in default and negotiation [Member] | Non-Related Party 13 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (2) [Line Items] | |||||||||||||||||||||||||||||||||||||||||||||||
Notes Payable | $ 70,000 | $ 120,000 | |||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 14,000 | ||||||||||||||||||||||||||||||||||||||||||||||
Long-Term Debt, Maturity, Year Two | $ 84,000 | ||||||||||||||||||||||||||||||||||||||||||||||
[1] | At June 30, 2019 and December 31, 2018, the balance of $1,387,877 and $1,469,690 net of discount of $1,000 and $17,870, respectively, consisted of the following loans: ● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At June 30, 2019 and December 31, 2018, we owed principal balance of $169,634 and $192,974, and accrued interest of $45,456 and $40,033, respectively. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020. We recorded a gain on settlement of debt in other income for $18,841. The Company repaid $4,500 during the six months ended June 30, 2019. At June 30, 2019, the balance owed is $99,500 including the accrued interest of $21,023. The remaining principal balance of $91,156 and accrued interest of $24,433 is being disputed in court and negotiation for settlement (See Note 11). ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2019 and December 31, 2018, the accrued interest is $3,242 and $2,739. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the outstanding principal balance is $50,000 and accrued interest is $43,834 and $37,801. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2019 and December 31, 2018, the outstanding principal balance is $50,000 and accrued interest is $37,033 and $31,000. ● In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest were restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest were restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018.The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest were restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and was due June 17, 2019. The note is in default and negotiation of settlement. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the six months ended June 30, 2019 and 2018 was $3,616 and $2,765, respectively. The debt discount at June 30, 2019 and December 31, 2018 was $0 and $3,616. At June 30, 2019 and December 31, 2018, the principal balance is $282,983, and the accrued interest is $36,977 and $2,830, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. In January 2019, the principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). The remaining note of $15,000 was assigned to an unrelated third party and is in negotiation of settlement. At June 30, 2019 and December 31, 2018, the principal balance is $15,000 and $75,000, and the accrued interest is $1,371 and $17,271, respectively. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the accrued interest is $33,333 and $27,300. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the accrued interest is $2,573 and $1,944. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of June 30, 2019. At December 31, 2017, the principal balance of the loan was $191,329 and in negotiation of settlement. During June 2018, the loan was settled for $170,402 with scheduled repayments of approximately $7,000 per month through July 2020. We recorded a gain on settlement of debt in other income for $20,927 in June 2018. The Company repaid $34,976 during 2018 and $13,848 during the six months ended June 30, 2019. At June 30, 2019 and December 31, 2018, the principal balance is $121,578 and $135,426. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the principal balance of the note is $50,000. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 each due in September 2019 and 2020, respectively. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and is due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the six months ended June 30, 2019 and 2018 was $5,000 and $1,500, respectively. The debt discount at June 30, 2019 and December 31, 2018 is $2,500 and $6,000. Repayments of $1,500 and $7,000 have been made during 2017 and 2018, respectively. During the six months ended June 30, 2019, repayment of $1,500 has been made. The Note is under personal guarantee by Mr. Deitsch. At June 30, 2019 and December 31, 2018, the principal balance of the note is $31,000 and $27,500, net of debt discount of $1,000 and $6,000, respectively. The note is in default and in negotiation of settlement. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment. The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the six months ended June 30, 2019 was $1,587 and $6,667. Amortization for the debt discount and original issuance discount was $3,616 and $4,617, respectively for the six months ended June 30, 2018. As of June 30, 2019 and December 31, 2018, the amount due is $70,000 and $61,746, net of discount of $0 and $8,254. During January and July 2020, this Note and the Note of $76,076 amended in August 2018(See Note 6(3)) were combined and restated and was due January 2021. The Note is in negotiation of restatement. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. 1,500,000 shares of common stocks were issued due to the default of repayments with a fair value of $2,250 in 2018. During March 2020, $50,000 of the Note of $120,000 with original issuance discount of 20,000 originated in November 2017 was settled for 125,000,000 shares. An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $119,700. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. At June 30, 2019 and December 31, 2018, the principal balance of the loan is $120,000. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600 during 2018. At June 30, 2019 and December 31, 2018, the principal balance of the note is $18,000 and the accrued interest is $2,000 and $0, respectively. |
DEBTS (Details) - (3)
DEBTS (Details) - (3) - USD ($) | Jun. 06, 2019 | May 31, 2019 | May 06, 2019 | Mar. 19, 2018 | Jul. 26, 2017 | Mar. 14, 2014 | May 31, 2019 | Aug. 31, 2018 | Feb. 28, 2018 | Oct. 31, 2017 | Jul. 31, 2016 | Mar. 31, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | Oct. 31, 2020 | Jul. 31, 2020 | Sep. 30, 2019 | Jul. 31, 2018 | Jul. 31, 2017 | Jan. 31, 2017 | Dec. 31, 2016 |
DEBTS (Details) - (3) [Line Items] | |||||||||||||||||||||||
Convertible Notes Payable | $ 2,821,182 | $ 511,319 | |||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 1,000 | $ 1,000 | $ 17,870 | ||||||||||||||||||||
Deposit Liabilities, Accrued Interest | 150,372 | 141,808 | |||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 250,000,000,000,000 | 250,000,000,000,000 | 250,000,000,000,000 | ||||||||||||||||||||
Amortization of Debt Discount (Premium) | 62,078 | 207,837 | |||||||||||||||||||||
Common Stock, Value, Issued | $ 5,038,246 | $ 4,046,746 | |||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 105,000 | 235,913 | |||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 5,038,246,111 | 4,046,746,110 | |||||||||||||||||||||
Convertible Notes Payable, Current | $ 1,156,341 | ||||||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 10,000 | ||||||||||||||||||||||
Non-Related Party [Member] | |||||||||||||||||||||||
DEBTS (Details) - (3) [Line Items] | |||||||||||||||||||||||
Convertible Notes Payable | $ 46,999 | $ 814,016 | 751,955 | ||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 6,710 | 29,371 | |||||||||||||||||||||
Common Stock, Value, Issued | $ 147,220 | $ 298,575 | |||||||||||||||||||||
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two and Three | $ 32,400 | ||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 105,157,409 | 179,800,000 | |||||||||||||||||||||
Convertible Notes Payable, Current | $ 110,000 | ||||||||||||||||||||||
Minimum [Member] | |||||||||||||||||||||||
DEBTS (Details) - (3) [Line Items] | |||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | 8.00% | |||||||||||||||||||||
Maximum [Member] | |||||||||||||||||||||||
DEBTS (Details) - (3) [Line Items] | |||||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 20.00% | 12.00% | |||||||||||||||||||||
Convertible Debtentures Issued March 2014 [Member] | |||||||||||||||||||||||
DEBTS (Details) - (3) [Line Items] | |||||||||||||||||||||||
Convertible Notes Payable | $ 500,000 | $ 27,000 | |||||||||||||||||||||
Repayments of Convertible Debt | $ 15,000 | 3,000 | |||||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 8.00% | ||||||||||||||||||||||
Debt Instrument, Convertible, Stock Price Trigger (in Dollars per share) | $ 0.20 | ||||||||||||||||||||||
Deposit Liabilities, Accrued Interest | 11,412 | ||||||||||||||||||||||
Gain (Loss) on Extinguishment of Debt | 38,412 | ||||||||||||||||||||||
Convertible Note Issued July 2016 [Member] | |||||||||||||||||||||||
DEBTS (Details) - (3) [Line Items] | |||||||||||||||||||||||
Convertible Notes Payable | $ 76,076 | $ 50,000 | $ 76,076 | 75,126 | $ 60,000 | $ 56,567 | |||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 3,800 | $ 4,035 | 0 | 950 | |||||||||||||||||||
Debt Instrument, Interest Rate, Effective Percentage | 2.50% | 2.50% | 2.00% | 2.50% | |||||||||||||||||||
Debt Instrument, Convertible, Stock Price Trigger (in Dollars per share) | $ 0.05 | $ 0.05 | |||||||||||||||||||||
Deposit Liabilities, Accrued Interest | $ 10,476 | $ 65,600 | 12,150 | 8,177 | |||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 5,000,000 | 1,000,000 | |||||||||||||||||||||
Amortization of Debt Discount (Premium) | $ 950 | 2,850 | |||||||||||||||||||||
Promissory Note Issued October 2017 [Member] | |||||||||||||||||||||||
DEBTS (Details) - (3) [Line Items] | |||||||||||||||||||||||
Convertible Notes Payable | $ 60,000 | 60,000 | $ 60,000 | ||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 10,000 | ||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 1,000,000 | ||||||||||||||||||||||
Common Stock, Value, Issued | $ 1,500 | ||||||||||||||||||||||
20 Convertible Notes Issued 2018 [Member] | |||||||||||||||||||||||
DEBTS (Details) - (3) [Line Items] | |||||||||||||||||||||||
Convertible Notes Payable | 618,250 | ||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 255,655 | $ 62,950 | |||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 10,250,000 | ||||||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 249,113 | ||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium), Net | 62,950 | ||||||||||||||||||||||
20 Convertible Notes Issued 2018 [Member] | Minimum [Member] | |||||||||||||||||||||||
DEBTS (Details) - (3) [Line Items] | |||||||||||||||||||||||
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger | 0.0003% | ||||||||||||||||||||||
20 Convertible Notes Issued 2018 [Member] | Maximum [Member] | |||||||||||||||||||||||
DEBTS (Details) - (3) [Line Items] | |||||||||||||||||||||||
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger | 0.001% | ||||||||||||||||||||||
Convertible Notes Issued During Three Months Ended March 31, 2019 [Member] | |||||||||||||||||||||||
DEBTS (Details) - (3) [Line Items] | |||||||||||||||||||||||
Convertible Notes Payable | 70,000 | 677,940 | $ 589,829 | ||||||||||||||||||||
Repayments of Convertible Debt | $ 10,000 | ||||||||||||||||||||||
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two and Three | $ 5,000 | ||||||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0005 | ||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 110,000,000 | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.001 | ||||||||||||||||||||||
Warrants and Rights Outstanding | $ 8,147 | ||||||||||||||||||||||
Amortization | 43,058 | $ 144,062 | |||||||||||||||||||||
Debt Instrument, Unamortized Discount | 6,710 | 28,421 | |||||||||||||||||||||
Convertible Notes Issued During Three Months Ended March 31, 2019 [Member] | Restated [Member] | |||||||||||||||||||||||
DEBTS (Details) - (3) [Line Items] | |||||||||||||||||||||||
Common Stock, Value, Issued | 1,800 | ||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium), Net | $ 8,200 | ||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 6,000,001 | ||||||||||||||||||||||
Convertible Notes Payable, Current | $ 6,400 | ||||||||||||||||||||||
Restricted Stock [Member] | Promissory Note Issued October 2017 [Member] | |||||||||||||||||||||||
DEBTS (Details) - (3) [Line Items] | |||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 3,300 | ||||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | 5,000,000 | ||||||||||||||||||||||
Convertible Common Stock [Member] | 20 Convertible Notes Issued 2018 [Member] | |||||||||||||||||||||||
DEBTS (Details) - (3) [Line Items] | |||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 6,542 |
DEBTS (Details) - (4)
DEBTS (Details) - (4) - USD ($) | 1 Months Ended | 2 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||||||||||||||||||||||||||
Mar. 31, 2020 | Jul. 31, 2019 | Jun. 30, 2019 | Feb. 28, 2019 | Jan. 31, 2019 | Nov. 30, 2018 | Sep. 30, 2018 | Aug. 31, 2018 | Jul. 31, 2018 | Jun. 30, 2018 | May 31, 2018 | Apr. 30, 2018 | Mar. 31, 2018 | Feb. 28, 2018 | Dec. 31, 2017 | May 31, 2017 | Dec. 31, 2016 | May 31, 2016 | Mar. 28, 2016 | Jun. 30, 2019 | Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | Dec. 31, 2017 | Oct. 31, 2020 | Sep. 30, 2020 | Jun. 17, 2019 | Oct. 31, 2018 | Jul. 12, 2018 | Nov. 30, 2017 | Oct. 31, 2017 | Oct. 20, 2017 | Sep. 30, 2017 | Jul. 31, 2017 | Jan. 31, 2017 | Oct. 31, 2016 | Sep. 26, 2016 | Jul. 31, 2016 | Jun. 30, 2016 | Apr. 30, 2016 | |
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 2,821,182 | $ 2,821,182 | $ 2,821,182 | $ 2,821,182 | $ 511,319 | |||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | $ 1,156,341 | |||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 5,038,246,111 | 5,038,246,111 | 5,038,246,111 | 5,038,246,111 | 4,046,746,110 | |||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 5,038,246 | $ 5,038,246 | $ 5,038,246 | $ 5,038,246 | $ 4,046,746 | |||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 2,821,182 | 2,821,182 | 2,821,182 | 2,821,182 | 1,156,341 | |||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | 10,000 | |||||||||||||||||||||||||||||||||||||||||
Derivative, Loss on Derivative | 1,275,111 | $ 849,376 | 1,404,528 | $ 1,982,864 | ||||||||||||||||||||||||||||||||||||||
Notes Payable | 4,991,581 | 4,991,581 | 4,991,581 | 4,991,581 | 3,389,986 | |||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 110,000 | 219,879 | 32,400 | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 1,000 | 1,000 | 1,000 | 17,870 | ||||||||||||||||||||||||||||||||||||||
Non-Related Party [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 814,016 | $ 46,999 | 814,016 | 814,016 | 814,016 | 751,955 | ||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | $ 110,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 105,157,409 | 179,800,000 | ||||||||||||||||||||||||||||||||||||||||
Principal Amount Outstanding of Loans Held-in-portfolio | $ 63,001 | |||||||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 147,220 | 298,575 | ||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | $ 147,314 | $ 147,314 | ||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 2,820 | |||||||||||||||||||||||||||||||||||||||||
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two and Three | 32,400 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 6,710 | 6,710 | 6,710 | 6,710 | 29,371 | |||||||||||||||||||||||||||||||||||||
Non-Related Party 2 [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 34,819 | |||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | $ 49,819 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 52,244,433 | |||||||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 37,011 | |||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 90,965 | 90,965 | 90,965 | 90,965 | $ 62,508 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 3,242 | $ 2,739 | ||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 24.00% | |||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 15,000 | |||||||||||||||||||||||||||||||||||||||||
Notes Payable | $ 10,000 | |||||||||||||||||||||||||||||||||||||||||
Non-Related Party 3 [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 200,000 | |||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | $ 200,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 5,000,000 | |||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 520,037 | 520,037 | 520,037 | 520,037 | $ 358,665 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 43,834 | 37,801 | ||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 24.00% | |||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 25,000 | |||||||||||||||||||||||||||||||||||||||||
Derivative, Loss on Derivative | $ 1,646,242 | |||||||||||||||||||||||||||||||||||||||||
Notes Payable | 50,000 | 200,000 | $ 75,000 | 50,000 | 50,000 | 50,000 | ||||||||||||||||||||||||||||||||||||
Non-Related Party 4 [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | $ 65,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 169,012 | 169,012 | 169,012 | 169,012 | 115,165 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 37,033 | 31,000 | ||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 24.00% | |||||||||||||||||||||||||||||||||||||||||
Derivative, Loss on Derivative | $ 110,700 | |||||||||||||||||||||||||||||||||||||||||
Notes Payable | 50,000 | 50,000 | 50,000 | 50,000 | 50,000 | $ 50,000 | ||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 100,000 | |||||||||||||||||||||||||||||||||||||||||
Non-Related Party 5 [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | $ 60,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 5,000,000 | 10,000,000 | 2,000,000 | |||||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 5,500 | |||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 153,556 | 153,556 | 153,556 | 153,556 | 107,329 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 36,977 | 2,830 | ||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 24.00% | |||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | 220,506 | |||||||||||||||||||||||||||||||||||||||||
Derivative, Loss on Derivative | $ 48,418 | |||||||||||||||||||||||||||||||||||||||||
Notes Payable | 282,983 | $ 60,000 | 282,983 | 282,983 | 282,983 | 282,983 | $ 220,506 | $ 180,250 | $ 150,000 | |||||||||||||||||||||||||||||||||
Non-Related Party 6 [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | $ 60,000 | $ 60,000 | $ 60,000 | |||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | 8.00% | 8.00% | |||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 153,556 | 153,556 | 153,556 | 153,556 | 105,334 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 15,900 | 1,371 | 17,271 | |||||||||||||||||||||||||||||||||||||||
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two and Three | 15,000 | |||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 24.00% | 24.00% | 24.00% | |||||||||||||||||||||||||||||||||||||||
Derivative, Loss on Derivative | $ 68,067 | |||||||||||||||||||||||||||||||||||||||||
Notes Payable | 15,000 | 60,000 | 15,000 | 15,000 | 15,000 | 75,000 | $ 75,000 | |||||||||||||||||||||||||||||||||||
Non-Related Party 7 [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | $ 60,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 148,033 | 148,033 | 148,033 | 148,033 | 106,681 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 33,333 | 27,300 | ||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 24.00% | |||||||||||||||||||||||||||||||||||||||||
Derivative, Loss on Derivative | $ 59,257 | |||||||||||||||||||||||||||||||||||||||||
Notes Payable | 120,000 | 120,000 | 120,000 | 120,000 | $ 50,000 | |||||||||||||||||||||||||||||||||||||
Non-Related Party 8 [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | $ 31,500 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 75,133 | 75,133 | 75,133 | 75,133 | 55,409 | |||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 2,573 | 1,944 | ||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 24.00% | |||||||||||||||||||||||||||||||||||||||||
Derivative, Loss on Derivative | $ 23,794 | |||||||||||||||||||||||||||||||||||||||||
Notes Payable | $ 12,500 | |||||||||||||||||||||||||||||||||||||||||
Non-Related Party 9 [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 29,381 | 63,144 | $ 29,381 | $ 29,381 | ||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | $ 64,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 50,670,000 | 50,670,000 | 50,670,000 | |||||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 70,938 | $ 70,938 | $ 70,938 | |||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 90,948 | 185,765 | 90,948 | 90,948 | 90,948 | 63,315 | 185,765 | |||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 8,607 | $ 12,442 | ||||||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 20.00% | |||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | 34,060 | $ 21,399 | 13,848 | 34,976 | ||||||||||||||||||||||||||||||||||||||
Notes Payable | 121,578 | $ 170,402 | 191,329 | 121,578 | 121,578 | $ 170,402 | 121,578 | $ 170,402 | 135,426 | 191,329 | 200,000 | |||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 856 | |||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Penalty | $ 6,400 | |||||||||||||||||||||||||||||||||||||||||
Brewer And Associates Consulting LLC [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 20,000 | |||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | $ 120,000 | |||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 75,219 | 75,219 | 75,219 | 75,219 | 47,481 | |||||||||||||||||||||||||||||||||||||
Line of Credit Facility, Interest Rate at Period End | 20.00% | |||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | 60,000 | $ 40,000 | ||||||||||||||||||||||||||||||||||||||||
Extinguishment of Debt, Nature of Restrictions on Assets Set Aside for Scheduled Payments | $7,000 | |||||||||||||||||||||||||||||||||||||||||
Derivative, Collateral, Obligation to Return Cash | $ 36,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Description | The conversion price is equal to 55% of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. | |||||||||||||||||||||||||||||||||||||||||
Non-Related Party 10 [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 50,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 130,626 | 130,626 | 130,626 | 130,626 | 96,157 | |||||||||||||||||||||||||||||||||||||
Derivative, Loss on Derivative | $ 46,734 | |||||||||||||||||||||||||||||||||||||||||
Notes Payable | 50,000 | 50,000 | 50,000 | 50,000 | 50,000 | $ 50,000 | ||||||||||||||||||||||||||||||||||||
Non-Related Party 11 [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 20,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 52,019 | 52,019 | 52,019 | 52,019 | 38,297 | |||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | 1,500 | 7,000 | 1,500 | |||||||||||||||||||||||||||||||||||||||
Derivative, Loss on Derivative | $ 17,829 | |||||||||||||||||||||||||||||||||||||||||
Notes Payable | 31,000 | 31,000 | 31,000 | 31,000 | $ 27,500 | $ 33,000 | $ 36,000 | |||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 3,000 | |||||||||||||||||||||||||||||||||||||||||
Non-Related Party 12 [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | 60,000 | |||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 5,000,000 | 1,000,000 | 10,000,000 | 5,000,000 | 5,000,000 | |||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 1,700 | $ 3,000 | ||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 202,400 | 202,400 | 202,400 | 202,400 | ||||||||||||||||||||||||||||||||||||||
Debt Instrument, Increase, Accrued Interest | 15,900 | |||||||||||||||||||||||||||||||||||||||||
Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two and Three | $ 76,076 | |||||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 10,000 | $ 10,000 | ||||||||||||||||||||||||||||||||||||||||
Derivative, Loss on Derivative | 75,900 | |||||||||||||||||||||||||||||||||||||||||
Notes Payable | 70,000 | 75,000 | $ 60,000 | $ 60,000 | $ 60,000 | 70,000 | 70,000 | 70,000 | 61,746 | $ 60,000 | $ 50,000 | |||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | 0 | 0 | 0 | 0 | $ 8,254 | |||||||||||||||||||||||||||||||||||||
Non-Related Party 13 [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 119,879 | $ 119,879 | $ 119,879 | $ 119,879 | ||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable, Current | $ 1,000,000 | |||||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 125,000,000 | 750,000,000 | 750,000,000 | 750,000,000 | 750,000,000 | 1,500,000 | 10,000,000 | |||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 119,700 | |||||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | $ 319,678 | $ 319,678 | $ 319,678 | $ 319,678 | ||||||||||||||||||||||||||||||||||||||
Repayments of Notes Payable | $ 50,000 | 27,000 | $ 2,250 | |||||||||||||||||||||||||||||||||||||||
Derivative, Loss on Derivative | 335,576 | |||||||||||||||||||||||||||||||||||||||||
Notes Payable | 219,879 | $ 120,000 | ||||||||||||||||||||||||||||||||||||||||
Debt Conversion, Original Debt, Amount | 100,000 | |||||||||||||||||||||||||||||||||||||||||
Repayments of Debt | $ 11,412 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Fair Value Disclosure | 275,000 | 275,000 | 275,000 | 275,000 | ||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 20,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Convertible, Terms of Conversion Feature | The Noteholder has the right to convert the note into shares of Common Stock at a conversion price of the lower of $0.0005 or 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion. | |||||||||||||||||||||||||||||||||||||||||
Non-Related Party 15 [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 240,000 | $ 240,000 | $ 240,000 | $ 240,000 | ||||||||||||||||||||||||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 16,000,000 | 16,000,000 | 16,000,000 | 16,000,000 | ||||||||||||||||||||||||||||||||||||||
Common Stock, Value, Issued | $ 4,688 | $ 4,688 | $ 4,688 | $ 4,688 | ||||||||||||||||||||||||||||||||||||||
Convertible Debt, Fair Value Disclosures | 640,000 | 640,000 | 640,000 | 640,000 | ||||||||||||||||||||||||||||||||||||||
Derivative, Loss on Derivative | 240,000 | |||||||||||||||||||||||||||||||||||||||||
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $ 40,000 | $ 40,000 | $ 40,000 | $ 40,000 | ||||||||||||||||||||||||||||||||||||||
Currently in default and negotiation [Member] | Brewer And Associates Consulting LLC [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Convertible Notes Payable | $ 20,000 | |||||||||||||||||||||||||||||||||||||||||
Restated Note [Member] | Non-Related Party 12 [Member] | ||||||||||||||||||||||||||||||||||||||||||
DEBTS (Details) - (4) [Line Items] | ||||||||||||||||||||||||||||||||||||||||||
Notes Payable | $ 75,900 |
DEBTS (Details) - Schedule of O
DEBTS (Details) - Schedule of Other Debt - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 | |
Schedule of Other Debt [Abstract] | |||
Note payable– Related Party (Net of discount of $1,200 and $2,400, respectively) | [1] | $ 13,200 | $ 12,000 |
Notes payable – Unrelated third parties (Net of discount of $1,000 and $17,870, respectively) | [2] | 1,387,877 | 1,469,690 |
Convertible notes payable – Unrelated third parties (Net of discount of $6,710 and $29,371, respectively) | [3] | 814,016 | 751,955 |
Convertible notes payable, at fair value | [4] | 2,776,488 | 1,156,341 |
Ending balances | 4,991,581 | 3,389,986 | |
Less: Long-term portion-Notes payable-Unrelated third parties | (4,616) | (51,410) | |
Less: Long-term portion-Convertible Notes payable-Unrelated third parties | (119,879) | ||
Current portion | $ 4,867,086 | $ 3,338,576 | |
[1] | During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At June 30, 2019 and December 31, 2018, we owed this director accrued interest of $150,372 and $141,808. The interest expense for the six-months ended June 30, 2019 and 2018 was $8,564 and $7,611, respectively, and $4,368 and $3,882 for the three-months ended June 30, 2019 and 2018, respectively. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. At June 30, 2019 and December 31, 2018, the principal balance of the loan is $13,200 and $12,000, net of debt discount of $1,200 and $2,400, respectively. The Note was settled in June 2020. | ||
[2] | At June 30, 2019 and December 31, 2018, the balance of $1,387,877 and $1,469,690 net of discount of $1,000 and $17,870, respectively, consisted of the following loans: ● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At June 30, 2019 and December 31, 2018, we owed principal balance of $169,634 and $192,974, and accrued interest of $45,456 and $40,033, respectively. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020. We recorded a gain on settlement of debt in other income for $18,841. The Company repaid $4,500 during the six months ended June 30, 2019. At June 30, 2019, the balance owed is $99,500 including the accrued interest of $21,023. The remaining principal balance of $91,156 and accrued interest of $24,433 is being disputed in court and negotiation for settlement (See Note 11). ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2019 and December 31, 2018, the accrued interest is $3,242 and $2,739. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the outstanding principal balance is $50,000 and accrued interest is $43,834 and $37,801. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2019 and December 31, 2018, the outstanding principal balance is $50,000 and accrued interest is $37,033 and $31,000. ● In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest were restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest were restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018.The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest were restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and was due June 17, 2019. The note is in default and negotiation of settlement. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the six months ended June 30, 2019 and 2018 was $3,616 and $2,765, respectively. The debt discount at June 30, 2019 and December 31, 2018 was $0 and $3,616. At June 30, 2019 and December 31, 2018, the principal balance is $282,983, and the accrued interest is $36,977 and $2,830, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. In January 2019, the principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). The remaining note of $15,000 was assigned to an unrelated third party and is in negotiation of settlement. At June 30, 2019 and December 31, 2018, the principal balance is $15,000 and $75,000, and the accrued interest is $1,371 and $17,271, respectively. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the accrued interest is $33,333 and $27,300. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the accrued interest is $2,573 and $1,944. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of June 30, 2019. At December 31, 2017, the principal balance of the loan was $191,329 and in negotiation of settlement. During June 2018, the loan was settled for $170,402 with scheduled repayments of approximately $7,000 per month through July 2020. We recorded a gain on settlement of debt in other income for $20,927 in June 2018. The Company repaid $34,976 during 2018 and $13,848 during the six months ended June 30, 2019. At June 30, 2019 and December 31, 2018, the principal balance is $121,578 and $135,426. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the principal balance of the note is $50,000. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 each due in September 2019 and 2020, respectively. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and is due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the six months ended June 30, 2019 and 2018 was $5,000 and $1,500, respectively. The debt discount at June 30, 2019 and December 31, 2018 is $2,500 and $6,000. Repayments of $1,500 and $7,000 have been made during 2017 and 2018, respectively. During the six months ended June 30, 2019, repayment of $1,500 has been made. The Note is under personal guarantee by Mr. Deitsch. At June 30, 2019 and December 31, 2018, the principal balance of the note is $31,000 and $27,500, net of debt discount of $1,000 and $6,000, respectively. The note is in default and in negotiation of settlement. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment. The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the six months ended June 30, 2019 was $1,587 and $6,667. Amortization for the debt discount and original issuance discount was $3,616 and $4,617, respectively for the six months ended June 30, 2018. As of June 30, 2019 and December 31, 2018, the amount due is $70,000 and $61,746, net of discount of $0 and $8,254. During January and July 2020, this Note and the Note of $76,076 amended in August 2018(See Note 6(3)) were combined and restated and was due January 2021. The Note is in negotiation of restatement. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. 1,500,000 shares of common stocks were issued due to the default of repayments with a fair value of $2,250 in 2018. During March 2020, $50,000 of the Note of $120,000 with original issuance discount of 20,000 originated in November 2017 was settled for 125,000,000 shares. An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $119,700. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. At June 30, 2019 and December 31, 2018, the principal balance of the loan is $120,000. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600 during 2018. At June 30, 2019 and December 31, 2018, the principal balance of the note is $18,000 and the accrued interest is $2,000 and $0, respectively. | ||
[3] | At June 30, 2019 and December 31, 2018, the balance of $814,016 and $751,955 net of discount of $6,710 and $29,371, respectively, consisted of the following convertible loans: ● On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. The first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014. The notes carry interest at 8% and were due on March 19, 2018. The note holders have the right to convert the notes into shares of Common Stock at a price of $0.20. During 2018, repayment of $3,000 was made. At December 31, 2018, the principal balance of the note is $27,000 and the accrued interest is $11,412. The two outstanding Notes were settled in connection with issuance of the convertible note in the amount of up to $1,000,000 in February 2019 (See Note 6(4)), as a result, we recorded a gain on settlement of debt in other income for $38,412. ● During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and is due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The remaining debt discount of $950 was fully amortized during the three months ended March 31, 2019. The note is under personal guarantee by Mr. Deitsch. At June 30, 2019 and December 31, 2018, the convertible note payable was recorded at $76,076 and $75,126, net of discount of $0 and $950, respectively. The accrued interest as of June 30, 2019 and December 31, 2018 is $12,150 and $8,177. During January and July 2020, this Note and the Note of $60,000 amended in November 2018(See Note 6(2)) were combined and restated and was due January 2021. The Note is in negotiation of restatement. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of June 30, 2019. The loan is in default and in negotiation of settlement. 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500 during 2018. At June 30, 2019 and December 31, 2018, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock. The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. These Notes are in default and in negotiation of settlement. During the first quarter of 2019, we issued convertible notes payable of $70,000 with original issuance discount of $5,000. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price of $0.0005 per share. In addition, upon the issuance of convertible notes, the Company granted the total of 110,000,000 warrants at an exercise price of $0.001 per share. The warrants were valued at $8,147 using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. The Notes were further restated in December 2019, and August and October 2020. They are in default and in negotiation of settlement. During the second quarter of 2019, we restated two convertible notes payable with additional original issue discount of $6,400 and issued 6,000,001 shares of common stock with a fair value of $1,800 (See Note 7). The two restated notes were due in August 2019 and are in default. The total discount of $8,200 was amortized over the term of the notes. Repayment of $10,000 was made in May 2019. Amortization for the six months ended June 30, 2019 and 2018 was $43,058 and $144,062. At June 30, 2019 and December 31, 2018, the principal balance of the notes, net of discount of $6,710 and $28,421 is $677,940 and $589,829. | ||
[4] | At June 30, 2019 and December 31, 2018, the balance of $2,821,182 and $1,156,341, respectively, consisted of the following convertible loans: ● During December 2016, we issued a Convertible Debenture to an unrelated third party in the amount of $110,000. The note carries interest at 12% and matured on September 8, 2017. Unless previously converted into shares of restricted common stock, the Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading prices of our restricted common stock for the twenty-five trading days preceding the conversion date. During June and July 2017, the Note holder made conversions of a total of 179,800,000 shares of stock satisfying the principal balance of $63,001 and accrued interest for a fair value of $298,575. At December 31, 2017, the convertible note payable, at fair value, was recorded at $147,314. During February 2018, the remaining balance of $46,999 with accrued interest of $2,820 was assigned and sold to an unrelated third party in the form of a Convertible Redeemable Note. As part of the debt sale, the Company entered into a settlement agreement with the original noteholder for a settlement of a default penalty of the original debt. During February and July, 2018, we issued a total of 105,157,409 shares of our restricted common stock to the original Note holder with a fair value of $147,220. At December 31, 2018, the Company owed additional shares to the original noteholder and recorded an accrual of $32,400 to account for the cost of the shares, and the shares were issued in January 2019 (See Notes 7). The new note of $49,819 carries interest at 8% and was due on February 13, 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Noteholder has the right to convert the note into shares of our restricted common stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five prior trading days including the conversion date. During September 2018, the Noteholder made a conversions of 52,244,433 shares of our restricted common stock with a fair value of $37,011 in satisfaction of principal balance of $15,000 and accrued interest in full. At June 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $34,819, at fair value, was recorded at $90,965 and $62,508. ● During February 2018, we issued a convertible denture in the amount of $200,000 to an unrelated third party. The note carries interest at 8% and was due in February 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $1,646,242. At June 30, 2019 and December 31, 2018, the convertible note payable with principal balance of $200,000, at fair value, was recorded at $520,037 and $358,665. The note carries additional $200,000 “Back-end Note” ($100,000 each) with the same terms as the original note. ● During April 2018, $65,000 of one of the $100,000 Back-end Note was funded. The note carries interest at 8% and is due in February 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $110,700. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $169,012 and $115,165. ● During March 2018, we issued a convertible denture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and was due in March 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $48,418. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $153,556 and $107,329. The note carries an additional “Back-end Note” with the same terms as the original note that enables the lender to lend to us another $60,000. ● During June 2018, the $60,000 Back-end Note was funded. The note carries interest at 8% and is due in March 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $68,067. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $153,556 and $105,334. ● During May 2018, we issued a convertible denture in the amount of $60,000 to an unrelated third party. The note carries interest at 8% and was due in May 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $59,257. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $148,033 and $106,681. ● During August 2018, we issued a convertible denture in the amount of $31,500 to an unrelated third party. The note carries interest at 8% and was due in August 2019. We have accrued interest at default interest rate of 24% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at sixty percent of the lowest trading price of our restricted common stock for the twenty-five trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $23,794. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $75,133 and $55,409. All of the above convertible notes with principal balance of a total of $511,319 were settled in October 2020 (See Note 12). ● During May 2017, we issued a Convertible Debenture in the amount of $64,000 to an unrelated third party. The note carries interest at 8% and was due on May 4, 2018. We have accrued interest at default interest rate of 20% after the note’s maturity date. The Note holder has the right to convert the note into shares of Common Stock at a sixty percent (60%) of the lowest trading price of our restricted common stock for the twenty trading days preceding the conversion date. During November 2017, the Note holder made a conversion of our restricted common stocks satisfying the principal balance of $856 and penalty of $6,400 for a fair value of $21,399. At December 31, 2017, the convertible note payable, at fair value, was recorded at $185,765. During February 2018, the remaining balance of $63,144 with accrued interest and penalty of $12,442 was assigned and sold to three unrelated third parties. During June 2018, a Note holder made a conversion of 50,670,000 shares of our restricted common stock with a fair value of $70,938 in satisfaction of the balance of $34,060 plus accrued interest of $8,607. At June 30, 2019 and December 31, 2018, the remaining principal of $29,381, at fair value, was recorded at $90,948 and $63,315. ● On March 28, 2016, we signed an expansion agreement with Brewer and Associates Consulting, LLC (“B+A”) to the original consulting agreement dated on October 15, 2015 for consulting services for twelve months for a monthly fee of $7,000. To relieve our cash obligation of $36,000 per original agreement, we issued three convertible notes for a total of $120,000 which includes the fees due under the original agreement and the new monthly fees due under the expansion agreement. The $40,000 and $60,000 of the Notes were paid in full as of December 31, 2016 and December 31, 2017, respectively. The remaining balance of $20,000 Notes is in default and negotiation of settlement. We have accrued interest at default interest rate of 20% after the note’s maturity date. The conversion price is equal to 55% of the average of the three lowest volume weighted average prices for the three consecutive trading days immediately prior to but not including the conversion date. At June 30, 2019 and December 31, 2018, the convertible notes payable with principal balance of $20,000, at fair value, were recorded at $75,219 and $47,481, respectively. ● During July 2018, we issued a convertible denture in the amount of $50,000 to an unrelated third party. The note carries interest at 8% and is due in July 2019. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $46,734. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $130,626 and $96,157. ● During August 2018, we issued a convertible denture in the amount of $20,000 to an unrelated third party. The note carries interest at 8% and is due in August 2019. The Note holder has the right to convert the note into shares of Common Stock at fifty five percent of the average three lowest trading price of our restricted common stock for the fifteen trading days including the date of receipt of conversion notice. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $17,829. At June 30, 2019 and December 31, 2018, the convertible note payable, at fair value, was recorded at $52,019 and $38,297. ● During January 2019, the principal balance of $60,000 from a promissory note of $75,000 originated in September 2016 (See Note 6(2)) and accrued interest of $15,900 was restated in the form of a Convertible Note. The new note of $75,900 was due in one year from the restatement of the note. The Noteholder has the right to convert the note into shares of Common Stock at 50% discount to the average trading price of the three lowest closing stock prices for the twenty days prior to the notice of conversion. In connection with the issuance of the convertible note payable, we recorded a day-one derivative loss of $75,900. At June 30, 2019, the convertible note payable, at fair value, was recorded at $202,400. |
DEBTS (Details) - Schedule of_2
DEBTS (Details) - Schedule of Other Debt (Parentheticals) - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 | |
Related Party [Member] | |||
DEBTS (Details) - Schedule of Other Debt (Parentheticals) [Line Items] | |||
Debt Discount | [1] | $ 1,200 | $ 2,400 |
Non-Related Party [Member] | |||
DEBTS (Details) - Schedule of Other Debt (Parentheticals) [Line Items] | |||
Debt Discount | [2] | 1,000 | 17,870 |
Convertible Notes Payable [Member] | |||
DEBTS (Details) - Schedule of Other Debt (Parentheticals) [Line Items] | |||
Debt Discount | [3] | $ 6,710 | $ 29,371 |
[1] | During 2010 we borrowed $200,000 from one of our directors. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. The loan is under personal guarantee by Mr. Deitsch. We repaid principal balance in full as of December 31, 2016. At June 30, 2019 and December 31, 2018, we owed this director accrued interest of $150,372 and $141,808. The interest expense for the six-months ended June 30, 2019 and 2018 was $8,564 and $7,611, respectively, and $4,368 and $3,882 for the three-months ended June 30, 2019 and 2018, respectively. In December 2017, we issued a promissory note to a related party in the amount of $12,000 with original issuance discount of $2,000. The note was amended in December 2018 with original issuance discount of $2,400 and was due in twelve months from the execution and funding of the note. At June 30, 2019 and December 31, 2018, the principal balance of the loan is $13,200 and $12,000, net of debt discount of $1,200 and $2,400, respectively. The Note was settled in June 2020. | ||
[2] | At June 30, 2019 and December 31, 2018, the balance of $1,387,877 and $1,469,690 net of discount of $1,000 and $17,870, respectively, consisted of the following loans: ● In August 2016, we issued two Promissory Notes for a total of $200,000 ($100,000 each) to a company owned by a former director of the Company. The notes carry interest at 12% annually and were due on the date that was six-months from the execution and funding of the note. Upon default in February 2017, the Notes became convertible at $0.008 per share. During March 2017, we repaid principal balance of $6,365. During April 2017, the Notes with accrued interest were restated. The restated principal balance of $201,818 bears interest at 12% annually and was due October 12, 2017. During June 2017, we repaid principal balance of $8,844. The loan was reclassified to notes payable – unrelated third parties after the director resigned in March 2018. At June 30, 2019 and December 31, 2018, we owed principal balance of $169,634 and $192,974, and accrued interest of $45,456 and $40,033, respectively. The principal balance of $101,818 and accrued interest of $21,023 were settled on February 15, 2019 for $104,000 with scheduled payments through May 1, 2020. We recorded a gain on settlement of debt in other income for $18,841. The Company repaid $4,500 during the six months ended June 30, 2019. At June 30, 2019, the balance owed is $99,500 including the accrued interest of $21,023. The remaining principal balance of $91,156 and accrued interest of $24,433 is being disputed in court and negotiation for settlement (See Note 11). ● On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), we agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where we agreed to pay $175,000, which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). We repaid $25,000 during the three months ended March 31, 2012. We did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 142,858 shares (5,714,326 shares pre reverse stock split) of our free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 penalty was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in June 2012. In August 2013 the debt of $281,772 reverted back to LPR. ● At December 31, 2012, we owed University Centre West Ltd. approximately $55,410 for rent, which was assigned and sold to Southridge is currently outstanding and carries no interest. ● In April 2016, we issued a promissory note to an unrelated third party in the amount of $10,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2019 and December 31, 2018, the accrued interest is $3,242 and $2,739. ● In May 2016, the Company issued a promissory note to an unrelated third party in the amount of $75,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. During April 2017, we accepted the offer of a settlement to issue 5,000,000 common shares as a repayment of $25,000. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the outstanding principal balance is $50,000 and accrued interest is $43,834 and $37,801. ● In June 2016, the Company issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and negotiation of settlement. At June 30, 2019 and December 31, 2018, the outstanding principal balance is $50,000 and accrued interest is $37,033 and $31,000. ● In August 2016, we issued a promissory note to an unrelated third party in the amount of $150,000 bearing monthly interest at a rate of 2.5%. The note was due in six months from the execution and funding of the note. During April 2017, the note with accrued interest were restated. The restated principal balance of $180,250 bears monthly interest at a rate of 2.5% and was due October 20, 2017. During January 2018, the note with accrued interest were restated. The restated principal balance of $220,506 bears monthly interest at a rate of 2.5% and was due July 12, 2018. In connection with this restated note, we issued 2,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,765 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the year ended December 31, 2018 was $2,765. During July 2018, we issued 5,000,000 restricted shares due to the default on repayment of the promissory note of $220,506 restated in January 2018.The shares were valued at fair value of $5,500. During December 2018, the note with accrued interest were restated. The restated principal balance of $282,983 bears monthly interest at a rate of 2.0% and was due June 17, 2019. The note is in default and negotiation of settlement. In connection with this restated note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,945 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization for the debt discount for the six months ended June 30, 2019 and 2018 was $3,616 and $2,765, respectively. The debt discount at June 30, 2019 and December 31, 2018 was $0 and $3,616. At June 30, 2019 and December 31, 2018, the principal balance is $282,983, and the accrued interest is $36,977 and $2,830, respectively. ● On September 26, 2016, we issued a promissory note to an unrelated third party in the amount of $75,000 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. In January 2019, the principal balance of $60,000 and accrued interest of $15,900 was restated in the form of a Convertible Note (See Note 6(4)). The remaining note of $15,000 was assigned to an unrelated third party and is in negotiation of settlement. At June 30, 2019 and December 31, 2018, the principal balance is $15,000 and $75,000, and the accrued interest is $1,371 and $17,271, respectively. ● In October 2016, we issued a promissory note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2%. The note was due in six months from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the accrued interest is $33,333 and $27,300. ● In June 2017, we issued a promissory note to an unrelated third party in the amount of $12,500 bearing interest at 10% annually. The note was due in one year from the execution and funding of the note. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the accrued interest is $2,573 and $1,944. ● During July 2017, we received a loan for a total of $200,000 from an unrelated third party. The loan was repaid through scheduled payments through August 2017 along with interest on average 15% annum. We have recorded loan costs in the amount of $5,500 for the loan origination fees paid at inception date. The debt discount was fully amortized as of June 30, 2019. At December 31, 2017, the principal balance of the loan was $191,329 and in negotiation of settlement. During June 2018, the loan was settled for $170,402 with scheduled repayments of approximately $7,000 per month through July 2020. We recorded a gain on settlement of debt in other income for $20,927 in June 2018. The Company repaid $34,976 during 2018 and $13,848 during the six months ended June 30, 2019. At June 30, 2019 and December 31, 2018, the principal balance is $121,578 and $135,426. ● In July 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issue discount of $10,000. The note was due in six months from the execution and funding of the note. The original issuance discount was fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. At June 30, 2019 and December 31, 2018, the principal balance of the note is $50,000. ● In September 2017, we issued a promissory note to an unrelated third party in the amount of $36,000 with original issue discount of $6,000. During September 2018 and 2019, the Note was amended with original issuance discount of $6,000 each due in September 2019 and 2020, respectively. The Note was further restated in September 2020. The restated principal balance was $33,000 with the original issuance discount of $3,000 and is due March 2021. The original issue discount is amortized over the term of the loan. Amortization for the debt discount for the six months ended June 30, 2019 and 2018 was $5,000 and $1,500, respectively. The debt discount at June 30, 2019 and December 31, 2018 is $2,500 and $6,000. Repayments of $1,500 and $7,000 have been made during 2017 and 2018, respectively. During the six months ended June 30, 2019, repayment of $1,500 has been made. The Note is under personal guarantee by Mr. Deitsch. At June 30, 2019 and December 31, 2018, the principal balance of the note is $31,000 and $27,500, net of debt discount of $1,000 and $6,000, respectively. The note is in default and in negotiation of settlement. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $50,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,200 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. At December 31, 2017, the principal balance of the note is $60,000. Debt discount and original issuance discount were fully amortized as of December 31, 2018. During April 2018, we issued a total of 1,000,000 restricted shares to a Note holder due to the default on repayment. The shares were valued at fair value of $1,700. During April 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due October 2018. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $8,678 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount and original issuance discount have been fully amortized as of December 31, 2018. During November 2018, the Note was restated in the amount of $60,000 including the original issuance discount of $10,000 due May 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,381 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Pursuant to the restatement of the Note, the Company agreed that the original issuance discount of $10,000 from the April 2018 Note would be paid to the lender upon execution of restated Note in November 2018. The settlement agreement executed in December 2018 provides that 10,000,000 shares are issued due to the late payment. The shares were valued at $3,000. During July 2019, payment of original issuance discount of $10,000 was made. The restated Note in November 2018 and prior notes are all under personal guarantee by Mr. Deitsch. Amortization of debt discount and original issuance discount for the six months ended June 30, 2019 was $1,587 and $6,667. Amortization for the debt discount and original issuance discount was $3,616 and $4,617, respectively for the six months ended June 30, 2018. As of June 30, 2019 and December 31, 2018, the amount due is $70,000 and $61,746, net of discount of $0 and $8,254. During January and July 2020, this Note and the Note of $76,076 amended in August 2018(See Note 6(3)) were combined and restated and was due January 2021. The Note is in negotiation of restatement. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $120,000 with original issuance discount of $20,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 10,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $5,600 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The loan is in default and in negotiation of settlement. 1,500,000 shares of common stocks were issued due to the default of repayments with a fair value of $2,250 in 2018. During March 2020, $50,000 of the Note of $120,000 with original issuance discount of 20,000 originated in November 2017 was settled for 125,000,000 shares. An additional 36,000,000 shares were issued to satisfy the default provision of the original note and 10,000,000 shares were issued along with the restatement. The total fair value of issued stock was $119,700. The remaining balance of $70,000 was restated with additional issuance discount of $14,000. The $84,000 due in September 2020 is in default and negotiation of further settlement. At June 30, 2019 and December 31, 2018, the principal balance of the loan is $120,000. ● In November 2017, we issued a promissory note to an unrelated third party in the amount of $18,000 with original issuance discount of $3,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $2,900 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of December 31, 2018. The note is in default and in negotiation of settlement. 7,000,000 shares of common stock were issued due to the default of repayments with a fair value of $5,600 during 2018. At June 30, 2019 and December 31, 2018, the principal balance of the note is $18,000 and the accrued interest is $2,000 and $0, respectively. | ||
[3] | At June 30, 2019 and December 31, 2018, the balance of $814,016 and $751,955 net of discount of $6,710 and $29,371, respectively, consisted of the following convertible loans: ● On March 19, 2014, we issued two Convertible Debentures in the amount of up to $500,000 each (total $1,000,000) to two non-related parties. The first tranche of $15,000 each (total $30,000) of the funds was received during the first quarter of 2014. The notes carry interest at 8% and were due on March 19, 2018. The note holders have the right to convert the notes into shares of Common Stock at a price of $0.20. During 2018, repayment of $3,000 was made. At December 31, 2018, the principal balance of the note is $27,000 and the accrued interest is $11,412. The two outstanding Notes were settled in connection with issuance of the convertible note in the amount of up to $1,000,000 in February 2019 (See Note 6(4)), as a result, we recorded a gain on settlement of debt in other income for $38,412. ● During July 2016, we issued a convertible note to an unrelated third party in the amount of $50,000 bearing monthly interest at a rate of 2.0% and convertible at $0.05 per share. During January 2017, the Note was restated with principal amount of $56,567 bearing monthly interest rate of 2.5%. The New Note of $56,567 was due on July 26, 2017 and convertible at $0.05 per share. During February 2018, the Notes with accrued interest of $65,600 was restated. The restated principal balance of $65,600 bears monthly interest at a rate of 2.5% and was due August 14, 2018. In connection with this restated note, we issued 1,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $4,035 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discount was fully amortized as of December 31, 2018. During August 2018, the Notes with accrued interest of $10,476 were restated. The restated principal balance of $76,076 bears monthly interest at a rate of 2.5% and is due February 2019. In connection with this restated note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,800 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. Amortization of debt discount of $2,850 has been recorded as of December 31, 2018. The remaining debt discount of $950 was fully amortized during the three months ended March 31, 2019. The note is under personal guarantee by Mr. Deitsch. At June 30, 2019 and December 31, 2018, the convertible note payable was recorded at $76,076 and $75,126, net of discount of $0 and $950, respectively. The accrued interest as of June 30, 2019 and December 31, 2018 is $12,150 and $8,177. During January and July 2020, this Note and the Note of $60,000 amended in November 2018(See Note 6(2)) were combined and restated and was due January 2021. The Note is in negotiation of restatement. ● In October 2017, we issued a promissory note to an unrelated third party in the amount of $60,000 with original issuance discount of $10,000. The note was due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, we issued 5,000,000 shares of our restricted common stock. We recorded a debt discount in the amount of $3,300 to reflect the value of the common stock as a reduction to the carrying amount of the debt and a corresponding increase to common stock and additional paid-in capital. The debt discounts were fully amortized as of June 30, 2019. The loan is in default and in negotiation of settlement. 1,000,000 shares of common stock were issued due to the default of repayments with a fair value of $1,500 during 2018. At June 30, 2019 and December 31, 2018, the principal balance of the note is $60,000. ● During January through December 2018, we issued convertible notes payable to the 20 unrelated third parties for a total of $618,250 with original issue discount of $62,950. The notes are due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price ranging from $0.0003 to $0.001 per share. The difference between the conversion price and the fair value of the Company’s common stock on the date of issuance of the convertible notes resulted in a beneficial conversion feature in the amount of $249,113. In addition, upon the issuance of convertible notes, the Company issued 10,250,000 shares of common stock. The Company has recorded a debt discount in the amount of $6,542 to reflect the value of the common stock as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stock and additional paid-in capital. The total discount of $255,655 and original issuance discount of $62,950 was amortized over the term of the debt. These Notes are in default and in negotiation of settlement. During the first quarter of 2019, we issued convertible notes payable of $70,000 with original issuance discount of $5,000. The notes were due in six months from the execution and funding of each note. The notes are convertible into shares of Company’s common stock at a conversion price of $0.0005 per share. In addition, upon the issuance of convertible notes, the Company granted the total of 110,000,000 warrants at an exercise price of $0.001 per share. The warrants were valued at $8,147 using the Black-Scholes method and recorded as a debt discount that was amortized over the life of the notes. The Notes were further restated in December 2019, and August and October 2020. They are in default and in negotiation of settlement. During the second quarter of 2019, we restated two convertible notes payable with additional original issue discount of $6,400 and issued 6,000,001 shares of common stock with a fair value of $1,800 (See Note 7). The two restated notes were due in August 2019 and are in default. The total discount of $8,200 was amortized over the term of the notes. Repayment of $10,000 was made in May 2019. Amortization for the six months ended June 30, 2019 and 2018 was $43,058 and $144,062. At June 30, 2019 and December 31, 2018, the principal balance of the notes, net of discount of $6,710 and $28,421 is $677,940 and $589,829. |
STOCKHOLDERS' DEFICIT (Details)
STOCKHOLDERS' DEFICIT (Details) - USD ($) | 1 Months Ended | 2 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||
Jan. 31, 2021 | Jul. 31, 2020 | Jan. 31, 2020 | Sep. 30, 2019 | Jul. 31, 2019 | Jun. 30, 2019 | May 30, 2019 | Apr. 30, 2019 | Jan. 31, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018 | Dec. 31, 2018 | |
STOCKHOLDERS' DEFICIT (Details) [Line Items] | ||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 110,000 | $ 219,879 | $ 32,400 | |||||||||||||
Common Stock, Shares, Issued (in Shares) | 5,038,246,111 | 5,038,246,111 | 5,038,246,111 | 5,038,246,111 | 4,046,746,110 | |||||||||||
Common Stock, Value, Issued | $ 5,038,246 | $ 5,038,246 | $ 5,038,246 | $ 5,038,246 | $ 4,046,746 | |||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 105,000 | $ 235,913 | ||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 16,000,000 | 750,000,000 | ||||||||||||||
Share-based Goods and Nonemployee Services Transaction, Stockholders' Equity | 20,000 | $ 10,000 | 50,000 | $ 10,000 | ||||||||||||
Stock Issued During Period, Value, Other | $ 107,500 | $ 700 | $ 45,000 | $ 4,000 | $ 1,500 | $ 4,688 | $ 275,000 | |||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $ 23,500 | 23,500 | 23,500 | 23,500 | ||||||||||||
Increase (Decrease) in Notes Payable, Current | $ 100,000 | |||||||||||||||
Restricted Stock [Member] | ||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) [Line Items] | ||||||||||||||||
Common Stock, Shares, Issued (in Shares) | 81,000,000 | |||||||||||||||
Common Stock, Value, Issued | $ 32,400 | |||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 32,400 | |||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 15,000,000 | 120,000,000 | 100,000,000 | 3,500,000 | ||||||||||||
Shares Issued, Price Per Share (in Dollars per share) | $ 0.0012 | $ 0.0012 | $ 0.0012 | |||||||||||||
Stock Issued During Period, Value, Other | $ 6,000 | $ 24,000 | $ 1,050 | |||||||||||||
Share-based Payment Arrangement, Employee [Member] | ||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) [Line Items] | ||||||||||||||||
Share-based Goods and Nonemployee Services Transaction, Stockholders' Equity | $ 6,500 | |||||||||||||||
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax | $ 6,500 | |||||||||||||||
Convertible Notes Payable [Member] | ||||||||||||||||
STOCKHOLDERS' DEFICIT (Details) [Line Items] | ||||||||||||||||
Stock Issued During Period, Shares, Other (in Shares) | 6,000,001 | |||||||||||||||
Stock Issued During Period, Value, Other | $ 1,800 |
STOCKHOLDERS' DEFICIT (Detail_2
STOCKHOLDERS' DEFICIT (Details) - Schedule of Stockholders' Equity - USD ($) shares in Millions | Jun. 06, 2019 | May 31, 2019 | May 06, 2019 |
Schedule of Stockholders' Equity [Abstract] | |||
Number of shares converted | 250,000,000 | 250,000,000 | 250,000,000 |
Fair Value of Debt Converted | $ 100,000 | $ 100,000 | $ 75,000 |
STOCK WARRANTS (Details)
STOCK WARRANTS (Details) - USD ($) | Mar. 31, 2017 | Apr. 04, 2016 | Mar. 03, 2016 | Apr. 01, 2014 | Sep. 12, 2013 | Sep. 03, 2013 | Mar. 01, 2013 | Oct. 31, 2020 | Aug. 31, 2020 | Dec. 31, 2019 | Feb. 28, 2019 | Apr. 30, 2014 | Mar. 31, 2013 | Jun. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 |
STOCK WARRANTS (Details) [Line Items] | ||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 39,930,000 | 92,100,000 | 44,000,000 | |||||||||||||
Notes Payable | $ 4,991,581 | $ 3,389,986 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested | $ 0 | |||||||||||||||
Share Price (in Dollars per share) | $ 0.0004 | |||||||||||||||
Warrants Granted March 2013 [Member] | ||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | ||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 65,000 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.01 | |||||||||||||||
Investment Warrants Expiration Date | Mar. 22, 2018 | |||||||||||||||
Warrants Granted September 3rd 2013 [Member] | ||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | ||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 500,000 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.025 | |||||||||||||||
Investment Warrants Expiration Date | Sep. 12, 2018 | |||||||||||||||
Warrants Granted September 12th 2013 [Member] | ||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | ||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 375,000 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.01 | |||||||||||||||
Investment Warrants Expiration Date | Sep. 12, 2018 | |||||||||||||||
Warrants Granted March 31, 2017 [Member] | ||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | ||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 6,000,000 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.005 | |||||||||||||||
Investment Warrants Expiration Date | Mar. 30, 2020 | |||||||||||||||
Notes Payable | $ 80,000 | |||||||||||||||
Warrants Not Settleable in Cash, Fair Value Disclosure | $ 1,203 | 977 | ||||||||||||||
Warrants Granted March 3rd 2016 [Member] | ||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | ||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 2,500,000 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.03 | |||||||||||||||
Investment Warrants Expiration Date | Mar. 3, 2021 | |||||||||||||||
Warrants Not Settleable in Cash, Fair Value Disclosure | 731 | 491 | ||||||||||||||
Warrants Granted April 4th 2016 [Member] | ||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | ||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 4,000,000 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.05 | |||||||||||||||
Investment Warrants Expiration Date | Apr. 4, 2019 | |||||||||||||||
Warrants Not Settleable in Cash, Fair Value Disclosure | 0 | 0 | ||||||||||||||
Warrants Granted April 2014 [Member] | ||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | ||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 100,000 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.025 | |||||||||||||||
Investment Warrants Expiration Date | Apr. 9, 2019 | |||||||||||||||
Warrants Not Settleable in Cash, Fair Value Disclosure | $ 0 | $ 0 | ||||||||||||||
Warrants Granted February 2019 [Member] | ||||||||||||||||
STOCK WARRANTS (Details) [Line Items] | ||||||||||||||||
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 110,000,000 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.001 | |||||||||||||||
Warrants Not Settleable in Cash, Fair Value Disclosure | $ 8,147 |
STOCK WARRANTS (Details) - Sche
STOCK WARRANTS (Details) - Schedule of Warrants Outstanding - $ / shares | 6 Months Ended | 12 Months Ended |
Jun. 30, 2019 | Dec. 31, 2018 | |
Schedule of Warrants Outstanding [Abstract] | ||
Number of shares, Beginning | 12,600,000 | 13,540,000 |
Weighted average exercise price, Beginning (in Dollars per share) | $ 0.026 | $ 0.023 |
Number of shares, Exercised | ||
Weighted average exercise price Exercised (in Dollars per share) | ||
Number of shares, Issued | 110,000,000 | |
Weighted average exercise price Issued | 0.001 | |
Number of shares, Forfeited | (4,100,000) | (940,000) |
Weighted average exercise price Forfeited (in Dollars per share) | $ 0.021 | $ 0.015 |
Number of shares, End | 118,500,000 | 12,600,000 |
Weighted average exercise price, End (in Dollars per share) | $ 0.01 | $ 0.026 |
STOCK WARRANTS (Details) - Sc_2
STOCK WARRANTS (Details) - Schedule of Fixed-Price Warrants Outstanding - $ / shares | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2019 | Dec. 31, 2018 | Dec. 31, 2017 | |
STOCK WARRANTS (Details) - Schedule of Fixed-Price Warrants Outstanding [Line Items] | |||
Weighted Average Number Outstanding (in Shares) | 86,233,702 | 12,600,000 | |
Weighted Average Contractual Life | 200 days | 1 year 40 days | |
Weighted Average Exercise Price | $ 0.01 | $ 0.026 | $ 0.023 |
Minimum [Member] | |||
STOCK WARRANTS (Details) - Schedule of Fixed-Price Warrants Outstanding [Line Items] | |||
Exercise Price | 0.001 | 0.005 | |
Maximum [Member] | |||
STOCK WARRANTS (Details) - Schedule of Fixed-Price Warrants Outstanding [Line Items] | |||
Exercise Price | $ 0.03 | $ 0.05 |
ACCRUED EXPENSES (Details) - Sc
ACCRUED EXPENSES (Details) - Schedule of Accrued Expenses - USD ($) | Jun. 30, 2019 | Dec. 31, 2018 |
Schedule of Accrued Expenses [Abstract] | ||
Accrued consulting fees | $ 192,050 | $ 161,550 |
Accrued settlement expenses | 315,000 | 347,400 |
Accrued payroll taxes | 144,093 | 120,182 |
Accrued interest | 217,972 | 180,509 |
Accrue others | 18,833 | 22,208 |
Total | $ 887,948 | $ 831,849 |
PREPAID EXPENSES AND OTHER CU_3
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - Prepaid Venom [Member] - USD ($) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2019 | Dec. 31, 2018 | |
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) [Line Items] | ||
SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease) | $ 0 | $ 47,757 |
Deferred Tax Assets, Valuation Allowance | $ 200,911 | $ 200,911 |
PREPAID EXPENSES AND OTHER CU_4
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - Schedule of Prepaid Expenses - USD ($) | Jun. 30, 2019 | Mar. 31, 2018 |
Schedule of Prepaid Expenses [Abstract] | ||
Supplier advances for future purchases | $ 221,759 | $ 200,911 |
Reserve for supplier advances | (200,911) | (200,911) |
Net supplier advances | 20,848 | |
Prepaid professional fees | 13,000 | |
Deferred stock compensation | 23,500 | 50,000 |
Total | $ 44,348 | $ 63,000 |
COMMITMENTS AND CONTINGENCIES_2
COMMITMENTS AND CONTINGENCIES (Details) - Operating Leases - Recepto Pharm [Member] | Aug. 01, 2017USD ($)$ / item | Feb. 29, 2016$ / mo |
COMMITMENTS AND CONTINGENCIES (Details) - Operating Leases [Line Items] | ||
Lessor, Operating Lease, Term of Contract | 3 years | |
Operating Leases, Rent Expense, Monthly | 6,900 | 3,200 |
Lessor, Operating Lease, Renewal Term | 5 years | |
Increase (Decrease) in Prepaid Interest | $ 0.05 |
COMMITMENTS AND CONTINGENCIES_3
COMMITMENTS AND CONTINGENCIES (Details) - Consulting Agreements - USD ($) | 1 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||
Dec. 31, 2016 | Oct. 31, 2015 | Jul. 30, 2015 | Jun. 30, 2019 | Dec. 31, 2018 | Jan. 31, 2021 | Oct. 31, 2020 | Sep. 30, 2020 | Jul. 31, 2020 | Jan. 31, 2020 | Sep. 30, 2019 | Aug. 31, 2019 | |
COMMITMENTS AND CONTINGENCIES (Details) - Consulting Agreements [Line Items] | ||||||||||||
Common Stock, Shares, Issued | 5,038,246,111 | 4,046,746,110 | ||||||||||
Debt Instrument, Face Amount | $ 166,926 | $ 84,000 | $ 333,543 | $ 22,000 | $ 148,225 | $ 60,000 | $ 282,983 | |||||
Consultant Agreement 2 [Member] | ||||||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Consulting Agreements [Line Items] | ||||||||||||
Accrued Liabilities for Commissions, Expense and Taxes | $ 19,150 | $ 19,150 | ||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted | 2,500,000 | |||||||||||
Payment on a monthly basis | $ 3,000 | |||||||||||
Deferred Compensation Arrangement with Individual, Recorded Liability | $ 31,750 | |||||||||||
Deferred Compensation Arrangement with Individual, Shares Issued | 1,000,000 | |||||||||||
Share Based Compensation, Shares Not Yet Issued | 1,500,000 | 1,500,000 | ||||||||||
Patricia Meding, et. al. v. ReceptoPharm, Inc. [Member] | ||||||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Consulting Agreements [Line Items] | ||||||||||||
Consulting Services Agreement, Term | 5 years | |||||||||||
Common Stock, Shares, Issued | 500,000 | |||||||||||
Debt Instrument, Term | 1 year | |||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 8.00% | |||||||||||
Debt Instrument, Face Amount | $ 50,000 | |||||||||||
Shares Issued, Price Per Share | $ 0.18 | |||||||||||
Accrued Liabilities for Commissions, Expense and Taxes | $ 142,500 |
COMMITMENTS AND CONTINGENCIES_4
COMMITMENTS AND CONTINGENCIES (Details) - Litigation - USD ($) | Feb. 15, 2019 | Aug. 01, 2018 | Aug. 26, 2016 | Aug. 17, 2015 | Jul. 01, 2015 | Jun. 01, 2015 | Apr. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2019 | Dec. 31, 2018 |
COMMITMENTS AND CONTINGENCIES (Details) - Litigation [Line Items] | ||||||||||
Loss Contingency, Name of Plaintiff | Patricia Meding, et. al. | |||||||||
Loss Contingency, Name of Defendant | ReceptoPharm, Inc. f/k/a Receptogen, Inc. | |||||||||
Patricia Meding, et. al. v. ReceptoPharm, Inc. [Member] | ||||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Litigation [Line Items] | ||||||||||
Loss Contingency, Settlement Agreement, Terms | The settlement agreement executed on June 1, 2015 provides that ReceptoPharm will pay Ms. Meding a total of $360,000 over 35 months. The first payment of $20,000 was made on July 1, 2015. A second payment of $20,000 was made on August 17, 2015 with 32 subsequent monthly $10,000 payments due on the 15th of every month thereafter. | |||||||||
Litigation Settlement, Amount Awarded to Other Party | $ 360,000 | |||||||||
Litigation Settlement Term Of Payments | 35 months | |||||||||
Payments for Legal Settlements | $ 20,000 | |||||||||
Loss Contingency, Discounted Amount of Insurance-related Assessment Liability, Payment Period | $20,000 | |||||||||
Litigation Settlement Term Of Payments, Monthly Payments | $ 10,000 | |||||||||
Payment increase in event of default | $ 200,000 | |||||||||
Gain (Loss) Related to Litigation Settlement | $ 200,000 | |||||||||
Paul Reid et al. v. Nutra Pharma Corp. et al. [Member] | ||||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Litigation [Line Items] | ||||||||||
Loss Contingency, Name of Plaintiff | Paul Reid et al. | |||||||||
Loss Contingency, Name of Defendant | Nutra Pharma Corp. et al. | |||||||||
Loss Contingency, Lawsuit Filing Date | August 26, 2016 | |||||||||
Loss Contingency, Damages Sought, Value | $ 315,000 | |||||||||
Get Credit healthy, Inc. v. Nutra Pharma Corp. and Rik Deitsch [Member] | ||||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Litigation [Line Items] | ||||||||||
Loss Contingency, Name of Plaintiff | Get Credit Healthy, Inc | |||||||||
Loss Contingency, Name of Defendant | Nutra Pharma Corp. and Rik Deitsch | |||||||||
Loss Contingency, Settlement Agreement, Terms | ultimately, the parties were able to reach a Confidential Settlement Agreement to resolve the dispute, and an Agreed Order was entered dismissing the lawsuit. The lawsuit was settled on February 15, 2019 for $104,000 with scheduled payments. The repayments were made in full as of November 2020 (See Note 6). | |||||||||
Payments for Legal Settlements | $ 104,000 | |||||||||
Loss Contingency, Lawsuit Filing Date | August 1, 2018 | |||||||||
Loss Contingency, Damages Sought, Value | $ 100,000 | |||||||||
Long-term Debt | $ 101,818 | |||||||||
Debt Instrument, Increase, Accrued Interest | $ 21,023 | |||||||||
CSA 8411, LLC v. Nutra Pharma Corp [Member] | ||||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Litigation [Line Items] | ||||||||||
Loss Contingency, Name of Plaintiff | CSA 8411, LLC | |||||||||
Loss Contingency, Name of Defendant | Nutra Pharma Corp. | |||||||||
Loss Contingency, Settlement Agreement, Terms | Opposing counsel reached out to schedule mediation, and mediation was set for June 21, 2019 in Plantation, FL however the mediation was unsuccessful. At June 30, 2019, we owed principal balance of $91,156 and accrued interest of $24,433 (See Note 6) if the defenses and our new claims are deemed to be of no merit | |||||||||
Loss Contingency, Lawsuit Filing Date | October 12, 2018 | |||||||||
Loss Contingency, Damages Sought, Value | $ 100,000 | |||||||||
Securities and Exchange Commission v. Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus [Member] | ||||||||||
COMMITMENTS AND CONTINGENCIES (Details) - Litigation [Line Items] | ||||||||||
Loss Contingency, Name of Plaintiff | Securities and Exchange Commission | |||||||||
Loss Contingency, Name of Defendant | Nutra Pharma Corporation, Erik Deitsch, and Sean Peter McManus | |||||||||
Loss Contingency, Lawsuit Filing Date | September 28, 2018 | |||||||||
Loss Contingency, Allegations | The violations alleged against the Company by the SEC include: (a) raising over $920,000 in at least two private placement offerings for which the Company failed to file required registration statements with the SEC; (b) issuing a series of materially false or misleading press releases; (c) making false statements in at least one Form 10-Q; and (d) failing to make required public filings with the SEC to disclose the Company’s issuance of millions of shares of stock. The lawsuit makes additional allegations against Mr. McManus and Mr. Deitsch, including that Mr. McManus acted as a broker without SEC registration and defrauded at least one investor by making false statements about the Company, that Mr. Deitsch engaged in manipulative trades of the Company’s stock by offering to pay more for shares he was purchasing than the amount the seller was willing to take, and that Mr. Deitsch failed to make required public filings with the SEC. The lawsuit seeks both injunctive and monetary relief |
COMMITMENTS AND CONTINGENCIES_5
COMMITMENTS AND CONTINGENCIES (Details) - Schedule of ReceptoPharm Lease Cost | 6 Months Ended |
Jun. 30, 2019USD ($) | |
Lease cost | |
Operating lease cost | $ 29,288 |
Shor-term lease cost | 33,776 |
Total lease cost | 63,064 |
Balance sheet information | |
Operating ROU Assets | 251,887 |
Operating lease obligations, current portion | 68,806 |
Operating lease obligations, non-current portion | 181,379 |
Total operating lease obligations | $ 250,185 |
Weighted average remaining lease term (in years) – operating leases | 3 years 62 days |
Weighted average discount rate-operating leases | 8.00% |
Cash paid for amounts included in the measurement of operating lease liabilities | $ 46,211 |
COMMITMENTS AND CONTINGENCIES_6
COMMITMENTS AND CONTINGENCIES (Details) - Operating Leases | Jun. 30, 2019USD ($) |
Operating Leases [Abstract] | |
2020 | $ 86,345 |
2021 | 89,651 |
2022 | 93,122 |
2023 | 15,567 |
Total future lease payments | 284,685 |
Less imputed interest | 34,500 |
Total | $ 250,185 |
SUBSEQUENT EVENTS (Details) - C
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable - Promissory [Member] - USD ($) | Sep. 01, 2019 | Nov. 30, 2020 | Oct. 31, 2020 | Sep. 30, 2020 | Aug. 31, 2020 | Aug. 30, 2020 | Jul. 31, 2020 | Mar. 31, 2020 | Jan. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | Jul. 31, 2019 | Mar. 31, 2021 | Feb. 29, 2020 | Mar. 31, 2020 | Dec. 31, 2020 | Dec. 30, 2019 | Nov. 30, 2019 | Feb. 28, 2019 |
Note Holder 1 [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||||||||||
Debt Instrument, Face Amount | $ 55,000 | ||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 5,000 | ||||||||||||||||||
Note Holder 12 [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 205,080,000 | 500,000,000 | |||||||||||||||||
Convertible Notes Payable | $ 102,540 | $ 175,000 | |||||||||||||||||
Stock Issued During Period, Value, Other | 2,100,612 | $ 425,000 | |||||||||||||||||
Notes Payable | $ 19,373 | ||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 13,200 | ||||||||||||||||||
Note Holder 12 [Member] | Subsequent Event [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||||||||||
Debt Instrument, Face Amount | 22,000 | ||||||||||||||||||
Debt Instrument, Unamortized Discount | 2,000 | ||||||||||||||||||
Note Holder 6 [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||||||||||
Debt Instrument, Face Amount | $ 333,543 | $ 137,500 | |||||||||||||||||
Debt Instrument, Unamortized Discount | $ 12,500 | ||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.000275 | ||||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 10,000,000 | ||||||||||||||||||
Stock Issued During Period, Value, Other | $ 6,000 | ||||||||||||||||||
Note Holder 5 [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||||||||||
Debt Instrument, Face Amount | $ 148,225 | $ 22,000 | |||||||||||||||||
Debt Instrument, Unamortized Discount | $ 2,000 | ||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0002 | ||||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 75,000,000 | ||||||||||||||||||
Stock Issued During Period, Value, Other | $ 45,000 | ||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 20,000 | ||||||||||||||||||
Note Holder 7 [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||||||||||
Debt Instrument, Face Amount | $ 68,750 | $ 68,750 | |||||||||||||||||
Debt Instrument, Unamortized Discount | 6,250 | 6,250 | |||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0005 | ||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | 5,500 | ||||||||||||||||||
Note Holder 8 [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||||||||||
Debt Instrument, Face Amount | 22,000 | 22,000 | |||||||||||||||||
Debt Instrument, Unamortized Discount | $ 2,000 | $ 2,000 | |||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0003 | $ 0.0003 | |||||||||||||||||
Stock Issued During Period, Value, Other | $ 900 | ||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 20,000 | ||||||||||||||||||
Note Holder 9 [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||||||||||
Debt Instrument, Face Amount | $ 84,000 | 5,500 | $ 5,500 | ||||||||||||||||
Debt Instrument, Unamortized Discount | $ 500 | $ 500 | |||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0002 | $ 0.0002 | |||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 1,500,000 | ||||||||||||||||||
Stock Issued During Period, Value, Other | $ 900 | ||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 5,000 | ||||||||||||||||||
Note Holder 10 [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||||||||||
Debt Instrument, Face Amount | $ 22,000 | 5,500 | $ 5,500 | ||||||||||||||||
Debt Instrument, Unamortized Discount | $ 500 | $ 500 | |||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0005 | $ 0.0005 | |||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 1,000,000 | 5,000,000 | |||||||||||||||||
Stock Issued During Period, Value, Other | $ 700 | ||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 3,300 | ||||||||||||||||||
Note holder 13 [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||||||||||
Debt Instrument, Face Amount | 20,900 | $ 60,000 | |||||||||||||||||
Debt Instrument, Unamortized Discount | $ 1,900 | $ 10,000 | |||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.00052 | ||||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 10,000,000 | ||||||||||||||||||
Stock Issued During Period, Value, Other | $ 4,000 | ||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 15,273 | ||||||||||||||||||
Note Holder 3 [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||||||||||
Debt Instrument, Face Amount | 5,500 | ||||||||||||||||||
Debt Instrument, Unamortized Discount | $ 500 | ||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0005 | ||||||||||||||||||
Debt Instrument, Convertible, Beneficial Conversion Feature | $ 1,100 | ||||||||||||||||||
Note Holder 4 [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 100,000,000 | ||||||||||||||||||
Convertible Notes Payable | $ 75,900 | ||||||||||||||||||
Stock Issued During Period, Value, Other | 120,000 | ||||||||||||||||||
Notes Payable | $ 55,900 | ||||||||||||||||||
Convertible Notes Payable, Current | 20,000 | ||||||||||||||||||
Note Holder 4 [Member] | Subsequent Event [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||||||||||
Convertible Notes Payable | $ 20,000 | ||||||||||||||||||
Restated Note [Member] | Note Holder 1 [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||||||||||
Debt Instrument, Face Amount | 16,500 | $ 38,500 | $ 22,000 | ||||||||||||||||
Debt Instrument, Unamortized Discount | $ 1,650 | $ 7,550 | |||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0005 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share) | $ 0.001 | ||||||||||||||||||
Restated Note [Member] | Note Holder 12 [Member] | |||||||||||||||||||
SUBSEQUENT EVENTS (Details) - Convertible Notes Payable [Line Items] | |||||||||||||||||||
Debt Instrument, Convertible, Conversion Price (in Dollars per share) | $ 0.0005 |
SUBSEQUENT EVENTS (Details) - P
SUBSEQUENT EVENTS (Details) - PPP Loan - PPP Loan [Member] - Subsequent Event [Member] | 1 Months Ended |
May 31, 2020USD ($) | |
SUBSEQUENT EVENTS (Details) - PPP Loan [Line Items] | |
Proceeds from Issuance of Long-term Debt | $ 64,895 |
Debt Instrument, Interest Rate, Stated Percentage | 1.00% |
Debt Instrument, Term | 24 months |
SUBSEQUENT EVENTS (Details) - E
SUBSEQUENT EVENTS (Details) - Economic Injury Disaster Loan - Economic Injury Disaster Loan [Member] - Subsequent Event [Member] | 3 Months Ended |
Jun. 30, 2020USD ($) | |
SUBSEQUENT EVENTS (Details) - Economic Injury Disaster Loan [Line Items] | |
Proceeds from Issuance of Long-term Debt | $ 154,900 |
Debt Instrument, Interest Rate, Stated Percentage | 3.75% |
Payments for Loans | $ 731 |
Advance On Federal Loan | $ 5,000 |
SUBSEQUENT EVENTS (Details) - R
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes - Subsequent Event [Member] - USD ($) | 1 Months Ended | 7 Months Ended | |||||||||
Feb. 28, 2021 | Dec. 31, 2020 | Oct. 31, 2020 | Jul. 31, 2020 | Jun. 30, 2020 | Mar. 31, 2020 | Aug. 30, 2019 | Aug. 30, 2018 | Jan. 31, 2020 | Dec. 31, 2019 | Sep. 30, 2019 | |
Note Holder 1 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 282,983 | ||||||||||
Convertible Notes Payable | $ 333,543 | ||||||||||
Common Stock, Shares, Issued (in Shares) | 20,000,000 | ||||||||||
Common Stock, Value, Issued | $ 5,090 | ||||||||||
Note Holder 2 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Debt Instrument, Face Amount | 36,000 | ||||||||||
Convertible Notes Payable | 36,000 | ||||||||||
Debt Instrument, Unamortized Discount | $ 6,000 | ||||||||||
Note Holder 3 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 60,000 | ||||||||||
Convertible Notes Payable | $ 183,619 | $ 166,926 | 88,225 | ||||||||
Common Stock, Shares, Issued (in Shares) | 29,072,500 | ||||||||||
Common Stock, Value, Issued | $ 343,056 | ||||||||||
Debt Instrument, Unamortized Discount | $ 10,000 | ||||||||||
Accrued Interest Rate | 2.00% | 2.50% | |||||||||
Debt Instrument, Increase, Accrued Interest | 23,258 | ||||||||||
Gain (Loss) on Extinguishment of Debt | 319,798 | ||||||||||
Amortization of Debt Issuance Costs and Discounts | $ 16,693 | ||||||||||
Note Holder 4 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 12,000 | ||||||||||
Common Stock, Shares, Issued (in Shares) | 1,500,000 | ||||||||||
Common Stock, Value, Issued | $ 450 | ||||||||||
Debt Instrument, Unamortized Discount | 2,000 | ||||||||||
Repayments of Notes Payable | $ 3,500 | $ 12,000 | |||||||||
Note Holder 5 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 9,900 | ||||||||||
Common Stock, Shares, Issued (in Shares) | 40,000,000 | ||||||||||
Common Stock, Value, Issued | $ 24,000 | ||||||||||
Debt Instrument, Unamortized Discount | 900 | ||||||||||
Note Holder 6 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 49,684 | ||||||||||
Common Stock, Shares, Issued (in Shares) | 260,000,000 | ||||||||||
Common Stock, Value, Issued | $ 130,000 | ||||||||||
Debt Instrument, Unamortized Discount | 2,700 | ||||||||||
Note Holder 7 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 46,500 | ||||||||||
Common Stock, Shares, Issued (in Shares) | 500,000,000 | ||||||||||
Common Stock, Value, Issued | $ 300,000 | ||||||||||
Accounts Payable, Current | $ 39,000 | ||||||||||
Note Holder 8 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 511,319 | ||||||||||
Common Stock, Shares, Issued (in Shares) | 107,817,770 | 107,133,333 | |||||||||
Debt Instrument, Increase, Accrued Interest | $ 10,345 | $ 10,140 | |||||||||
Repayments of Notes Payable | 22,000 | $ 22,000 | |||||||||
Note Holder 9 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 120,000 | ||||||||||
Common Stock, Shares, Issued (in Shares) | 125,000,000 | ||||||||||
Common Stock, Value, Issued | $ 119,700 | ||||||||||
Debt Instrument, Unamortized Discount | 20,000 | ||||||||||
Repayments of Notes Payable | 50,000 | ||||||||||
Note Holder 10 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Debt Instrument, Face Amount | $ 14,400 | ||||||||||
Common Stock, Shares, Issued (in Shares) | 5,000,000 | ||||||||||
Common Stock, Value, Issued | $ 3,000 | ||||||||||
Debt Instrument, Unamortized Discount | 2,400 | ||||||||||
Repayments of Notes Payable | $ 14,400 | ||||||||||
Sold to Non-Related Party [Member] | Note Holder 8 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Convertible Notes Payable | 467,000 | ||||||||||
Debt Instrument, Increase, Accrued Interest | 166,168 | ||||||||||
Debt Securities, Held-to-maturity, Sold at Par Value | $ 250,000 | ||||||||||
Restated Note [Member] | Note Holder 3 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Convertible Notes Payable | $ 148,225 | ||||||||||
Accrued Interest Rate | 2.00% | ||||||||||
Restated Note [Member] | Note Holder 9 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Convertible Notes Payable | $ 70,000 | ||||||||||
Common Stock, Shares, Issued (in Shares) | 10,000,000 | ||||||||||
Debt Instrument, Unamortized Discount | $ 14,000 | ||||||||||
Further Restated [Member] | Note Holder 3 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Convertible Notes Payable | $ 148,225 | ||||||||||
Debt Instrument, Increase, Accrued Interest | $ 18,701 | ||||||||||
Currently in default and negotiation [Member] | Note Holder 4 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Other Notes Payable | $ 8,500 | ||||||||||
Currently in default and negotiation [Member] | Note Holder 9 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Other Notes Payable | $ 84,000 | ||||||||||
Additional Shares Issued [Member] | Note Holder 9 [Member] | |||||||||||
SUBSEQUENT EVENTS (Details) - Restatement of Promissory Notes [Line Items] | |||||||||||
Common Stock, Shares, Issued (in Shares) | 36,000,000 |
SUBSEQUENT EVENTS (Details) - A
SUBSEQUENT EVENTS (Details) - Advances | May 30, 2020USD ($) |
Subsequent Events [Abstract] | |
Investments in and Advance from Affiliates, Subsidiaries, Associates, and Joint Ventures | $ 175,000 |
SUBSEQUENT EVENTS (Details) -_2
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments - USD ($) | Sep. 01, 2019 | Jan. 31, 2021 | Oct. 31, 2020 | Sep. 30, 2020 | Jul. 31, 2020 | Jan. 31, 2020 | Sep. 30, 2019 | Aug. 31, 2019 | Jul. 31, 2019 | Jun. 30, 2019 | Jun. 30, 2019 | Aug. 31, 2020 | Mar. 31, 2020 | Dec. 31, 2019 | Nov. 30, 2019 | Feb. 28, 2019 |
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments [Line Items] | ||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 25,000,000 | 1,500,000 | 10,000,000 | 1,000,000 | 75,000,000 | 10,000,000 | 5,000,000 | |||||||||
Stock Issued During Period, Value, Other | $ 107,500 | $ 700 | $ 45,000 | $ 4,000 | $ 1,500 | $ 4,688 | $ 275,000 | |||||||||
Debt Instrument, Face Amount | 166,926 | $ 84,000 | $ 333,543 | $ 22,000 | $ 148,225 | 60,000 | $ 282,983 | |||||||||
Debt Instrument, Unamortized Discount | $ 10,000 | |||||||||||||||
Note Holder 1 [Member] | Subsequent Event [Member] | ||||||||||||||||
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments [Line Items] | ||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 2,000,000 | |||||||||||||||
Stock Issued During Period, Value, Other | $ 700 | |||||||||||||||
Note Holder 3 [Member] | Subsequent Event [Member] | ||||||||||||||||
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments [Line Items] | ||||||||||||||||
Stock Issued During Period, Value, Other | $ 107,500 | |||||||||||||||
Note Holder 10 [Member] | ||||||||||||||||
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments [Line Items] | ||||||||||||||||
Stock Issued During Period, Value, Other | 1,500 | |||||||||||||||
Debt Instrument, Face Amount | $ 282,983 | |||||||||||||||
PPP Loan [Member] | Subsequent Event [Member] | ||||||||||||||||
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments [Line Items] | ||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 25,000,000 | |||||||||||||||
Debt Instrument, Face Amount | $ 166,926 | |||||||||||||||
Promissory [Member] | Note Holder 1 [Member] | ||||||||||||||||
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments [Line Items] | ||||||||||||||||
Debt Instrument, Face Amount | $ 55,000 | |||||||||||||||
Debt Instrument, Unamortized Discount | $ 5,000 | |||||||||||||||
Promissory [Member] | Note Holder 8 [Member] | ||||||||||||||||
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments [Line Items] | ||||||||||||||||
Stock Issued During Period, Value, Other | $ 900 | |||||||||||||||
Debt Instrument, Face Amount | $ 22,000 | |||||||||||||||
Debt Instrument, Unamortized Discount | 2,000 | |||||||||||||||
Promissory [Member] | Note Holder 3 [Member] | ||||||||||||||||
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments [Line Items] | ||||||||||||||||
Debt Instrument, Face Amount | $ 5,500 | |||||||||||||||
Debt Instrument, Unamortized Discount | $ 500 | |||||||||||||||
Promissory [Member] | Note Holder 10 [Member] | ||||||||||||||||
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments [Line Items] | ||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 1,000,000 | 5,000,000 | ||||||||||||||
Stock Issued During Period, Value, Other | $ 700 | |||||||||||||||
Debt Instrument, Face Amount | 22,000 | 5,500 | ||||||||||||||
Debt Instrument, Unamortized Discount | 500 | |||||||||||||||
Promissory [Member] | Note holder 13 [Member] | ||||||||||||||||
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments [Line Items] | ||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 10,000,000 | |||||||||||||||
Stock Issued During Period, Value, Other | $ 4,000 | |||||||||||||||
Debt Instrument, Face Amount | 20,900 | $ 60,000 | ||||||||||||||
Debt Instrument, Unamortized Discount | $ 1,900 | $ 10,000 | ||||||||||||||
Promissory [Member] | Note Holder 5 [Member] | ||||||||||||||||
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments [Line Items] | ||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 75,000,000 | |||||||||||||||
Stock Issued During Period, Value, Other | $ 45,000 | |||||||||||||||
Debt Instrument, Face Amount | $ 148,225 | $ 22,000 | ||||||||||||||
Debt Instrument, Unamortized Discount | $ 2,000 | |||||||||||||||
Promissory [Member] | Note Holder 6 [Member] | ||||||||||||||||
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments [Line Items] | ||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 10,000,000 | |||||||||||||||
Stock Issued During Period, Value, Other | $ 6,000 | |||||||||||||||
Debt Instrument, Face Amount | $ 333,543 | $ 137,500 | ||||||||||||||
Debt Instrument, Unamortized Discount | $ 12,500 | |||||||||||||||
Promissory [Member] | Note Holder 9 [Member] | ||||||||||||||||
SUBSEQUENT EVENTS (Details) - Common Stock Issued for Default Payments [Line Items] | ||||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in Shares) | 1,500,000 | |||||||||||||||
Stock Issued During Period, Value, Other | $ 900 | |||||||||||||||
Debt Instrument, Face Amount | $ 84,000 | 5,500 | ||||||||||||||
Debt Instrument, Unamortized Discount | $ 500 |
SUBSEQUENT EVENTS (Details) - S
SUBSEQUENT EVENTS (Details) - Schedule of Warrants Issued - USD ($) | 1 Months Ended | ||
Oct. 31, 2020 | Aug. 31, 2020 | Dec. 31, 2019 | |
Schedule of Warrants Issued [Abstract] | |||
Number of Warrants | 39,930,000 | 92,100,000 | 44,000,000 |
Fair Value of Warrants | $ 9,497 | $ 22,879 | $ 7,370 |
Month of Expiration | 2022-10 | 2021-08 | 2020-08 |
SUBSEQUENT EVENTS (Details) -_3
SUBSEQUENT EVENTS (Details) - Schedule of Shares Converted - USD ($) | Mar. 03, 2021 | Oct. 05, 2020 | Sep. 22, 2020 | Feb. 25, 2020 | Feb. 18, 2020 | Jan. 21, 2020 |
Note Holder 17 [Member] | ||||||
SUBSEQUENT EVENTS (Details) - Schedule of Shares Converted [Line Items] | ||||||
Number of Shares Converted | 67,380,000 | 137,700,000 | 250,000,000 | 250,000,000 | ||
Fair Value of Debt Converted | $ 599,682 | $ 1,500,930 | $ 275,000 | $ 150,000 | ||
Note Holder 18 [Member] | ||||||
SUBSEQUENT EVENTS (Details) - Schedule of Shares Converted [Line Items] | ||||||
Number of Shares Converted | 107,817,770 | 107,133,333 | ||||
Fair Value of Debt Converted | $ 64,691 | $ 171,413 |